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Abstract 
Mammals survive on the ability of the mother to feed the young with copious amounts of 
milk secreted by the mammary gland. Lactation makes the juvenile nutritionally 
dependent on the mother well after it is mechanically independent of her. The mammary 
gland is a unique organ to study and the mouse mammary gland particularly, is an 
attractive experimental model due to its localization and ease of access. Mammary gland 
involution occurs at weaning and is a physiological process associated with rapid 
apoptosis of the lactating mammary epithelial cells followed by remodelling of the 
mammary gland to a pre-pregnant state. The loss of secretory alveolar epithelium is 
attributed to a number of factors such as mild ischemia as a result of milk engorgement 
and compression of vasculature, falling levels of prolactin upon cessation of suckling, 
factors in milk that promote cell death, physical distension of the luminal epithelium and 
increased activity of the basement membrane degrading enzymes (matrix 
metalloproteinases). Mammary gland involution in the mouse is a two-step process 
according to its reversibility. Early involution, occurring within the first 24-48 hours, is 
reversible and induced by local factors. If weaning is re-initiated during this phase, the 
process of programmed cell death can be reversed. The second phase, a remodelling 
programme initiated to return the gland to a pre-pregnant state, is irreversible and requires 
systemic factors. Although the myriad of signaling pathways mediating apoptosis during 
involution have been characterized, the trigger of both these phases of involution remains 
unidentified. This thesis investigates the role of milk, extracellular matrix and mammary 
adipocytes in regulating mammary gland function during involution in mice and explores 
the use of an in vitro culture model (mammosphere model system).  
Chapter 2 established the use of the mammosphere model to study mammary involution 
and identified the effect of extracellular matrix (ECM) isolated from involuting mice 
mammary glands on mammary epithelial cell growth and hormone responsiveness. A 
mammosphere is a three dimensional in vitro model of polarized epithelial cells on an 
ECM and has similar functionality to a secretory alveoli.  Epithelial cells cultured on early 
involuting matrices (days 0, 1 & 2) remained viable in culture and polarized to form 
mammospheres. The ECM-cell interactions regulated cell polarity and milk protein gene 
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expression upon lactogenic hormone induction. Up-regulation of regulators of cell 
polarity, Afadin and Scribble, confirmed the polarization of the cells and up-regulation 
of beta-casein gene expression confirmed the hormone responsiveness of the 
mammospheres. Matrix remodelling during the second phase of involution contributed to 
the loss of polarity and hormone responsiveness of cells cultured on day 3 involution 
matrix. Possible action of matrix metalloproteinases on cleaving ECM constituents 
facilitated cell detachment and cell death due to anoikis on day 4 involution matrix. The 
complete loss of 3-dimensional acini structure when polarized mammospheres formed on 
early involution matrices were transferred to late involution matrices, revealed a role for 
the ECM in the transition cascade from reversible to irreversible phase of involution. 
Thus, the extracellular matrix controls the ability of mammary epithelial cells to form 3-
dimensional structures in culture resembling the secretory alveoli in the mammary gland. 
Further, the ECM and its components contribute to maintaining the irreversibility of the 
two step involution process by signaling apoptosis in late involution, but does not 
contribute to the initial apoptosis seen at the onset of involution.  
Cessation of milk removal from the mammary gland leads to significant changes in the 
mammary tissue and is concurrent with the initiation of involution. Chapter 3 investigated 
the effect of milk collected from involuting mice on the in vitro culture model established 
in chapter 2 and analysis of microarray data to identify genes coding for secreted proteins 
that contribute to the apoptotic events during involution. Cell death was observed when 
milk from involuting mice at days 0-3 was added to polarized mammospheres formed on 
early involution matrices within 24 hours. The accumulation of milk-borne pro-apoptotic 
factors in the mammary gland act as a trigger for phase I involution. Although much is 
known about the target genes that are induced by the involution switch, the role of milk 
protein candidates and milk borne factors in regulating the transition from phase 1 to 
phase 2 involution remains unknown. Analysis of microarray data generated a list of 
differentially regulated genes coding for secreted proteins with possible triggers that 
belong to the functional category of genes which are involved in the regulation of cell 
growth such as the insulin like growth factor binding proteins. Another protein, caveolin 
1 was identified to belong to the differentially regulated genes list coding for secreted 
proteins that were up-regulated between lactation and involution and is involved in 
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regulating the mammary gland during involution by paracrine signaling. A negative 
correlation exists between the expression of caveolin 1 localized in myoepithelial cells 
and adipocytes and milk protein gene expression in mammary epithelial cells confirming 
a paracrine regulation of cell-cell interaction in the mammary gland. The 3T3L1 
adipocytes expressing caveolin 1 upon insulin induction served as an excellent model to 
investigate this regulation. Decreased expression of milk protein genes in mammary 
epithelial cells in the presence of conditioned media from 3T3L1 adipocytes expressing 
caveolin 1 was observed. This effect was reversed in the presence of anti-caveolin 1 
antibody in the media confirming the secretory nature of this protein and its effect on 
decreased milk production during involution. Thus, milk-borne factors and cell-cell 
interactions in the mammary gland contribute to the apoptotic events involved in the 
involution cascade.  
During involution, factors present in milk that are normally removed during nursing cause 
down-regulation of milk protein gene expression and mammary gland remodeling by cell 
death. The involuting mammary gland employs mechanisms that suppress the potentially 
damaging effects of a cellular inflammatory response during the transition from lactation 
to involution and harnessing this apoptotic machinery in the absence of an immune 
response is important for cancer therapy where reduced immune response is favorable. 
Chapter 4 successfully developed and characterised a silicon nanocarrier system for the 
delivery of alpha-lactalbumin-oleic acid payload to breast cancer cells. The apoptosis 
inducing component of alpha-lactalbumin (LALBA) is a folding variant that undergoes a 
conformational change towards a molten globule-like state and is stabilized by the 
incorporation of a fatty acid co-factor such as oleic acid. Synthesizing and loading the 
complex onto a biocompatible and biodegradable nanocarrier like silicon without 
chemical modification was a significant step in the study. The cytotoxic activity of the 
complex was tested on MCF-7 breast cancer cell line and it induced significant cell death.  
Taken together, the findings in this thesis have demonstrated that during the first 2 days 
of cessation of lactation (reversible phase of involution), the mammary ECM supports 
alveolar differentiation, formation of mammospheres and hormone responsiveness and 
maintains the reversibility of this phase. The initial trigger for apoptosis arises from pro-
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apoptotic factors accumulated in the milk and the down-regulation of milk protein genes 
is due to paracrine signalling from cell-cell interactions in the mammary gland. During 
the subsequent 2 days of involution (irreversible phase), the ECM does not support 
alveolar structure and function suggesting the programming of irreversible apoptosis to 
negate the reversibility of the process. Harnessing the natural triggers of involution like 
alpha-lactalbumin as a therapeutic agent paves way to develop exceptional anti-cancer 
agents eliminating potential side effects.  
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1.1 Introduction 
The neo-Darwinian theory of evolution states that all living forms have arisen from a 
single form of life by slow gradual changes. The gradual evolution of one plant or animal 
into another occurs by accumulation of mutations through natural selection of favored 
variants. The time between the origin of life and abrupt appearance of fossil records of 
complex invertebrate forms of life is estimated to be nearly three billion years (Gish 
1980). The time required for one of these invertebrates to evolve into vertebrates and 
fishes is estimated at about 100 million years (Gish 1980). The production of a live young 
is seen in all classes of extant vertebrates except birds (Sadlier 1973). Mammals are 
unique as their survival depends on the ability of the mother to feed the young by 
producing milk from a specialized gland and they owe their name to this unique 
characteristic (Veltmaat, Mailleux et al. 2003). Lactation, the nourishment of the young 
with copious milk secreted by the mammary gland, makes the juvenile nutritionally 
dependent on the mother well after it is mechanically independent of her (Pond 1977). 
Although lactation is the most defining characteristics of mammals, its evolution has long 
been shrouded in mystery. Upon recognizing the uniqueness of the mammary gland, 
Linnaeus, in 1758, united the terrestrial forms, quadrupeds with the aquatic cetaceans in 
a new group called the Mammalia, creatures with breasts (Gregory 1910). Although 
animals like sharks, salamanders and skinks nourish their young with secretions of the 
oviduct or uterus or placental transfer, mammals secrete complex nutritive fluids from 
elaborate cutaneous glands, the mammary glands, to feed their young (Wourms 1981, 
Blackburn, Vitt et al. 1984, Blackburn 1992, Baranes and Fishelson 1998).  
Significant components of mammary gland development occur relatively late in 
comparison to other tissues in the body, making it a unique organ to study at an 
anatomical, biochemical, physiological and subcellular level. A number of features make 
the mouse mammary gland a particularly attractive experimental model. It is the only 
organ that undergoes most of its development postnatally, making it best suited to study 
developmental processes; and since it localizes to the underside of the ventral skin, it can 
be easily accessed. Furthermore, there is abundant mammary gland tissue; the mouse has 
5 pairs of mammary glands and cells can be isolated from them in large numbers too 
(Brisken and O'Malley 2010). Although there are hormonal and architectural differences 
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between the mouse and human mammary gland, the mouse model system is widely used 
by researchers because the gland is amenable to sophisticated in vivo and in vitro 
manipulations (Macias and Hinck 2012). Normal female mammary gland development 
involves a well-orchestrated sequence of events which are marked by extensive 
proliferation at puberty followed by proliferation and differentiation during pregnancy. 
This process is regulated by hormones, growth factors and stromal factors (Rudel, Fenton 
et al. 2011). Mammary gland development during pregnancy, lactation and involution 
involves complex interactions that are tightly regulated by autocrine, paracrine and 
endocrine factors. 
A major role of the endocrine system is to coordinate mammary function with the 
reproductive state of the animal and milk demands of the young. This physiological 
synchronization is an extremely complex process involving the action and interaction of 
multiple hormones and the interplay between circulating hormones and local regulation 
of the mammary response to these hormones (Wall and McFadden 2012). The levels of 
these hormones, which include estrogen (E), progesterone (P), placental lactogen (PL), 
prolactin (PRL) and oxytocin, change with the reproductive state of the animal (Neville, 
Morton et al. 2001). All these hormones have a direct action on the mammary gland: E 
(Delouis, Dijiane et al. 1980, Schams, Russe et al. 1984, Woodward, Beal et al. 1993) 
and P (Brisken 2002) are required for proliferation and ductal development, PL has a role 
in mammary epithelial cell differentiation (Schams 1972, Akers 1985, Forsyth 1986), 
PRL acts on the luminal epithelial cells to maintain milk secretion (Nguyen, Parlow et al. 
2001) and oxytocin acts on the myoepithelial cells to produce milk ejection (Gimpl and 
Fahrenholz 2001).  The metabolic hormones are primarily responsible for coordinating 
the body’s response to metabolic stress and changes, but are often found to have direct 
effects on the mammary gland (Svennersten-Sjaunja and Olsson 2005). These hormones 
include, insulin (I) which has been reported to play a role in mammary epithelial cell 
development and differentiation in culture (Topper, Nicholas et al. 1984), particularly for 
the expression of milk protein genes (Bolander, Nicolas et al. 1981, Kulski, Nicholas et 
al. 1983, Nicholas, Sankaran et al. 1983), glucocorticoids (Cowie, Forsyth et al. 1980) 
and thyroid hormones (Blaxter, Reineke et al. 1949, Vonderhaar 1979) are necessary for 
milk secretion and mammary development, and growth hormone (GH) (Hovey, Trott et 
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al. 2002) plays a role in ductal development. Mammary explant culture model 
experiments have revealed the requirements of combinations of the aforementioned 
hormones to induce mammary epithelial cell differentiation and milk protein synthesis 
(Topper and Freeman 1980). In addition to the endocrine regulation of the mammary 
gland, the gland also secretes hormones and growth factors in an autocrine/paracrine 
fashion, including growth hormone, prolactin (Clevenger and Plank 1997), parathyroid 
hormone related protein (PTHrP), fibroblast growth factor (FGF) and insulin-like growth 
factor-I (IGF-I). These hormones play important roles in mammary epithelial cell 
proliferation (Hovey, Davey et al. 2001, Hadsell, Bonnette et al. 2002) and mammary 
ductal morphogenesis (Mol, Lantinga-van Leeuwen et al. 2000). 
The production of milk by the mammary gland is essential to supply nutrition to the 
neonate before they can digest other types of food. Not only is breast milk, containing 
proteins, lipids and carbohydrates, a rich source of nutrients for the infant, but milk 
components also include bioactive factors that play a role in host defense mechanisms 
and provide immune protection (Newburg 2005). Increasing evidence also suggests that 
milk components secreted by the mammary epithelial cells have autocrine/paracrine 
functions that are involved in mammary gland regulation. It has been postulated that 
marsupial whey acidic protein (WAP) has a proliferative effect on epithelial cells 
(Brennan, Sharp et al. 2007b). Another milk protein, feedback inhibitor of lactation (FIL) 
has been shown to act specifically on the apical surface of mammary epithelial cells to 
reduce secretory efficiency by inhibiting the movement of proteins and is sensitive to the 
frequency and completeness of milk removal from the gland (Wilde, Addey et al. 1995, 
Hendry, Simpson et al. 1998). It has been proposed that as mammary derived signals are 
responsible for initiating the first phase of involution, the trigger may be an 
autocrine/paracrine milk-borne factor which may be present in the accumulated milk due 
to cessation of suckling (Quarrie, Addey et al. 1996, Li, Liu et al. 1997, Green and Streuli 
2004). Although the myriad of downstream signaling pathways mediating the trigger into 
an apoptotic response have been extensively characterized by Streuli and Watson (Green 
and Streuli 2004, Watson 2006), the trigger of involution remains unidentified.  
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Throughout the repeated cycles of pregnancy, lactation and involution that the mammary 
gland undergoes, the interaction of the mammary epithelial cells with the surrounding 
extracellular matrix (ECM), in particular the specialized ECM, the basement membrane 
(BM), contributes to the signals for proliferation, differentiation and survival (Streuli and 
Gilmore 1999, Prince, Klinowska et al. 2002). These survival signals from the ECM are 
known to be very specific, because culture of primary mammary cells and epithelial cell 
lines on collagen-I does not permit survival, whereas the basement membrane provides 
sufficient signalling responses for long-term survival (Boudreau, Sympson et al. 1995, 
Pullan, Wilson et al. 1996). The basement membrane separates the epithelium from the 
stroma, which includes the fibrous connective tissue ECM proteins and a wide variety of 
cell types, such as inter- and intra-lobular fibroblasts, endothelial cells, adipocytes and 
innate immune cells (both mast cells and macrophages) (Streuli 2003). This stroma is the 
support network, providing both nutrients and blood supply to the epithelium and immune 
defenses, in addition to contributing to the physical structure of the gland (Sternlicht 
2006). The ECM not only serves scaffolding and biochemical functions, but also affects 
the mechanical environment. Cells within the mammary gland respond to changes in 
stiffness of their environment, thus demonstrating that cellular force and mechano-
signaling events play an important role in the normal development and differentiation of 
the mammary gland at puberty, pregnancy, lactation and involution (Schedin and Keely 
2011).  
The stunning capacity of the mammary gland to produce milk is matched by another 
spectacular event in which the milk producing cells are removed when they are no longer 
required. This stage in the mammary development cycle, called involution, follows the 
mechanism of programmed cell death, or apoptosis, in the destruction of the secretory 
epithelium (Watson 2006). In order to maintain cellular homeostasis in adult organisms, 
cell death is essential during embryonic development for organogenesis and tissue 
sculpting. When there is excessive apoptosis, it can lead to degenerative diseases, whereas 
insufficient apoptosis can lead to cancer (Watson 2006). Thus, the study of apoptosis in 
the mammary gland is essential for understanding the normal biological events in post-
lactational regression/involution and also in understanding the events that lead to breast 
tumourigenesis. The following review thus focuses on the development and regulation of 
 6 
 
the mammary gland and highlights the areas that require further investigation to better 
understand the underlying mechanisms that can potentially lead to breast tumourigenesis.  
 
1.2 Mammary gland development 
Mammals are unique as their survival depends on the ability of the mother to feed the 
young by producing milk from a specialized gland. Mammalia develop mammary glands 
and they owe their name to this unique characteristic (Veltmaat, Mailleux et al. 2003). 
The mammary gland is one of the few tissues which can repeatedly undergo growth, 
functional differentiation and regression. Mammogenesis is the term used to describe the 
development of the mammary gland.  
Rodents have 10 mammary glands (Fig. 1.1) located on the abdomen that contain a 
mesodermally derived stromal compartment rich in adipocytes (fat pad) and an 
ectodermally derived epithelial compartment (Topper and Freeman 1980).  
 
 
Fig. 1. 1. Topography of the mouse mammary gland.  Scheme representing the 
localization of the 5 pairs of mammary glands in the mouse – three pairs situated in the 
thoracic region and two in the abdominal region. Modified and adapted from Veltmaat, 
Mailleux et al. (2003). 
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The mammary gland undergoes a dramatic series of cyclical changes in the life cycle of 
a female. They go through morphogenesis, preparing the gland for pregnancy induced 
lactogenesis, followed by lactation and involution. This cycle continues and repeats with 
each subsequent pregnancy (Vonderhaar 1988). The development of the mammary gland 
as a specialized epidermal appendage begins during embryogenesis and is not fully 
completed until the beginning of lactation. Creating a mammary gland involves a series 
of developmental tasks that run in parallel and require the coordination of numerous 
biological and cell signaling processes (Cowin and Wysolmerski 2010). The organ is 
composed of a combination of a diverse array of cell types forming an intricate interaction 
network that is essential for normal and proper development and function (Polyak and 
Kalluri 2010). A schematic representation of mouse mammary gland development is seen 
in Fig. 1.2.  
 
Fig. 1. 2. Mouse mammary gland development. A schematic of the stages (A-F) of 
mammary gland development in an adult mouse, from pre-puberty through to pregnancy, 
lactation and involution. A) A few weeks after birth, the mammary tree undergoes 
allometric growth forming terminal end buds. B) The end buds proliferate and cause 
ductal elongation, resulting in generation of ductal branches. C-E) Extensive side-
branching and alveologenesis occur during pregnancy to facilitate synthesis and secretion 
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of copious amounts of milk during lactation. F) Apoptosis during involution returns the 
gland to a pre-pregnant state. Abbreviations: LN - Lymph Node. Modified and adapted 
from Watson and Khaled (2008).  
 
1.2.1 Embryonic mammary gland development  
The development of the mouse mammary gland begins on day 10 of gestation with the 
formation of milk or mammary lines at the ventral aspect of the Wolfian ridge (Sakakura 
1987). These bilateral ectodermal ridges stretch in a rostral-caudal orientation between 
the fore and hind limb buds. The ectodermal cells within the mammary lines become 
multilayered and columnar as opposed to the single layered epithelial sheet comprising 
the surrounding epidermis (Veltmatt, Van Veelen et al. 2004). Within 24-36 hours of 
formation of the mammary line, it resolves into 5 pair of placodes (3 thoracic and 2 
inguinal) along the ventral-lateral border of the embryo. The placodal cells are not 
uniformly orientated and are formed by the migration of cells from the mammary line 
(Propper 1978, Hens and Wysolmerski 2005, Robinson 2007). Each placode expands and 
invaginates into the underlying mesenchyme forming a mammary bud and this early bud 
lies elevated above the plane of the surrounding epidermis. This process is completed by 
embryonic day 14 (E14) (Watson and Khaled 2008). The formation of the mammary 
epithelial bud is accompanied by dramatic changes in the underlying mesenchyme 
(Sakakura 1987, Dunbar, Dann et al. 1999, Foley, Dann et al. 2001). The mature bud has 
a sphere of concentrically arrayed epithelial cells connected by a stalk of epidermal-like 
cells to the skin surface. This structure is surrounded by primary mammary mesenchyme. 
The mammary buds remain quiescent from E14 to E16 in female mice. Male mice have 
either no mammary epithelial ducts or rudimentary ducts (Dunbar, Dann et al. 1999). The 
ductal branching morphogenesis begins on E16 and extends to the perinatal period 
resulting in the formation of a primary duct and 10-15 branches (Hens and Wysolmerski 
2005). The growth of the epithelial duct system occurs slowly until puberty followed by 
a second round of rapid expansion (Watson and Khaled 2008). Two other significant 
morphological processes take place simultaneously – formation of a ductal lumen and 
remodelling of the skin overlying the primary mesenchyme into a typical nipple structure 
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(Foley, Dann et al. 2001). The primary mesenchyme becomes a dense connective tissue 
associated with the nipple and the ducts are contained within the loose fatty connective 
tissue of the mammary fat pad. The mammary gland, at the end of embryonic 
development, consists of a short primary duct ending in a small branched ductal tree 
embedded in one end of a large mammary fat pad. This ductal system acts as a scaffold 
for further development during puberty and pregnancy, eventually producing a mature 
milk-producing gland during lactation (Cowin and Wysolmerski 2010). The regulatory 
genes involved during this development stage can be divided into three groups – those 
required for normal mammogenesis such as FGF signaling components (Mailleux, 
Spencer-Dene et al. 2002), Wnt signaling components (Van Genderen, Okamura et al. 
1994, Andl, Reddy et al. 2002), parathyroid related hormone PTHrH and its receptor 
(Wysolmerski, Philbrick et al. 1998), Msx2 (Satakota, Ma et al. 2000), those genes that 
are indispensable for the process such as estrogen (Couse and Korach 1999) and 
progesterone receptor (Hovey, Trott et al. 2002) and those genes whose functions remain 
unclear such as Hedgehog signaling (Lewis, Ross et al. 1999, Lewis, Ross et al. 2001), 
Bmp4 (Phippard, Weber-Hall et al. 1996) and Bmp2.  
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Fig. 1. 3. Schematic representation of mouse embryonic mammogenesis. At E11.5, 
the mammary rudiment exists as a placode and appears as a slight elevation above the 
ectoderm (ec). At E12.5, the placode is transformed into a bulb of epithelial cells. Each 
bud with the mesenchyme is elevated as a knob or dome. At E13.5, the buds sink into the 
dermal mesenchyme (dm) and mesenchyme adjacent to the bud is referred to as mammary 
mesenchyme (mm). At E14.5, the deeper mesenchyme differentiates into the fat pad 
precursor (fpp). At E15.5, the bud elongates and forms the mammary sprout along with 
the ectodermal cells of the epidermis. At E16.5, the sprout forms a lumen and the nipple 
sheath is formed by epidermal invagination. At E18.5, 1 day before birth, the sprout 
develops into an arborized gland invading the fat pad.  Abbreviations: ec - ectoderm, dm 
- dermal mesenchyme, mm - mammary mesenchyme, fpp – fat pad precursor, ns - nipple 
sheath. Adapted from Sakakura (1987). 
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1.2.2 Pubertal mammary gland development  
At birth, the mammary gland is only a rudimentary ductal system, yet it is fully competent 
to produce milk. The gland undergoes a period of allometric growth until puberty, 
keeping up with the overall body development, when expansive proliferation occurs, 
filling the fat pad under the influence of growth factors and hormones (Hovey, Trott et 
al. 2002). Terminal end bud bifurcation results in the generation of the primary ductal 
structure and it is regulated by the surrounding stroma. The cap cells of the end bud 
differentiate into myoepithelial cells and form the outer layer of the tubular ductal bilayer 
that encircles the inner luminal cells (Williams and Daniel 1983). Secondary branches 
sprout from the primary ducts and occupy 60% of the fatty stroma, leaving abundant 
space for infilling that occurs under the influence of pregnancy hormones. Ovarian 
stimulation causes the formation of short tertiary branches that fully blossom into milk 
secreting units under the influence of pregnancy hormones. The ovarian hormone, 
estrogen, is a critical regulator of pubertal mammary development and contributes to the 
tremendous surge in growth occurring during this period (Lieberman, Maurer et al. 1978). 
Products of the pituitary gland, including growth hormone and prolactin, largely regulate 
mammary pubertal development (Trott, Vonderhaar et al. 2008). Growth hormone effects 
are mediated largely, or entirely, through insulin-like growth factor 1 (Igf1) (Gallego, 
Binart et al. 2001). Mammary gland ductal morphogenesis is positively influenced by 
members of the EGF and FGF families of growth factors through signals from their 
respective tyrosine kinase receptors (Coleman, Silberstein et al. 1988, Luetteke, Qiu et 
al. 1999, Kenney, Bowman et al. 2003, Ciarloni, Mallepell et al. 2007).  
1.2.3 Adult mammary gland development  
1.2.3.1 Pregnancy 
The mammary gland undergoes numerous changes, including gland maturation and 
alveologenesis to prepare for lactation (Brisken and Rajaram 2006). The first 
transformation of pregnancy is symbolized by a tremendous increase in secondary and 
tertiary ductal branching. This provides ductal arbors for the second transformation, 
alveolar development (Macias and Hinck 2012). The alveolar buds are generated by 
proliferating mammary epithelial cells which further cleave and differentiate into distinct 
alveoli, becoming milk secreting lobules during lactation. As these proliferating epithelial 
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cells occupy the interductal spaces, the interstitial adipose tissue starts to disappear. By 
mid-pregnancy, there is increased vascularization and the alveoli are surrounded by a  
basket-like network of capillaries (Djonov, Andres et al. 2001). The alveoli encompass 
the majority of the fat pad by late pregnancy and show secretory activity as pregnancy 
approaches term. Progesterone, an ovarian hormone, is responsible for alveologenesis 
and the extensive side-branching required to create a lactation-competent gland (Lydon, 
DeMayo et al. 1995, Brisken, Park et al. 1998). Along with prolactin, it also promotes 
differentiation of the alveoli, which synthesize and secrete milk during lactation (Brisken, 
Kaur et al. 1999, Naylor, Lockefeer et al. 2003).  
1.2.3.2 Lactation 
The culmination of mammary epithelial cell differentiation through lactogenesis 
predisposes the mammary gland for copious milk secretion post-partum. Lactogenesis 
has been documented in two stages (Hartmann 1973). Lactogenesis I begins in mid-
pregnancy and is distinguished morphologically by the development of cytoplasmic lipid 
droplets in the mammary epithelium (Neville, McFadden et al. 2002). There is also 
progressive expression of many genes involved in milk component synthesis, including 
β-casein and WAP in the mouse (Brisken and Rajaram 2006). The second stage of 
lactogenesis, lactogenesis II, occurs around parturition and includes a second set of 
developmental processes leading to secretion of colostrum and eventually milk (Neville, 
McFadden et al. 2002). This stage is distinguished from stage 1 by the closure of tight 
junctions between alveolar cells, the movement of casein micelles and cytoplasmic lipid 
droplets into the alveolar lumina and a significant increase in the expression of milk 
protein genes (Neville, McFadden et al. 2002). Colostrum formation is also characterized 
by a transient increase of immunoglobulins and other protective substances (Neville, 
Morton et al. 2001). There is a further increase in the expression of most genes involved 
in milk secretion as suckling begins (Traurig 1967). After the establishment of lactation, 
it is referred to as galactopoesis and is maintained by the removal of milk from the 
mammary gland (Brisken and Rajaram 2006). Eutherian milk is a complex biological 
fluid and contains a number of different constituents. This will be further discussed in the 
next section (1.3).  
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1.2.3.3 Involution 
Involution remodels the mammary gland back to its original adult state. The process of 
removal of the milk producing epithelial cells and remodeling of the epithelial tree back 
to a simple ductal architecture is initiated by the lack of demand at weaning, causing milk 
to stagnate in the mammary epithelium (Macias and Hinck 2012). Two distinct phases of 
involution have been defined (Watson 2006). The first stage is reversible and the 
resumption of suckling during this phase re-establishes milk supply. It is characterized 
by alveolar cell detachment, and accumulation of shed cells into the lumen (Pai and 
Horseman 2011). After 48 hours, a transition into the second phase of involution begins 
(Green and Streuli 2004). This phase is irreversible and regardless of whether or not 
suckling is re-initiated, milk supply is lost. Breakdown of the extra-cellular matrix and 
activation of proteases induces a second wave of apoptosis during this phase. This period 
is characterized by massive tissue remodeling leading to removal of the secretory 
epithelium and subsequent replacement by adipocytes (Clarkson, Wayland et al. 2004). 
The gland then becomes morphologically similar to a virgin gland, although it is 
molecularly distinct with respect to gene expression (D'Cruz, Moody et al. 2002, Balogh, 
Heulings et al. 2006). The process of murine mammary gland involution will be discussed 
in more detail in section (1.5).  
 
1.3 Milk and its constituents 
Although the developmental principles underlying lactation are conserved, milk 
composition varies between species and also, in some species it changes during the 
lactation cycle (Brennan, Sharp et al. 2007a). The variation in milk composition among 
different species is thought to be driven by the reproductive strategy, developmental 
requirements of the young and environmental factors (Nicholas, Wilde et al. 1995). Milk 
composition is also impacted by the length of the lactation period and maternal nutrition 
strategy (Lemay, Lynn et al. 2009). Table 1.1 lists variations in the overall composition 
of milk constituents across different species (Webb, Johnson et al. 1974).  Water is the 
major requirement for growth and development in every animal and mother’s milk acts 
as an important source in supplying this to the neonate. Water from milk also contributes 
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greatly to the temperature regulating mechanisms of the newborn (Vorherr 1978). Not 
only is milk a well-known source of nutrients for the new-born, it also has a more complex 
role in providing bio-active molecules which play important roles in the growth and 
development of the young (Baldi, Ionnis et al. 2005, Donovan 2006, Kwek, De Longh et 
al. 2009), and provide growth factors for the development and function of the mammary 
gland (Brennan, Sharp et al. 2007b, Joss, Molloy et al. 2009, Topcic, Auguste et al. 2009, 
Wanyonyi, Sharp et al. 2011). Milk also plays a crucial role in initiating involution in the 
mammary gland, following cessation of suckling (Watson 2006, Khalil, Digby et al. 
2011) and is known to contain bio-active molecules that take part in host defense 
mechanisms (immune protection) (Newburg 2005), such as immune transfer through 
immunoglobulins and antimicrobials (lysozyme and lactoferrin) (Ellison and Giehl 1991, 
Bellamy, Takase et al. 1992, Lonnerdal 2003). Thus, milk can be defined as a complex 
mixture containing different constituents, including carbohydrates, fats, proteins, 
vitamins, minerals, water and other bio-active molecules that are tailored to the needs of 
the young (Oftedal and Iverson 1995, McManaman and Neville 2003, Ballard and 
Morrow 2013). 
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Table 1. 1. Composition of milk from different mammalian species 
Species Protein 
(g) 
Fat (g) Carbohydrate 
(g) 
Energy 
(kcal) 
Mouse 9.0 13.1 3.0 171 
Human 1.1 4.2 7.0 72 
Cow 3.2 3.7 4.6 66 
Water Buffalo 4.1 9.0 4.8 118 
Goat 2.9 3.8 4.7 67 
Donkey 1.9 0.6 6.1 38 
Elephant 4.0 5.0 5.3 85 
Monkey 1.6 4.0 7.0 73 
Whale 10.9 42.3 1.3 443 
Seal 10.2 49.4 0.1 502 
 
Composition calculated per 100g of fresh milk.  Data adapted from Webb, Johnson et al. 
(1974). 
 
1.3.1 Carbohydrate 
The carbohydrate content in milk varies from being virtually absent in some aquatic 
animals to greater than 70g/L in some primates, including humans (Table 1.1) (Davies, 
Holt et al. 1983). The predominant milk carbohydrate in most species is lactose (a 
disaccharide composed of D-glucose and D-galactose) (Jenness, Regehr et al. 1964). It is 
the major osmolar factor in milk and its synthesis is responsible for drawing water into 
the milk as it is being formed in the mammary gland (Davies, Holt et al. 1983). Lactose 
is also responsible for the increased absorption of calcium. It is completely absent in some 
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sea lions and fur seals (Jennes and Sloan 1970), whereas it forms a minor component of 
milk in some other species, such as marsupials (Messer and Green 1979), monotremes 
(Messer and Kerry 1973) and bears (Urashima, Kusaka et al. 1997, Urashima, Sumiyoshi 
et al. 1999, Urashima, Yamashita et al. 2000). A variety of other oligosaccharides are 
dominant in the milk of these species. It is possible that some of these species have a 
special need for these other milk oligosaccharides, since they are very altricial at hatching 
(monotremes) or birth (marsupials and bears) (Oftedal and Iverson 1995). 
Oligosaccharides are a major component of human milk (Boehm and Stahl 2007) and 
they are presumably an important energy source in these species and are likely to have 
specific biological functions (Urashima, Saito et al. 2001). The galactose and sialic acid 
in milk oligosaccharides are required for optimal development of the infant brain, 
especially in species whose central nervous system is not fully developed at birth (e.g. 
humans) (Kunz, Rudloff et al. 1999). Milk oligosaccharides may contribute to the 
postnatal development of intestinal flora, since they are thought to have anti-bacterial 
properties (Boehm and Stahl 2007). They act as receptor analogues and help to prevent 
gastric and urinary infections caused by the adhesion of pathogenic microorganisms to 
the intestinal and urinary tracts respectively (Boehm and Stahl 2007). Additionally, 
oligosaccharides function as prebiotics in milk, promoting the growth of benign microbes 
like Bifidobacterium bifidus within the lower gastrointestinal tract, thus inhibiting the 
proliferation of pathogenic organisms (Urashima, Saito et al. 2001).  
1.3.2 Fat 
Milk fat content in eutherians is the most variable component between different species. 
It varies from 0.2% in the black rhinoceros to 60% in some species of seals (Jenness 
1995). It has been reported in many studies that maternal diet affects the fat composition 
of milk while the total fat content remains more constant within species (Dils 1986, Smith 
and Martini 2002). The concentration and chemical composition of in the milk is also 
influenced by breed, stage of lactation, number of lactations and season (Davies, Holt et 
al. 1983). It is also known that a maternal high fat diet has a negative effect on the milk 
content (Beaulieu and Palmquist 1993), while starvation alters milk secretion in many 
species (Williamson 1990). Milk fat acts as an important source of energy, fat soluble 
nutrients and bio-active lipids for mammals, including diacylglycerides, 
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triacylglycerides, saturated and poly-unsaturated fatty acids and phospholipids (Bracco, 
Hidalgo et al. 1972, German, Dillard et al. 2002, German and Dillard 2006). Milk fat is 
the major source of lipid used by the mammalian newborn for accumulation of adipose 
tissue in the body (Davies, Holt et al. 1983). Triacylglycerides, which are composed of 
three fatty acids covalently bound to a glycerol molecule by ester bonds, forms the major 
lipid class (up to 98%) in milk fat (Davies, Holt et al. 1983). The remainder of the lipid 
fraction consists of diacylglycerols, cholesterol, phospholipids and free fatty acids (Kurtz 
1965, Bracco, Hidalgo et al. 1972, Kinsella 1973). The fatty acids in milk are primarily 
derived from two sources: de novo synthesis in the mammary gland and the plasma lipids, 
which are directly obtained from the diet or released from adipose tissue in the mother’s 
body (Dils 1983, Mather and Keenan 1998). Milk lipids also possess anticancer, anti-
inflammatory, antimicrobial and immunosuppression properties (German and Dillard 
2006).  
1.3.3 Protein 
Milk protein content also varies among different species, but not as much as the fat 
content in milk (Table 1.1). It has been reported in the literature that milk protein 
concentration greatly varies between mouse species and even between strains (Piletz and 
Ganschow 1981). Also, in distinct mouse strains, the composition of major milk proteins 
varies over the lactation period (Boumahrou, Bevilacqua et al. 2011). A majority of milk 
proteins (80-90% depending on the species) are synthesized within the mammary 
epithelial cells, transported through the secretory pathway, packaged in secretory vesicles 
and released by exocytosis following the fusion of the vesicles to the apical plasma 
membrane (Franke, Luder et al. 1976). Caseins and whey proteins are the two major 
constituents of the total protein in milk (Jennes and Sloan 1970, Burgoyne and Duncan 
1998).  
1.3.3.1 Caseins 
Caseins are the major milk proteins of mammals. They are the main source of amino acids 
for the newborn and are required for the transport of calcium and phosphate (Ginger and 
Grigor 1999). Total casein concentration in milk, the expression levels and the secretion 
of individual casein proteins is known to vary in different species (Ginger and Grigor 
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1999). The casein family consists of five genes and not all species express the entire 
complement (Ginger and Grigor 1999). There are two types of casein genes: the calcium 
sensitive caseins, α-s1 (Csna or CSN1S1), β- (Csnb or CSN2) and α-s2 (Csng and Csnd 
or CSN2S2, A and B) and the calcium-insensitive, physically and functionally linked κ-
casein (Csnk or CSN3) gene (Rijnkels 2002). Human milk contains α-s1, β, α-s2A and κ-
caseins, while mouse milk contains α, β, γ, δ and κ-caseins and bovine milk contains α-
s1, α-s2A, α-s2B, β and κ-caseins (Rijnkels 2002). The caseins are composed of several 
similar proteins that form a multi-molecular granular structure, along with the essential 
ingredient of calcium phosphate called casein micelle (Woodward 1976, De Kruif and 
Holt 2003). These micelle structures, with average diameters of 150-200 nm (De Kruif 
1998), are an important part of milk digestion in the stomach and the basis of many milk 
products like cheese (Davies, Holt et al. 1983). Caseins have been reported to have a 
degree of secondary structure but lack an ordered tertiary structure, making them 
susceptible to proteolysis by protease enzymes (Swaisgood 2003, Phadungath 2005). It 
has been shown recently that the gastrointestinal proteolytic digestion of casein produces 
a number of bioactive peptides that may contribute to a lower incidence of type-1 
diabetes, cardiovascular disease, schizophrenia, dental caries and autism (Bell, Grochoski 
et al. 2006, Ferrazzano, Cantile et al. 2007).  
1.3.3.2 Whey proteins 
In contrast to the limited number of casein proteins, the whey fraction constitutes a 
significant number of proteins. The whey proteins are compact, globular proteins that 
have a high level of secondary, tertiary and quaternary structure and contain 
intermolecular disulphide bonds that stabilize their structure (Aimutis 2004). They are 
also less sensitive to proteolysis by protease enzymes (DeMann 1999). The major whey 
proteins in most mammalian species are α-lactalbumin (LALBA), β-lactoglobulin (BLG), 
lactoferrin (LF), whey acidic protein (WAP), serum albumin, lysozyme, transferrin (TF) 
and immunoglobulins (Simpson and Nicholas 2002). The specific set of whey proteins 
found in mammary secretions varies with the species (Simpson and Nicholas 2002). For 
example, α-lactalbumin, serum albumin, lactoferrin and immunoglobulins are present in 
the milk of human and other species (Alvarez 2007). However, BLG and WAP are 
pseudogenes in humans, but secreted in milk of other species such as mouse, rat, pig, 
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camel and tammar wallaby (Campbell, Rosen et al. 1984, Beg, von Bahr-Lindstrom et al. 
1986, Nicholas, Simpson et al. 1997, Nukumi, Seki et al. 2006). Some of these proteins, 
including BLG, LALBA and WAP are only synthesized in the mammary secretory cell, 
whereas other proteins, such as immunoglobulins, transferrin and serum albumin are 
transferred from blood (Jordon and Morgan 1970). Lactoferrin is synthesized by 
mammary epithelial cells, but it is also found in many mucosal secretions, like saliva and 
tears (Levay and Viljoen 1995, Baik, Lee et al. 1998).   
1.3.3.3 Whey acidic protein 
 WAP is the major milk whey protein in many species such as mouse (Hennighausen, 
Sippel et al. 1982a), rat (Dandelkar, Robinson et al. 1982) and rabbit (Devinoy, Hubert et 
al. 1988). It is also present in the milk of pig (Simpson, Bird et al. 1998), tammar wallaby 
(Simpson, Ranganathan et al. 2000), echidna, platypus (Sharp, Lefevre et al. 2007a) and 
brushtail possum (Demmer, Stasiuk et al. 2001). WAP is believed to have a nutritional 
role for the newborn. In addition, WAP may also be involved in regulating terminal 
differentiation of the mammary epithelial cells, as over-expression of WAP in pigs and 
mice caused disruption in cellular proliferation and lobulo-alveolar formation (Burdon, 
Wall et al. 1991, Shamay, Pursel et al. 1992). Literature also suggests that over-
expression of the WAP gene has an inhibitory effect on the proliferation of mouse 
mammary epithelial cells (MMECs) and human mammary epithelial cells (HuMECs) in 
vitro (Ikeda, Kato et al. 2002, Nukumi, Iwamori et al. 2005, Nukumi, Iwamori et al. 
2007). On the contrary, tammar wallaby WAP has a proliferative effect on tammar 
wallaby mammary epithelial cells and HC11 cells, and is postulated to act as a protease 
inhibitor in marsupials (Demmer, Stasiuk et al. 2001, Simpson and Nicholas 2002). WAP 
has also been classed as a protease inhibitor due to its homology with several families of 
protease and ATPase inhibitors that share a conserved four-disulfide core domain, and 
hence WAP may have a role in remodeling of the mammary gland at specific stages of 
the lactation cycle (Burdon, Sankaran et al. 1991). The temporal expression of WAP in 
the mouse, pig and rabbit is confined to late pregnancy and lactation (Simpson, Bird et 
al. 1998, Simpson and Nicholas 2002). In the mouse, β-casein gene expression is first 
detected around 10-12 days of pregnancy and WAP gene expression is first seen around 
14-15 days (Pittius and Sankaran 1988). In the tammar wallaby, the down-regulation of 
 20 
 
WAP is associated with an increase in mammary gland growth and, contrastingly, the 
same is associated with weaning and involution of the mouse mammary gland (Li and Hu 
1996). Recent studies have also demonstrated the antibacterial activity of WAP purified 
from rat milk (Iwamori, Nukumi et al. 2010). Despite a significant research focus on 
WAP, precise biological functions for this protein are yet to be established, although a 
number of reports and evidence suggest multiple roles.     
1.3.3.4 Lactoferrin and transferrin 
Lactoferrin (LF) and transferrin (TF) are glycoproteins that bind and transport iron and 
also have bacteriostatic properties in the mammary gland (Groves 1971, Bexkorovainy 
1977, Schanbacher, Goodman et al. 1993). They are differentiated by their origin and 
iron-binding capacities. TF is located primarily in the blood-stream and is predominantly 
synthesized by the liver, although it is also synthesized in the mammary cells of some 
species (Baker, Baker et al. 2002). Contrastingly, LF is synthesized by glandular 
epithelial cells and neutrophils (Masson and Heremans 1971, Baker, Baker et al. 2002). 
Additionally, LF binds iron at a much lower pH than TF (Peterson, Anderson et al. 2000). 
The LF content in milk varies between species and with the developmental state of the 
mammary gland (Masson and Heremans 1971, Schanbacher, Goodman et al. 1993). The 
milk of rats and rabbits lacks LF but is comparatively rich in TF, whereas both LF and 
TF are secreted by mouse, cow, horse, guinea pig, goat and pig (Bayat-Sarmadi and 
Puissant 1994). Lactoferrin is found in abundance in the mouse mammary gland at the 
end of lactation period (Teng, Pentecost et al. 1989) and is significantly upregulated 
during involution (Nakamura, Tomita et al. 2006). LF is an important milk bioactive 
compound for the iron-dependent, non-specific antimicrobial defences of milk and the 
mammary gland (Bullen, Rogers et al. 1978). LF also modulates the microbial intestinal 
environment and stimulates the establishment of beneficial microflora in the 
gastrointestinal tract (Baldi, Ionnis et al. 2005).  
1.3.3.5 Alpha-lactalbumin  
Alpha-lactalbumin (LALBA) is synthesized only by mammary epithelial cells and is 
detected in the milk of most mammalian species (Lonnerdal and Lien 2003). It constitutes 
about 2% of the whey fraction of milk (Simpson and Nicholas 2002) and is secreted at a 
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steady state level throughout lactation (Kim and Jimenez-Flores 1994). The gene is highly 
conserved across most species, although it shows more divergence in rodents than in 
primates (Qasba and Kumar 1997). The fur seal is an exception where the LALBA gene 
is poorly expressed and transcripts fail to be translated (Sharp, Lefevre et al. 2008). The 
LALBA gene is known to be upregulated towards the end of gestation and just before 
parturition (Robinson, McKnight et al. 1995, Nicholas, Simpson et al. 1997). The 
biological function of LALBA is that it acts as a specific protein for lactose synthase in 
the formation of lactose from glucose and galactose (DeWit 1989). During lactation, 
alpha-lactalbumin complexes with an enzyme, galactosyltransferase, which is normally 
involved in the glycosylation of proteins, and forms the enzyme activity of lactose 
synthase (Noble, Rodriguez-Zas et al. 2002). Recently, it has been shown that chemically 
induced forms of LALBA kill cells by a mechanism that resembles apoptosis in 
transformed and immature cells, but spares the healthy epithelial cells (Hakansson, 
Zhivotovsky et al. 1995, Riley, Wynn et al. 2008). When the protein is partially unfolded 
and bound to a fatty acid like oleic acid, it forms a complex molecule termed BAMLET 
(Bovine α-lactalbumin Made Lethal to Tumor cells) (or HAMLET with human LALBA), 
whereas the native form does not have any apoptotic function (Svensson, Fast et al. 2003, 
Hallgren, Aits et al. 2008). Investigations of bovine whey proteins indicated that some 
commercial preparations of bovine LALBA had apoptotic effects on the IEC-6 cell line, 
a non-transformed crypt cell line derived from the small intestine of rat (Xu, Sugiura et 
al. 2005). Preparations of bovine LALBA have also been shown to have direct apoptotic 
effects on primary seal mammary epithelial cells (Sharp, Lefevre et al. 2008). In addition 
to these functions, anti-microbial peptides have been generated from LALBA that have 
bactericidal effects predominantly on gram positive organisms (Pellegrini, Thomas et al. 
1999). The therapeutic potential of these commercial preparations of LALBA loaded in 
nanoparticles for treating breast cancer is further discussed in section (1.6.7).   
1.3.3.6 Beta-lactoglobulin  
Beta-lactoglobulin (BLG) is the major milk whey protein of ruminant species 
(Kontopidis, Holt et al. 2004) and a significant component of marsupial milk whey 
(Collet, Joseph et al. 1991, Nicholas, Simpson et al. 1997). This protein is absent in the 
milk of human, rodent and rabbit (Mercier and Vilotte 1993, Kontopidis, Holt et al. 2004), 
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although homologues of BLG have been found in the milk of dog, cat, horse, camel, 
dolphin and fur seal (Liberatori, Morisio Guidetti et al. 1979, Brew and Pervaiz 1986, 
Godovac-Zimmermann 1988, Sharp, Cane et al. 2005). BLG is a member of the lipocalin 
superfamily of proteins (Flower 1996) and although no clear function has been identified 
for the protein, it has been reported to bind to several hydrophobic molecules such as fatty 
acids and Vitamin A, suggesting a transport role (Kontopidis, Holt et al. 2004). BLG is 
an important source of biologically active peptides. These peptides are often found in an 
inactive state within the sequence of the BLG precursor protein, but are released by in 
vivo or in vitro proteolysis by enzymes (Hernandez-Ledesma, Recio et al. 2008). When 
these peptides are released, they play important roles in antimicrobial and antioxidant 
activities (Hernandez-Ledesma, Recio et al. 2008).  
1.3.3.7 Immunoglobulins 
Immunoglobulins are an important component of immunological activity in colostrum 
and milk, play a key role in the transmission of humoral immunity from mother to 
offspring (Davies, Holt et al. 1983). Among the several classes of immunoglobulins that 
are secreted, the main players are IgG, IgA and IgM (Butler 1974). In species, such as 
humans, which transfer IgG to the offspring via the placenta, the primary 
immunoglobulin in colostrum and milk is secretory IgA (Butler 1974, Mestecky and 
Lamm 2005). In species such as dogs, horses and prosimian primates where there is little 
or no maternal transfer of immunoglobulins during gestation, milk provides the only 
avenue for transmission of maternal immunity and, therefore, the milk of these species 
contain significant concentrations of IgG as well as IgA (Van de Perre 2003).  
1.3.4 Growth factors 
In addition to the nutrients in milk, it also contains different growth factors such as 
insulin-like growth factor (IGF), epidermal growth factor (EGF), granulocyte colony-
stimulating factor (G-CSF) and transforming growth factor (TGF). They have 
physiological significance in both the mother’s mammary gland development and infant 
development (Donovan and Odle 1994). These growth factors or mitogenic factors in 
milk have also been postulated to promote the growth of enterocytes and hepatocytes in 
the newborn (Klagsbrun 1978). Growth factors like IGF have been proven to mediate the 
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action of growth hormone in the mammary gland, and promote gastrointestinal tract 
development and maturation in the young (Brown and Corps 1987, Ma and Xu 1997). 
EGF present in milk also has similar roles (Brown and Corps 1987). TGF α and β present 
in milk have a potential role in mammary gland development (Plaut 1993). It has been 
reported that the milk of many species, including human and bovine (Rogers, Goddard et 
al. 1996), contains TGF β which has been implicated in epithelial cell growth and 
differentiation (Heikinheimo, Happonen et al. 1993, Plaut 1993), immune regulation 
(Letterio and Roberts 1998) and carcinogenesis (Buck and Ellenrieder 2006).  
1.3.5 Vitamins and minerals 
The vitamins in milk are essential for biological growth mechanisms and enzymatic 
systems involved in the energy metabolism of carbohydrates, protein and fat. They are 
the initiators and supporters of proper functioning of the respiratory, digestive and 
excretory systems of the neonate (Vorherr 1978). Breast milk is rich in fat soluble vitamin 
A and its carotenoid precursor, while the vitamin D content of human milk is inadequate 
and needs to be supplemented after the third month of nursing for the baby (Macy and 
Kelly 1961). Human milk is an outstanding source of the water soluble vitamins, B 
complex and vitamin C (Vorherr 1978). Minerals in the milk are found in varying 
concentrations in different species and this is attributed to the rate of growth of the young. 
The maternal calcium stores account for 10-15% of the milk calcium, which is 
independent of the amount of dietary calcium intake by the mother. An average full-term 
infant has a sufficient supply of iron since it is provided during intrauterine life and 
postnatally in breast milk (Vorherr 1978).  
1.3.6 Bioactives in milk 
The composition of milk of any mammalian species is indicative of the neonatal 
requirements of the young. It is a complete food for the offspring and the sole food during 
the early stages of rapid development. Apart from the nutritive elements that are present 
in milk, it also provides immunological protection and biologically active molecules to 
the adult and the neonate (Warner and Kanekanian 2001). Milk proteins form the major 
source of biologically active peptides. They normally occur in an inactive form, encrypted 
within the sequence of the parent protein, and are released and gain activity during 
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gastrointestinal digestion and processing. These bioactive peptides act as regulatory 
compounds in the body with hormone-like activity (Gobbetti, Stepaniak et al. 2002). 
Oligosaccharides, growth factors, hormones, gangliosides, mucin and endogenous 
peptides are some naturally available bioactive substances that are present in milk 
(Severin and Wenshui 2005). There are two theories explaining the significance of these 
peptides in milk; one theory suggests the elaborate provision for milk’s self-defense 
against degradative microbes (anti-microbial) and another theory supports the first line 
of defence for the offspring (immune functions) (Lahov and Regelson 1996). Milk 
derived products offer a variety of health benefits, including antimicrobial, opioidic, anti-
inflammatory, anti-carcinogenic and hypocholesterolemic or hypotensive effects 
(Severin and Wenshui 2005, Zimecki and Kruzel 2007).   
 
1.4 Regulation of mammary gland development 
A long list of signalling components are involved in the proper development and 
differentiation of the mammary gland (mammary morphogenesis), which leads to milk 
production and secretion. These include hormones, growth factors, receptor tyrosine 
kinases, proteases, extracellular matrix (ECM) molecules, milk-borne factors and 
morpho-dynamics due to cell-cell interaction from neighboring cell types (Polyak and 
Kalluri 2010, Lu, Weaver et al. 2012) (Fig. 1.4). The importance of such a defined 
microenvironment involving a variety of factors for normal mammary epithelial cell 
differentiation and mammary gland development is demonstrated in literature showing a 
lack of epithelial cell differentiation when they are cultured on plastic in contrast to milk 
protein production by these cells when cultured on basement membrane in the presence 
of lactogenic hormones (Peterson, Ronnov-Jessen et al. 1992, Howlett and Bissell 1993). 
These diverse regulatory factors are well characterized and studied in detail in a number 
of eutherian species. This section outlines the regulatory factors of lactogenesis (the 
beginning of milk production) and galactopoiesis (the maintenance of milk production).   
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Fig. 1. 4. Mammary morphogenesis - regulation and signals.  A long list of signals are 
implicated in the regulation of mammary morphogenesis, including extracellular matrix 
(ECM) molecules and proteases, milk-borne factors, hormones, and morpho-dynamics 
dictated by signalling between several cell types such as epithelial cells, myoepithelial 
cells and adipocytes. Modified and adapted from Joshi, Di Grappa et al. (2012). 
 
1.4.1 Hormonal regulation 
Hormones are major factors regulating the development and function of the mammary 
gland (Brisken 2002, Oakes, Hilton et al. 2006, Brisken and O'Malley 2010). These 
hormones that are necessary for mammary development, differentiation and milk 
secretion are broadly divided into two groups: the reproductive hormones including 
prolactin, estrogen, progesterone, oxytocin and placental lactogen, and the metabolic 
hormones including insulin, thyroid hormones and glucocorticoids. They act in two ways: 
1) a direct effect on mammary epithelial cells, or 2) indirectly by the local production of 
growth factors (Knight, Peaker et al. 1998). Among these hormones, the major lactogenic 
hormones are insulin (I), glucocorticoids (F) and prolactin (P) (Anderson and Larson 
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1970, Topper and Freeman 1980, Bolander, Nicolas et al. 1981, Nagaiah, Bolander et al. 
1981, Sheehy, Della-Vedova et al. 2004).  
1.4.1.1 Insulin  
Insulin is an integral component of cell culture media to maintain mammary organoids, 
alveoli and mammary epithelial cells for in vitro explant culture (Elias 1959). It has been 
difficult to elucidate the role of insulin in mammary development, since prolonged 
deprivation of the hormone leads to impaired metabolism in the animal (Neville, Webb 
et al. 2013). Recent studies using explant models of mouse, bovine and tammar wallaby 
have demonstrated that insulin is not required to maintain cultures of mammary tissue, 
but it is essential for milk protein gene expression (Brennan, Sharp et al. 2008). Thus, 
insulin plays a significant role in mammary gland differentiation (Topper and Freeman 
1980, Nicholas, Sankaran et al. 1983, Topper, Nicholas et al. 1984, Neville, Webb et al. 
2013). It was shown that insulin was required for the expression of milk protein genes in 
both cultured cells and explants in mice (Neville, Morton et al. 2001). The responsiveness 
of mouse mammary epithelial cells to insulin has been shown to vary according to the 
physiological state. More responsiveness has been observed during pregnancy and 
lactation, supporting terminal differentiation of mammary epithelium (Oka, Perry et al. 
1974). In order to identify if the ability of insulin in promoting milk protein gene 
expression is a unique ability of the hormone to maintain cells in culture, alternative 
factors were also tested for cell survival. Exogenous hormones like epidermal growth 
factor (EGF) (Bolander, Nicolas et al. 1981), fetal bovine serum (FBS) (Kulski, Nicholas 
et al. 1983) and insulin like growth factor 1 (IGF-1) (Bolander, Nicolas et al. 1981) did 
not to induce milk protein gene expression, but rather maintained the cells potential for a 
lactogenic response after delayed addition of insulin, cortisol and prolactin (IFP). Recent 
studies have shown a role for insulin in regulating the transcription of milk protein genes 
via the expression of Stat5a (Menzies, Lefevre et al. 2009).  
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1.4.1.2 Glucocorticoid 
The role of adrenal steroids in mammary gland differentiation and lactation has been 
shown by organ culture experiments (Topper and Freeman 1980, Brisken 2002) and organ 
ablation studies (Cowie, Forsyth et al. 1980). Glucocorticoids fall under the class of 
adrenal steroids and are important for maximal growth during mammary gland 
development and enhanced lobule formation during pregnancy (Topper and Freeman 
1980). During organ and explant culture, these hormones help in differentiation by 
maintenance of the extracellular matrix (Casey, Beocker et al. 2000). They also play a 
role in the maintenance and function of cell-cell contact in the mammary epithelium by 
inducing the formation of tight junctions (Zettl, Sjaastad et al. 1992). Due to their role in 
nutrient flux and maintaining high levels of glucose during starvation, they also have an 
indirect effect on lactation (Neville, McFadden et al. 2002). Glucocorticoids have been 
reported to act as lactogenic hormones both in vivo and in vitro, and play a role in the 
formation of rough endoplasmic reticulum, lactogenesis and casein mRNA expression 
(Topper and Freeman 1980).  
1.4.1.3 Prolactin 
Prolactin is secreted by the anterior pituitary gland and is involved in maintaining the 
secretion of estrogen and progesterone from the ovaries during early pregnancy in 
eutherians (Freeman, Kanyicska et al. 2000, Brisken 2002). Experiments with mammary 
explants show that prolactin is required for the induction of milk protein synthesis 
(Houdebine and Gaye 1975, Devinoy, Houdebine et al. 1978, Matusik and Rosen 1978, 
Nagaiah, Bolander et al. 1981, Kulski, Nicholas et al. 1983, Nicholas and Tyndale-Biscoe 
1985, Sheehy, Della-Vedova et al. 2004). Prolactin also stimulates lobulo-alveolar 
development during pregnancy in the mammary gland (Brisken 2002). It plays a 
dominant role in epithelial growth at parturition (Topper and Freeman 1980) by 
maintaining high levels coupled with a drop in progesterone levels for the activation of 
secretory cells leading to lactation (Neville, McFadden et al. 2002). The transcription of 
milk protein genes like caseins is regulated by prolactin, and it is essential to initiate and 
maintain milk production in the mammary gland (Norman and Litwack 1997, Trott, 
Vonderhaar et al. 2008). The role of prolactin in maintaining milk production and 
secretion in eutherians has been shown in studies where galactopoesis was suppressed 
 28 
 
when prolactin secretion was inhibited by bromocryptine (Kulski, Hartmann et al. 1978, 
Nicholas and Hartmann 1981) with a variable effect seen in ruminants (Benedek-
Jaszmann and Stermthal 1976). It has been reported that prolactin is also produced by 
mammary epithelial cells where it regulates mammary gland function in a paracrine 
fashion (Oakes, Hilton et al. 2006). Prolactin binds to the prolactin receptor (PRLR) 
resulting in the activation of both janus kinase (JAK)/signal transducer and activator of 
transcription (STAT) and protein kinase B (PKB)/thymoma viral proto-oncogene (AKT) 
pathways (Bole-Feysot, Goffin et al. 1998). This activates JAK2 and STAT5 transcription 
factors, required to induce the expression of most milk protein genes such as β-casein 
(Neville, Morton et al. 2001, Anderson, Rudolph et al. 2007).  
1.4.2 Extracellular matrix 
The extracellular matrix (ECM) is described as an interconnected meshwork of secreted 
proteins that interact with cells to form a functional unit (Bissell and Barcellos-Hoff 
1987). ECM synthesis and assembly in the mammary gland is a product of many different 
cell types including epithelial cells, myoepithelial cells, adipocytes, immune cells, 
endothelial cells and fibroblasts (Jalkanen, Rapraeger et al. 1988, Ekbolm, Lonai et al. 
2003, Kalluri 2003). The mammary ECM is divided into three broad structural categories 
- the highly specialized basal lamina directly abutting the basal side of the epithelial cells, 
inter and intralobular stroma immediately adjacent to the lobules and alveoli, 
respectively, and the fibrous connective tissue devoid of epithelium (Maller, Martinson 
et al. 2010). The basement membrane refers to the ECM adjacent to the epithelium and 
the basal lamina is the structure lying immediately beneath the epithelium (Farquhar 
1988). The major constituents of the basal lamina are laminins, collagen, nidogens and 
perlecan. The ECM provides physical support for overall tissue architecture and confers 
cellular functions like cell adhesion, survival, apoptosis, polarity, proliferation and 
differentiation through structural properties such as physical support, boundary 
constraints, classical signal transduction pathways and mechanosensory cues (Butcher, 
Allison et al. 2009). The relationship between the ECM and mammary epithelial cells is 
dynamic, reciprocal and comprises two way communication, where the ECM supports 
and instructs the cells, while the cells build, shape and re-shape the ECM (Bissell, Hall et 
al. 1982). Changes in ECM properties are communicated to the epithelial cells through 
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transmembrane receptors, providing a conduit between the ECM, cytoskeleton and 
transcriptional machinery (DeMalli, Wennerberg et al. 2003).  
The ‘Dynamic Reciprocity’ model proposed by Bissell and co-workers postulated that 
the ECM exerts an influence on milk protein gene expression through transmembrane 
proteins and cytoskeleton components (Bissell, Hall et al. 1982). In mouse mammary 
epithelial cells, the ECM plays a primary role in the maintenance of tissue specific 
function in culture (Aggeler and Bissell 1987, Aggeler, Park et al. 1988). The ECM-cell 
interaction in the mammary gland regulates epithelial cell polarity and milk protein gene 
expression and this occurs along with the action of lactogenic hormones (Topper and 
Freeman 1980, Aggeler and Bissell 1987). Cunha and co-workers demonstrated the 
importance of stromal epithelial interaction in mammary differentiation where 
undifferentiated cells acquired a mammary epithelial phenotype when they were cultured 
on mammary mesenchyma and the stroma mediated the cell’s proliferative response to 
hormones (Cunha, Young et al. 1995). Literature also provides evidence for the role of 
the ECM or its individual components in regulating the expression of many eutherian 
milk protein genes such as murine WAP (Lin, Dempsey et al. 1995) and β-casein (Li, 
Aggeler et al. 1987, Streuli, Bailey et al. 1991), bovine β-casein (Schmidhauser, Bissell 
et al. 1990) and rabbit α-S1 casein (Jolivet, Meusnier et al. 2001).  
1.4.3 Other cell types 
In addition to the secretory epithelial cells, the mammary gland contains different cell 
types including myoepithelial cells, adipocytes, fibroblasts and immune cells and the cell-
cell interaction between these different cell types influences mammary gland function 
and regulates milk protein synthesis (Levine and Stockdale 1984, Levine and Stockdale 
1985, Polyak and Kalluri 2010). The different cell types generate signals in the mammary 
gland for local regulation of the secretory epithelium and these regulatory mechanisms 
are under paracrine control (Knight 1995).  
1.4.3.1 Myoepithelial cells 
One of the major cell types of the mammary gland that are in direct contact with the 
secretory epithelial cells are the myoepithelial cells. These are known to influence cell 
polarity, proliferation and differentiation of the epithelial cells, in addition to the 
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production of the basement membrane which forms a physical barrier for the mammary 
gland (Polyak and Kalluri 2010). The myoepithelial cells participate in the process of 
milk ejection by assisting in the contraction and release of milk from the epithelial cells 
into the alveolar lumen, thus playing a primary role in mammary gland function and 
lactation (Sopel 2010). Different factors control this contractile function, namely 
oxytocin, smooth muscle proteins, myosin light chains, transcription factors and 
appropriate cell-ECM interactions (Moumen, Chiche et al. 2011). In addition to these 
basic roles, myoepithelial cells may have other roles (Bonnet, Gourdou et al. 2002, 
Gudjonsson, Ronnov-Jessen et al. 2002, Adriance, Inman et al. 2005, Barsky and Karlin 
2005) that remain to be investigated in detail.  
1.4.3.2 Adipocytes and fibroblasts 
Stromal fibroblasts and adipocytes are the other cell types in the mammary gland that 
influence gland differentiation. The role of cell-cell interactions in mammary gland 
function was confirmed by co-culturing experiments where the mammary epithelial cells 
demonstrated a growth promoting activity due to interaction with adipocytes (Levine and 
Stockdale 1984). This also influences the sensitivity of the mammary epithelial cells to 
lactogenic hormones, thus resulting in increased milk protein production and mammary 
differentiation (Levine and Stockdale 1985). When these two cell types are co-cultured, 
there is a bidirectional regulatory interaction between the cells resulting in increased 
responsiveness of mammary epithelial cells to estrogen, which is essential for mammary 
gland function (Haslam 1988).  
1.4.3.3 Caveolins 
Caveolins form the primary structural component of flask shaped invaginations on the 
plasma membrane of almost all cell types (Bruns and Palade 2004). The caveolins are a 
family of three proteins: Caveolin 1, 2 and 3. Studies conducted in the past decade have 
demonstrated a role for the caveolin group of genes in regulating lactation in the mouse 
by prolactin via a Ras-p42/44 MAPK-dependent pathway (Park, Lee et al. 2001, Park, 
Lee et al. 2002). The expression of caveolin 1 and 2 genes in the mouse mammary gland 
was elevated before and during early pregnancy, down-regulated during lactation and 
subsequently up-regulated with the onset of involution to levels similar to the non-
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pregnant state (Park, Lee et al. 2001). In mice, genetic ablation of the caveolin 1 gene 
resulted in enhanced mammary gland development and premature onset of lactation 
through hyper-activation of STAT5 (Park, Lee et al. 2002, Sotgia, Schubert et al. 2006). 
This regulation came from the caveolins that were localized in the myoepithelial cells and 
adipocytes, and not the mammary epithelial cells (Hue-Beauvais, Pechoux et al. 2007). 
Thus, there is paracrine regulation of lactation due to cell-cell interaction between the 
mammary epithelial cells, adipocytes and myoepithelial cells, and this in turn is mediated 
by lactogenic hormones (Park, Lee et al. 2001, Sotgia, Casimiro et al. 2009). A recent 
study has shown that a complex interplay of hormones is involved in regulating the 
caveolin group of genes (Kuruppath, Sharp et al. 2014).  
 
1.5 Involution 
Post-natal mammary gland development occurs in a cyclical fashion with each 
pregnancy. Although lactation is the functionally climactic stage of the mammary gland, 
proper execution of involution, resolution and breakdown of the gland is also important 
for pristine functioning of the gland in subsequent lactation cycles (Pai and Horseman 
2011). Involution is the process of restoration of the lactating gland to a virgin-like state 
in which the epithelial cells return to a rudimentary state (Green and Streuli 2004, Watson 
2006). Several events occur in a harmonious manner to accomplish this process. These 
events include milk stasis and inhibition of milk secretion, cell death leading to epithelial 
regression, clearance of debris and immune response, disruption of epithelial tight 
junction and barrier regulation, ECM remodeling, adipose tissue repopulation and 
vascular remodeling. Fig. 1.5 briefly demonstrates the events involved in the involution 
process in a mouse mammary gland. 
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Fig. 1. 5. Mouse mammary gland involution. Schematic representation of the two 
phases of murine mammary gland involution – reversible first phase involution and 
irreversible second phase involution. Phase I involution is characterized by accumulation 
of milk due to cessation of suckling and is induced by local factors such as an increase in 
pro-apoptotic factors and activation of stretch receptors. Phase II involution is 
characterized by extensive ECM remodeling and re-population with adipocytes, returning 
the gland to a pre-pregnant state. Modified and adapted from Watson (2006).  
 
The physiology and genetics of cell death can be studied in the mouse mammary gland. 
Within 6 days of weaning, most of the secretory epithelium is removed and the gland is 
returned to a pre-pregnant state. Forced weaning facilitates the study of apoptosis in the 
mouse mammary gland, in which pups are removed from the mother at the peak of 
lactation and prior to natural weaning (Wilde, Knight et al. 1999). Earlier studies have 
demonstrated that forced involution and glucocorticoid administration reveals two phases 
of involution based on reversibility (Lund, Romer et al. 1996). The first phase is 
reversible and lasts for 48 hours and the second phase initiates a remodeling program 
returning the gland to a virgin-like state (Lund, Romer et al. 1996). Teat sealing 
experiments have revealed that if the pups are returned to the mother within 48 hours, 
apoptosis can be halted and lactation can re-commence (Green and Streuli 2004). The 
first phase of involution is regulated by local factors within the mammary gland (Li, Liu 
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et al. 1997, Marti, Feng et al. 1997) while the second phase is influenced by circulating 
factors such as hormones, and can be halted by the administration of glucocorticoids 
(Feng, Marti et al. 1995, Lund, Romer et al. 1996), possibly through the maintenance of 
tight junctions (Zettl, Sjaastad et al. 1992). The remodeling phase also depends on the 
activation of specific matrix metallo-proteases (MMPs), whose function is blocked by the 
expression of tissue inhibitors of metalloproteases (TIMPs) in the first phase of involution 
(Green and Lund 2005). 
A vast number of genes are implicated in involution and these are summarized in table 
1.2. Most of this data was obtained from genetically modified mice and subtle involution 
phenotypes, hence crosstalk between pathways needs to be considered. 
Table 1. 2. Regulators of apoptosis, involution and tissue remodeling 
 Gene  Function Assessment method 
Factors inhibiting involution and/or cell death 
IRF-1 Transcription factor Gene deletion 
Stat5 Transcription factor Overexpressing 
transgenic 
TIMP-3 MMP Inhibitor Gene deletion 
SOCS-3 Cytokine signalling 
regulator 
Conditional gene 
deletion 
Akt Serine/threonine kinase Overexpressing 
transgenic 
Sim2s Transcription factor Overexpressing 
transgenic 
Bcl2 Apoptosis regulator Overexpressing 
transgenic 
Bcl-x Apoptosis regulator Conditional gene 
deletion 
IGF-I Growth factor Overexpressing 
transgenic 
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IGF-II Growth factor Overexpressing 
transgenic 
JAK2 Kinase Constitutively active 
mutant 
Factors promoting involution and/or cell death 
Stat3 Transcription factor Conditional gene 
deletion 
c/ebpδ Transcription factor Gene deletion 
IKK2/β Regulatory kinase Conditional gene 
deletion 
 p53 Transcription factor Gene deletion 
PTEN Lipid phosphatase Overexpressing 
transgenic 
IL-6 Cytokine Gene deletion 
LIF Cytokine Gene deletion 
FasL Cytokine Gene deletion 
IL-10 Cytokine Gene deletion 
Bax Apoptosis regulator Gene deletion 
Cathepsin L Cysteine protease Specific inhibitor 
ATF4 Transcription factor Overexpressing 
transgenic 
Smad3 TGF- β signalling 
mediator 
Gene deletion 
IGFBP-5 IGF inhibitor Overexpressing 
transgenic 
Αlpha-lactabumin 
multimers 
Milk protein Culture studies 
Mnt Transcription repressor Conditional gene 
deletion 
Factors affecting remodeling and/or biosynthesis 
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Plasmin Serine protease Gene deletion 
Mfge8 Phagocytosis regulator Gene deletion 
Kallikrien Plasminogen activator Inhibitor studies 
MMP3 Protease Gene deletion 
   
Adapted from Watson and Kreuzaler (2011). 
 
1.5.1 Involution phase I 
Phase I of involution is characterized by the accumulation of milk within the lumen of 
the alveoli, reduction in milk protein production and mammary epithelial cell apoptosis 
(Furth 1999, Marti, Ritter et al. 2001, Green and Streuli 2004). Characteristic markers of 
this phase in mouse include the following: apoptotic morphology of the mammary 
epithelial cells, pronounced cleavage of chromatin into oligonucleasomal fragments 
forming DNA ladders on agarose gels and activation of intrinsic apoptosis regulators such 
as effector caspases. These markers are observed within two days of removal of the pups 
(Strange, Li et al. 1992, Lund, Romer et al. 1996, Metcalfe, Gilmore et al. 1999, Prince, 
Klinowska et al. 2002). At this stage, pro-apoptotic factors are up-regulated while 
survival factors are reduced (Green and Streuli 2004). During phase I of involution, the 
cells undergo a primary apoptotic process since apoptosis occurs when the basement 
membrane is largely intact (Lund, Romer et al. 1996). Recent microarray analysis has 
shown that the first 24 hours of involution in the mouse results in increased expression of 
acute phase response genes and inflammatory cytokines (Clarkson, Wayland et al. 2004). 
This is followed by induction of markers of matrix proteases, phagocyte activity, 
suppressors of neutrophils and soluble components of specific and innate immunity 
(Clarkson, Wayland et al. 2004). The damaging effects of a cellular inflammatory 
response at this stage are suppressed by immunomodulatory signals, which helps 
maintain an antimicrobial and phagocytic environment (Clarkson, Wayland et al. 2004). 
Transcriptional profiling data subdivides the two functional phases of involution into four 
discrete transcriptional events (Clarkson, Wayland et al. 2004, Stein, Morris et al. 2004). 
These are marked by four clusters of genes that have distinct temporal expression 
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patterns. One subset of genes is induced dramatically within 12 hours of forced involution 
and whose expression declines rapidly thereafter. This suggests that the mechanism 
triggering cell death in the first phase of involution is different than in the second phase. 
It is not clear whether these four distinct transcriptional events are different from the two 
morphological phases hence, demonstrating that cell death appears to be a stochastic 
process (Watson and Kreuzaler 2011). Also, the non-epithelial cells of the gland, both 
adipocytes and the vasculature, are modified during involution, and phagocytes are 
essential for clearing the cell debris and milk components from the gland (Watson and 
Kreuzaler 2011).  
1.5.2 Involution phase II 
The architecture of the mammary gland remains intact during the first phase of involution 
(Furth, Bar-Peled et al. 1997), however, post 48 hours, when the transition to the second 
phase occurs, the lobulo-alveolar structure begins to collapse due to the action of 
proteases (Sympson, Talhouk et al. 1995, Lund, Romer et al. 1996). Secondary apoptosis 
of the mammary epithelial cells occurs as the cells lose contact with the extracellular 
matrix and the basement membrane (Boudreau, Sympson et al. 1995, Boudreau, Werb et 
al. 1996). It has been reported that the percentage of cells undergoing apoptosis at any 
given time in this phase is less than the percentage of apoptotic cells observed in phase I 
involution (Heermeier, Benedict et al. 1996). The second phase of involution is regulated 
by MMPs and serine proteases, which break down the ECM and activate plasminogen 
resulting in secondary apoptosis and tissue remodeling (Green and Lund 2005) (Fig. 1.6). 
Stromal cells primarily express MMPs, and MMP2, MMP3, MMP9 and MMP11 are 
expressed during involution, when their function is remodeling of the matrix. MMPs 
cleave a variety of substrates such as collagen IV, E-cadherin and chemokines, which 
facilitates cell detachment (Watson and Kreuzaler 2011). Thus, MMPs have a dual role 
as remodelers of the architecture of the gland and facilitate apoptosis, as removal of the 
matrix induces epithelial cell apoptosis (Pullan, Wilson et al. 1996). Thus, cells that fail 
to respond to death signals in the first phase will be induced to die in the second phase of 
involution by detachment induced apoptosis, anoikis (Watson and Kreuzaler 2011). 
Anoikis is the form of apoptosis induced by lack of correct cell-ECM attachment 
(Gilmore 2005). In order to maintain the reversibility of the first phase, it is very 
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important that are the MMPs are not activated at that stage. This is achieved by the 
cognate inhibitors, TIMPs (Watson 2006). TIMP3, an inhibitor of MMP2 plays an 
important role in involution and this has been demonstrated by accelerated involution in 
TIMP3 deficient mammary glands and loss of reversibility of the first phase (Fata, Leco 
et al. 2001). Along with the loss of mammary epithelium, there is adipocyte 
differentiation to re-populate the fat pad and this process requires plasmin and MMP3 
(Lund, Romer et al. 1996, Alexander, Selvarajan et al. 2001). The remodelling process 
has another important constituent, phagocytosis. This involves both autophagy and 
phagocytosis by professional and non-professional phagocytes and removal of cells and 
debris (Monks, Rosner et al. 2005). The activated inflammatory mediators from phase I 
involution signal the influx of macrophages for debris clearance (Stein, Morris et al. 
2004). The anti-inflammatory mediators balance the activity of these signals and prevent 
overt inflammation (Clarkson, Wayland et al. 2004, Stein, Morris et al. 2004). Stat3 and 
NF-κB are two signalling pathways that moderate the death/survival balance and the 
inflammatory response (Chapman, Lourenco et al. 1999).  
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Fig. 1. 6. MMP protease systems and plasminogen involved in matrix remodeling 
during mammary gland involution. The stromal fibroblasts play a key role in ECM/BM 
remodeling. The first phase of involution sees high expression of maspin by myoepithelial 
cells and TIMPs by fibroblasts to prevent expression of MMPs. Further, the ECM 
breakdown is also facilitated by low levels of pro-uPA and pro-MMP expression by 
fibroblasts. During phase II of involution, there is down-regulation of TIMPs and maspin 
and a concomitant up-regulation of pro-uPA and pro-MMPs, resulting in uPA mediated 
generation of plasmin from circulating plasminogen. Plasmin breaks down the ECM/BM 
and activates MMPs. MMPs further induce ECM/BM breakdown. Abbreviations: BM - 
Basement Membrane, ECM - Extra-Cellular Matrix, MMPs - Matrix Metalloproteases, 
TIMPs - Tissue Inhibitor of MMP, uPA - urokinase Plasminogen Activator. Adapted 
from Pai and Horseman (2011). 
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 1.5.3 Triggers of involution 
The first phase of involution is thought to be initiated by mammary derived signals, since 
the artificial administration of exogenous lactogenic hormones to epithelial cells does not 
affect apoptosis, but it prevents remodeling of the mammary gland (Li, Liu et al. 1997). 
Milk stasis is likely to be the primary trigger, as teat sealing experiments have 
demonstrated that sealing one teat during lactation leads to accumulation of milk, thus 
inducing involution, whereas the other teats continue to lactate (Marti, Feng et al. 1997). 
Several mechanisms act as primary events to trigger apoptosis and involution (Green and 
Streuli 2004) (Fig. 1.7).  
 
 
Fig. 1. 7. Possible triggers of apoptosis at the onset of involution. (a) The columnar 
cells are normal, red ovals with tight junctions that seal their apical interfaces and interact 
with basally located myoepithelial cells (not shown in the figure) and the basement 
membrane (blue line). (b, c) When there is no milk removal, the alveoli expand leading 
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to luminal cell stretching. This may activate stretch receptors (b) or cause tension on cell-
cell adhesion molecules (c) that induces apoptosis. (d) Pro-apoptotic factors that are 
excreted in normal conditions accumulate due to cessation of suckling and trigger 
apoptosis through apically located receptors (green arrow). (e.f) Tight junction 
deregulation leads to re-location of pro-apoptotic factors to the basal cell surface, leading 
to direct triggering of apoptosis (e) and/or inhibition of survival factors (f). Adapted from 
Green and Streuli (2004).  
 
There are several theories suggesting how milk stasis might initiate involution, including 
build-up of secreted factors in milk or mechanical stretch of the alveolar epithelium due 
to retention of milk in the alveolar lumen (Quaglino, Salierno et al. 2009). The pro-
apoptotic factors in milk are normally removed from the mammary gland by nursing. 
Feedback inhibitor of lactation (FIL) is a protein that is known to be synthesized and 
secreted in milk, and acts specifically through interaction with the epithelial cell apical 
surface to reduce secretory efficiency by inhibiting protein movement (Wilde, Addey et 
al. 1995, Hendry, Simpson et al. 1998, Wilde, Addey et al. 1998). This autocrine 
mechanism causes sensitivity to frequency and completeness of milk removal. This 
feedback mechanism of FIL matches the supply of milk to the demands of the suckling 
offspring (Rennison, Kerr et al. 1993, Peaker and Wilde 1996, Hendry, Simpson et al. 
1998, Wilde, Addey et al. 1998). It has been shown that chemically induced forms of 
LALBA and its fragments can cause apoptosis of mammary epithelial cells (Hakansson, 
Andreasson et al. 1999, Permyakov, Pershikova et al. 2004). When multimeric LALBA 
(MAL) was isolated from human casein by ion-exchange chromatographic fractionation 
at low pH, it comprised monomeric and oligomeric forms (Hakansson, Zhivotovsky et al. 
1995, Svensson, Sabharwal et al. 1999). The apoptosis inducing component was a folding 
variant of MAL that had undergone a conformational change to a molten globule-like 
state, and it was stabilized by the incorporation of fatty acids (Kohler, Gogvadze et al. 
2001). The native LALBA can be converted from a monomer into an apoptosis inducing 
variant and exposure to this new form, HAMLET (Human LALBA made lethal to tumor 
cells), causes apoptosis in tumor cells and spares healthy cells (Svensson, Hakansson et 
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al. 2000). In order to bring about partial unfolding of the LALBA protein to bind a fatty 
acid co-factor and acquire apoptotic potential, the bound calcium was removed with 
EDTA, followed by application of the partially unfolded protein to an oleic acid 
conditioned ion-exchange matrix. The resulting product was eluted with a high 
concentration of salt (Svensson, Hakansson et al. 2000). Commercial preparations of 
bovine LALBA have shown direct apoptotic effects on the IEC-6 cell line, a non-
transformed crypt cell line from rat small intestine (Xu, Sugiura et al. 2005). Apoptotic 
effects of bovine LALBA on primary seal mammary epithelial cells has also been 
demonstrated (Sharp, Lefevre et al. 2008). Fur seals are a unique example, where milk 
stasis is uncoupled from epithelial regression (Sharp, Lefevre et al. 2007b). Lactating fur 
seals go on long foraging trips mandating the suspension of suckling. Also, the 
composition of milk in these animals is very different from that of other mammals 
(Schmidt, Walker et al. 1971, Urashima, Arita et al. 2001). Specifically, the milk protein 
LALBA, present in most other species, is completely absent in fur seals, emphasizing the 
important role of LALBA in epithelial regression (Sharp, Lefevre et al. 2008). Thus, it 
has been suggested that a LALBA structure with properties similar to HAMLET is 
naturally found in milk and may be a trigger of involution. 
When there is cessation of suckling, milk accumulation can cause engorgement of the 
mammary gland leading to changes in cell shape and stretching of mammary epithelial 
cells. This could be another possible trigger of involution. Two possible mechanisms for 
this trigger are: firstly, milk accumulation in the lumen leads to activation of stretch 
receptors (Green and Streuli 2004) and secondly, the interaction of epithelial cells with 
the ECM can be altered through focal adhesion complexes (Singh, Dobson et al. 2005). 
When milk accumulates, cell-cell adhesion complexes such as tight junctions and 
adherent junctions become stretched and leaky (Green and Streuli 2004). The formation 
of these tight junctions is dependent on glucocorticoids and studies have revealed that 
implantation of glucocorticoid pellets in lactating mouse mammary gland prevents 
involution (Zettl, Sjaastad et al. 1992, Feng, Marti et al. 1995). Thus, declining hormone 
levels lead to fragility of tight junctions, causing diffusion of pro-apoptotic factors from 
the apical to the basolateral side of the epithelial cells inducing apoptosis and involution 
(Stelwagen, Davis et al. 1994, Stelwagen, Farr et al. 1997).  
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In response to cessation of suckling, milk accumulates locally within the mammary gland, 
increasing the expression of transforming growth factor β (TGF- β), leukemia inhibitory 
factor (LIF) and death receptor ligands, which in turn trigger the induction of apoptosis 
through the death receptor pathways, JAK/STAT and PKB pathway (Watson 2006). For 
apoptosis to be induced, the signals of involution pathways need to connect to the 
apoptotic machinery. In general, apoptosis involves the activation of intracellular 
proteases called caspases, although some caspase independent mechanisms are also 
known (Lockshin and Zakeri 2002, Shi 2002). There are two independent mechanisms 
through which the link between the apoptotic signal and caspase activation can occur, 
namely, the intrinsic or extrinsic pathway. Some of the different caspases that are 
activated during involution of the mammary gland are caspases 1, 3, 7, 8, 9 and 10 (Marti, 
Ritter et al. 2001). There is an increase in shed cells positive for the activated form of 
caspase 3 by 12 hours and 72 hours of involution that can be detected within the alveolar 
wall (Prince, Klinowska et al. 2002, Baxter, Came et al. 2006). Caspase 3 plays an 
important role in the apoptosis of mammary epithelial cells, since it is frequently either 
lost or inactivated in breast cancer (Devarajan, Sahin et al. 2002).  
A recent study (Uejyo, Kuki et al. 2014) has investigated the temporal changes in milk 
production ability following weaning in conjunction with the progression of mammary 
involution. Based on the number and location of caspase-3 positive shed cells, the study 
revealed that the first phase of involution occurs approximately 24 hours after weaning 
and phase II occurs between 48 and 72 hours post-weaning. An interesting observation 
made in this study was that the alveolar epithelial cells displayed changes in certain 
aspects of milk production as early as 1 hour post weaning and gradually ceased milk 
production between 3 and 24 hours after weaning. The report concluded that mammary 
gland involution per se begins after the cessation of milk production in epithelial cells in 
mice (Uejyo, Kuki et al. 2014). This conclusion is more efficient in explaining the 
progression of events post weaning in the animal than if cessation of milk production and 
involution occur concurrently. It has also been shown that milk production by epithelial 
cells is down-regulated along with activation and inactivation of STAT3 and STAT5 
respectively (Fig. 1.8).  
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Fig. 1. 8. Functional time-course of involution. Milk production by epithelial cells is 
down-regulated before phase I of involution along with activation and inactivation of 
STAT3 and STAT5. Adapted from Uejyo, Kuki et al. (2014). 
 
Thus, the mammary epithelial cells follow a functional time course of involution and 
several changes in milk production ability occur in the cells after suckling and prior to 
involution. This also supports the thought that there is a paracrine regulation of lactation 
due to cell-cell interaction between the mammary epithelial cells, adipocytes and 
myoepithelial cells, possible through caveolins (reviewed earlier in section 1.4.3.3). 
Although historical observation and different research groups agree that accumulation of 
milk is fundamental for the onset of involution (Talhouk, Bissell et al. 1992, Lund, Romer 
et al. 1996, Quarrie, Addey et al. 1996, Li, Liu et al. 1997), the explicit signal for 
mammary epithelial cell apoptosis still remains to be identified. 
1.5.4 Mechanisms of cell death and mammary gland remodeling during involution 
Until recently, it was presumed that the mechanism for destruction of the secretory 
epithelial cells during involution is apoptosis, a form of programmed cell death that 
happens in all multicellular organisms. However, recent studies have made it apparent 
that there are multiple cell death pathways and as many as 10 genetically programmed 
cell death pathways that occur in different situations and in response to diverse stimuli 
(Melino, Knight et al. 2005). The dying cells that are shed into the alveolar lumen 
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following detachment have a morphology that is not classically apoptotic (Watson and 
Kreuzaler 2011). They appear swollen, lack membrane blebbing and have two 
hypercondensed nuclei. They also show no characteristic feature of entosis (Overholtzer, 
Mailleux et al. 2007). However, there was still activation of caspases, a characteristic 
apoptotic mechanism. This unusual morphology is attributed to induction of a lysosomal 
pathway of cell death by Stat3, and this pathway is independent of caspases (Kreuzaler, 
Staniszewska et al. 2011). Stat3 upregulates lysosomal enzymes cathepsin B and 
cathepsin L, while down-regulating expression of their inhibitor Spi2a. This cathepsin 
leak from the lysosomes initiated cell death during involution, resulting in shedding of 
cells into the alveolar lumen. In response to anoikis from detachment of neighbouring 
alveolar cells, caspases 3 and 6 become activated and cleaved. Another possible 
mechanism is the occurrence of macroautophagy during involution. Cells usually initiate 
this survival mechanism during starvation in order to recycle cellular components 
(Kroemer and Levine 2008). The reversibility of the first phase of involution could be 
explained by an autophagy mechanism, although there is no definitive evidence of this 
yet. 
In spite of extensive cell death during involution, the architecture of the gland does not 
change during the first 48 hours of involution. However, as soon as the transition to 
second phase occurs, the alveoli start to collapse and adipocytes begin to re-differentiate 
to fill the fat pad (Wilde, Knight et al. 1999, Watson 2006). It is still not clear what the 
trigger is for the switch to irreversible remodeling of the mammary gland. One theory 
postulates that it is a simple consequence to loss of too many epithelial cells, and 
reduction in adhesion between neighbouring cells (Green and Streuli 2004)t. Although it 
is clear that cells are stretched due to gland engorgement during involution, no obvious 
breaks in integrity have been observed to date. It is more likely that the transition is caused 
by changes in systemic hormone levels leading to induction of expression of ECM 
degrading proteases such as MMPs and serine proteases that activate plasminogen 
(Watson and Kreuzaler 2011).  
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1.5.5 Involution and its connection to breast disease  
The most common breast pathologies include mastitis, ectasia, inflammation and breast 
cancer. In spite of the variation in the causative agents of these pathologies, the common 
thread that connects them is the localized accumulation of secreted fluid as a result of 
ductal blockage. This fluid accumulation occurs at a time and place outside the normal 
homeostasis leading to the aforementioned complications. However, in theory, a 
persistent fluid accumulation should trigger localized involution related responses such 
as gene expression changes, cell shedding, apoptosis and ECM remodeling. Hence, there 
exists a critical connection between breast pathologies and the involution response. When 
these involution responses occur at a place and time when the mammary gland is not 
equipped with professional and non-professional phagocytes, it results in activation of 
immune components resulting in inflammation. Such breast pathologies have been linked 
to increased breast cancer risk and facilitate aggressive and metastatic cancers (Clarkson, 
Wayland et al. 2004, Stein, Morris et al. 2004, Hayanama and Nagata 2005, Atabi, 
Sheppard et al. 2007). Involution is subject to extensive regulation and it has been shown 
in transcriptional profiling studies that rapid and extensive tissue remodeling mimics the 
wound healing process and pathological conditions such as tumourigenesis (Clarkson and 
Watson 2003), thus raising the possibility that involution might create a tumor 
microenvironment by facilitating the outgrowth of premalignant cells in the mammary 
gland (Schedin 2006). Experiments previously carried out have validated this possibility, 
where ECM isolated from post-lactational mammary glands have been shown to contain 
tumorigenic ECM fragments, which facilitate the invasiveness of breast cancer cells in 
culture and also increase metastasis in breast cancer animal models (Bemis and Schedin 
2000, McDaniel, Rumer et al. 2006). It has been shown in studies of MMP-9-null mice 
that proteases are crucial for the survival and establishment of distant metastases 
(Yamagushi, Lorenz et al. 2005). Thus, although involution is a highly controlled process, 
the process of tissue breakdown and remodelling is not without risk (Radisky and 
Hartmann 2009).   
Age-related lobular involution is another distinct process involving the replacement of 
glandular epithelium and interlobular connective tissues with fat. Unlike involution that 
occurs post-lactationally, this process happens with the age of the organism (Macias and 
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Hinck 2012). All that remains in an aged breast are a few acini and ducts embedded in 
thin strands of collagen. This epithelial tissue reduction has two benefits in the diagnosis 
and development of breast cancer. Firstly, the effectiveness of mammography is increased 
due to the high ratio of fat to epithelium, and secondly, the epithelial tissue reduction 
physiologically protects the breast from cancer. A recent clinical study has supported this 
with evidence that premenopausal women with breasts that have undergone partial or 
complete lobular involution have considerably decreased risk of breast cancer, while 
postmenopausal women with delayed lobular involution have elevated breast cancer risk 
(Milanese, Hartmann et al. 2006). Thus, a fundamental protective event, possibly the 
depletion of mammary stem cells in the aging breast that occurs with lobular involution 
reduces the risk of breast cancer (Macias and Hinck 2012). 
1.5.6 Experimental culture models to study involution 
The majority of in vitro experiments used to study the regulation of genes and molecular 
pathways involved in apoptosis have been cell culture based models (Gordon, Binas et 
al. 2000, Campbell and Watson 2009, Jechlinger, Podsypanina et al. 2009). However, 
whole organ culture and mammary explants have also been used to investigate mammary 
involution (Atwood, Ikeda et al. 1995, Casey, Chen et al. 1996). The alveoli and small 
terminal ducts of mouse explants show degeneration in the absence of added hormones, 
while the larger ducts retained their cellular architecture and contained viable cells (Elias 
1959). Mammary cells are maintained in their natural environment in mouse mammary 
whole organ culture (Ichinose and Nandi 1966). The mammary glands are hormonally 
stimulated to undergo lobulo-alveolar differentiation during whole organ culture and they 
express casein mRNA (Ganguly, Ganguly et al. 1981). Unlike mammary explants, the 
presence of insulin alone does not maintain the tissue, as removal of all hormones except 
insulin causes mammary epithelial cell apoptosis (Ganguly, Ganguly et al. 1981, Atwood, 
Ikeda et al. 1995).   
The mammary gland consists of ductal cells, milk producing alveolar epithelial cells 
embedded in stromal connective tissue and the mammary fat pad. The mammary 
epithelial cells are organized into three dimensional structures, which are strongly 
dependent on a polarized morphology, with specific attachment to an underlying 
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basement membrane and specialized cell-cell contacts (Fig. 1.9). Cellular organization is 
also influenced by signalling from neighbouring cells and mechanical forces. These 
features contribute to the proper control of cell survival, proliferation, differentiation, 
migration and milk protein secretion (Rodriguez-Boulan and Salas 1989, Bissell, Radisky 
et al. 2002, O'Brien, Zegers et al. 2002). Under normal conditions, mammary epithelial 
cells organize into spheroids called ‘acini’. These are characterized by a central, hollow 
lumen surrounded by polarized epithelial cells, and the three dimensional organization is 
largely dependent on specific cell-matrix and cell-cell interactions.   
 
 
 
 
 
 
 
 48 
 
 
  
Fig. 1. 9. Mammary epithelial cell architecture. Normal mammary epithelial cells 
(MECs) are organized into spheroids called acini with a hollow central lumen surrounded 
by polarized epithelial cells. The MECs are surrounded by other cell types such as 
myoepithelial cells and adipocytes and are in contact with the extracellular matrix (ECM). 
The 3 dimensional organization of the MECs regulates proliferation, migration and 
differentiation and strongly depends on specific cell-cell and cell-matrix interactions. 
Changes in mechanical stress cause disruption of these interactions leading to changes in 
the signalling pathways governing cellular architecture. Modified and adapted from 
McGee, Lanigan et al. (2006). 
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The mammosphere model is based on this organized architecture of the mammary 
epithelial cells in the mammary gland (Fig. 1.10). A mammosphere is a three dimensional 
in vitro model made of polarized epithelial cells having similar functionality to secretory 
alveoli (Romagnolo and DiAugustine 1994, Mailleux, Overholtzer et al. 2008) and they 
develop on an ECM. Mammary epithelial cells cultured on ECM form a hollow lumen 
and upon lactogenic hormone induction synthesize milk proteins that are secreted into the 
lumen (Romagnolo and DiAugustine 1994, Mailleux, Overholtzer et al. 2008).  
 
Fig. 1. 10. The mammosphere model. Mammary epithelial cells on an ECM form 
spheroids with a central lumen. Upon lactogenic hormone induction, milk is secreted into 
the lumen. Adapted from Romagnolo and DiAugustine (1994). 
 
This mammosphere model was used in our study to understand the extracellular matrix 
interactions, cell-cell interactions, effect of milk borne factors and other regulatory 
pathways that govern the organization of the mammary epithelial cells during murine 
mammary gland involution.  
 
Extracellular matrix 
Mammary epithelial cells 
form mammospheres 
Lumen 
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1.6 Alpha-lactalbumin and nano-oncology 
Cancer is a generic term representing a large group of diseases that can affect any part of 
the body. It is a leading cause of death worldwide and according to World Health 
Organization survey, it accounted for around 7.6 million deaths worldwide in 2008, which 
is approximately 13% of all deaths. The toll of death due to cancer has been projected to 
continue to increase to over 11 million in 2030 (American Cancer Society Facts and 
Figures). More than 30% of cancer deaths can be prevented by avoiding risk factors. The 
primary stage of cancer is when the cancerous tissue is still contained in the organ and is 
typically no more than 2-3 cm in size. When this tumour tissue metastases to other parts 
of the body, it becomes secondary stage cancer (Heppner 1984). Current treatment 
modalities include chemotherapy, radiation therapy, surgery and other hybrid therapies. 
Though there has been advancements in conventional therapies, we need new and more 
efficient treatment plans. This review (below) highlights ways to explore and harness the 
use of nanotechnology to provide new opportunities in the development of better 
treatment regimes for both primary and secondary tumours.  
1.6.1 Cancer 
As discussed previously, involution is linked to cancer (Section 1.5.5). Cancer is a large, 
heterogeneous group of diseases characterized by abnormal and uncontrolled 
proliferation of cells leading to invasion and destruction of adjacent tissues and 
sometimes metastasis (spreading to other locations of the body through the blood stream 
or lymphatic system) (Anand, Kunnumakkara et al. 2008). A malignant growth resulting 
from such a division of cells is called a tumour (Heppner 1984). A single cancerous cell 
in a normal, healthy tissue can replicate at a much higher rate when compared to the other 
cells, placing a constraint on the nutrient supply and elimination of metabolic waste. The 
healthy tissue finds it difficult to compete with the formed tumour mass for supply of 
nutrients from the blood stream. At a certain stage, the healthy cells get displaced by the 
tumour cells and this happens until the tumor reaches a diffusion limited maximal size. 
The continued supply of nutrients is obtained by the growing tumor mass from the dilated 
vasculature which was earlier used by the now extinct healthy tissue (Heppner 1984). The 
tumour grows beyond a particular size when it is able to establish a better connection with 
the circulatory system. This happens when it starts recruiting and controlling the 
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formation of blood vessels to fuel its expansion. A number of such diffusion limited 
maximal size tumours may exist in the body and in certain cases, their process of 
expansion may take several years (Jones and Harris 1998). Cancer can involve any kind 
of body tissue and has different forms in each body area with different rates of growth 
and spreading. Tumours can be malignant or benign depending on their properties (Dingli 
and Nowak 2006). Benign tumours are not cancerous as they do not have uncontrolled 
growth, invasion locally or metastatic properties (Boveri 2008). Cancer can be broadly 
classified based on the tumour resemblance and origin into the following categories: 
Carcinoma – derived from epithelial cells. Eg: breast, colon, prostrate, lung and pancreas, 
Lymphoma and leukemia – arising from hematopoietic cells, Sarcoma – derived from 
connective tissue (fat, nerve, bone, cartilage), Blastoma – arising from embryonic tissue 
or immature precursor cells and Germ cell tumour – derived from pluripotent cells present 
in the ovary and testicle. 
 
1.6.2 Current treatment plans and their drawbacks 
The treatment plans for cancer depend on the stage and type of cancer. Current cancer 
therapy involves chemotherapy, the use of drugs to shrink the tumour, surgery to remove 
it completely (if possible), intrusive methods such as the application of catheters to deliver 
chemotherapeutic drugs, radiation therapy, hormone therapy and other biologic therapy 
(Bezjak, Lee et al. 2008). Side-effects of these treatments depend on the specificity of the 
therapeutic agent and the dosage (Zhao and Rodriguez 2013). The effectiveness of any 
treatment lies in its ability to target and kill specifically the cancer cells while affecting 
as few healthy cells as possible. Unfortunately, the conventional treatments have a lot of 
side effects and poor specificity (Camphausen and Lawrence 2008). In order to deliver a 
therapeutic agent successfully and efficiently to the tumour cells, the following problems 
must be overcome: drug resistance at the tumour and cellular levels (physiological 
barriers, cellular and non-cellular based mechanisms), and absorption, distribution, 
metabolism (biotransformation) and elimination of the anti-cancer drugs (Farokhzad and 
Langer 2009). The poorly vascularized and developed tumour regions may pose a non-
cellular resistance mechanism reducing drug access and protecting the cancer cells from 
cytotoxic drugs. Low microvascular pressure and high interstitial pressure impedes 
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extravasation of the anticancer drugs (Jain 1987). The cellular based resistance 
mechanisms are due to alterations in the biochemistry of the cancer cells. There is a 
change in the activity of enzyme systems, transport processes, apoptosis regulation and 
the efflux system conferring multi drug resistance (Krishna and Mayer 2000).   
 
1.6.3 Role of nanotechnology in cancer therapy (nano-oncology) 
Nanoparticles can be engineered to overcome these shortcomings, limit secondary side 
effects and enhance cancer therapeutic modalities (Cuenca, Jiang et al. 2006). 
Nanotechnology is an interdisciplinary field which focuses on tailoring and manipulating 
man-made materials of the order of 100 nm or less. This study further narrows down to 
cancer nanotechnology, which facilitates the design and application of nanomaterials in 
the improvement of cancer diagnosis and treatment (Prados, Melguizo et al. 2014) (Fig. 
1.11). 
 
Fig. 1. 11. Role of nano-biotechnology in cancer management. The use of nano sized 
systems for the management of cancer. Nanoparticles are being used in different aspects 
of imaging, surgery and drug delivery in the detection and treatment of cancer. Adapted 
from Jones and Harris (1998).  
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Nanoparticles are being actively used for cancer applications as they can be tailored to 
have multi-functionality, proving to serve simultaneously as contrast agents in imaging, 
drug delivery vehicles and/or as therapeutic agents (Peer, Karp et al. 2007). Currently, 
nano-medicine is being applied to reformulate existing therapeutics in order to reduce 
toxicity associated with the conventional treatments and increase the efficacy of the 
therapeutic agents (Peer, Karp et al. 2007, Aslan, Ozpolat et al. 2013).  
 
Nanoparticles are normally taken up and cleared from the body by the spleen, liver and 
other parts of the reticulo-endothelial system based on their surface characteristics 
(Maeda 2010). Particles with greater ability to target the site of interest and those with 
longer circulation times are ideal for efficient drug delivery. This demands the 
development of stealth particles with a prolonged half-life in the blood (Moghimi, Hunter 
et al. 2001). The inherently leaky vasculature present in cancerous tissue is an important 
advantage in non- solution based cancer therapies (Daas and Choong 2006). In order to 
serve the fast growing tumour mass, there is a requirement for rapid vascularisation. This 
creates defective vascular architecture. When this is coupled with poor lymphatic 
drainage, it allows for an enhanced permeation and retention effect, thus helping in 
passive targeted drug delivery (Maeda 2010). An approach called the tumour activated 
prodrug therapy works in a unique fashion, in that the drug conjugated to a cancer specific 
molecule remains inactive until the complex reaches the site of interest (Maeda 2010). 
Also, cancer cells overexpress certain antigens and also express specific and ideal 
antigens/molecules which may not be expressed on healthy host cells, providing a means 
for tumor specific targeting (Amin, Sutradhar et al. 2014). However, targeting has got its 
own disadvantages. Particles with hydrophobic surfaces will be easily and preferentially 
taken up by the liver and eliminated out of the system rapidly. Also, the unpredictable 
and slow blood flow in the necrotic regions of the tumour and heterogeneous blood flow 
in the non-necrotic regions pose a challenge. In certain cases, the dug loses its potential 
after being linked to the targeting moiety (Moghimi, Hunter et al. 2001). The clinical 
outcomes are sometimes not desirable when the targeting linker is not stable enough in 
vivo and does not get cleaved off properly. It becomes a challenge to identify the ideal 
antigen which is expressed only on the tumour cells with no variation and mutation and 
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is essential for critical cellular function and cell survival (Desai 2012). There have been 
limited studies performed in this area and it still remains unclear whether active targeting 
helps in the increase of intracellular uptake of targeted nanoparticles in vivo or causes 
changes in the bio-distribution after systemic delivery (Brigger, Dubernet et al. 2002). 
These factors are dependent on the size, shape and surface characteristics of the 
nanoparticles, specificity of ligand attachment to the particle, ligand density, length of the 
spacer connecting the nanoparticles and the ligand, the tumour type, location and the 
physiologic disease state of the host under investigation (Teicher 2000). 
 
1.6.4 Nanoparticles 
What are nanoparticles? The accepted definition is that nanoparticles are particles or 
materials with one or more dimensions of the order of about 100 nm or less (Poole 2003). 
A particularly attractive property of these particles is that as the diameter decreases, there 
is a dramatic increase in the surface area of the particles (Jabir, Tabrez et al. 2012). This 
has stimulated the research of these nanoparticles in biomedical areas such as drug 
delivery, cell tracking, imaging, antimicrobial agents, disease modelling, etc. 
(Blanchetter, Brannon-Peppas et al. 2004). Small size leads to a difference in spacing and 
arrangement of surface atoms and thus changes in physical, electrical and chemical 
properties from the bulk material. The increase in surface area theoretically prolongs the 
circulation time and evades detection by the immune cells (Alexis, Pridgen et al. 2010). 
It also helps in the delivery of therapeutic agents to the specific target sites effectively 
concentrating the drug at the site of interest, the tumour (Brown, Palazuelos et al. 2010). 
The important advantages of nanoparticles are: their small size helps in their entry into 
different places; their increased resistance to heat and certain chemicals; their large 
surface to volume ratio enabling easy diffusion and capacity to carry high drug payloads 
(Auffran 2009). The particulate nature of nano-carriers helps in their accumulation in 
areas of leaky vasculature (particularly the tumour site) due to the enhanced permeation 
and retention effect. The size of the particles and the surface characteristics determine the 
biological fate of the carriers as these prevent their uptake and elimination by the 
members of the mononuclear phagocyte system (Jiang, Kim et al. 2008). It is desirable to 
have the nanoparticles removed or metabolized following payload delivery without toxic 
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side effects. Some nanoparticles have been proven to be safe due to their propensity to 
dissolve inside the cell and certain others consist of materials already in use in 
biomedicine (Soto, Garza et al. 2007).  
 
1.6.5 Silicon nanoparticles 
Porous inorganic nanoparticles have been in use for a long time in drug delivery and 
tissue engineering applications. Inorganic porous silicon nanoparticles exhibit a number 
of unique properties making it a novel and attractive material for various biomedical 
applications (Kotov 2010). These particles are also being investigated for applications in 
optoelectronics, microelectronics, biomedical devices, and as biological and chemical 
sensors (Collins, Fauchet et al. 1997). It has distinctive advantages such as 
biocompatibility, biodegradability, simple top down production method, surface 
modification for imaging, encoding property for multiplexed detection, 
photoluminescence, possibility of stabilization of the loaded peptides and drugs in the 
pores, extensive adsorbing surface area enabling loading of a large amount of carrier 
material mass and they can be tailored to withstand extreme conditions (Anglin, Cheng 
et al. 2008, Romero, Llansola-Portoles et al. 2013). 
 
Silicon is a common trace element in the human body and the degradation product of 
silicon, orthosilicic acid is naturally found in many tissues. It is harmless and can be easily 
absorbed by the body and renally cleared (Low, Voelcker et al. 2009). It has been reported 
that administered silicic acid is efficiently eliminated from the human body through the 
urine (Bimbo, Sarparanta et al. 2010). The use of porous silicon in vivo was first promoted 
and demonstrated in the mid-1990s. Subsequently, it has been employed as a matrix for 
the release of ibuprofen, doxorubicin, cis-platin, dexamethasone and various other drugs 
(Gary-Bobo, Hocine et al. 2012). Drug delivery across a cellular barrier was first 
performed to deliver insulin across Caco-2 cell monolayers (Foraker, Walczak et al. 
2003). Silicon nanoparticles can carry cargo such as drugs, enzymes, proteins and genes 
(Vallet-Regi, Balas et al. 2007). The optical properties of silicon can be used to perform 
diagnostics and therapeutic tasks such as photosensitizers in photodynamic therapy 
(Bakalova, Ohba et al. 2004). 
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The stealth shielding of nanoparticles helps them to circulate for longer in the system. 
This is normally done by surface modification using molecules such as PEG (poly-
ethylene glycol), dextran, etc. This renders the nanoparticles with a dynamic cloud of 
neutral and hydrophilic chains on the surface, repelling plasma proteins, and thus 
prolonging the circulation time and avoiding recognition and uptake by the mononuclear 
phagocytes and the reticuloendothelial system (Anglin, Cheng et al. 2008). 
Biocompatible silicon nanocrystals as quantum dots with surface functionalization have 
been reported to be developed for in vivo tumour targeting, multiplex imaging and 
sentinel lymph node mapping (Zhang, Liu et al. 2012).  
 
Silicon nanoparticles can be synthesized by a variety of routes, broadly classified into 
chemical and physical routes (Bley, Kauzlarich et al. 1996). Chemical methods produce 
particles in large amounts, but with less well defined size and composition. Physical 
routes involve high temperature or vacuum deposition methods (Zhang 2004). Some of 
the commonly used synthesis procedures are electrochemical etching and sonication, sol-
gel techniques, self-assembly, laser ablation, reactive sputtering, ball milling, 
decomposition of silanes, thermal vaporization, solution synthesis, thermal annealing, 
plasma processing and hybrid techniques (Zhang 2004, Anglin, Cheng et al. 2008, Bimbo, 
Makila et al. 2011).     
 
1.6.6 Peptides as therapeutics 
Understanding the molecular pathogenesis of cancer has in recent times led to the 
development of targeted therapies for cancer (Ruoslahti, Bhatia et al. 2010). These novel 
targeting compounds act on specific targets which contribute to the development and 
progression of cancer. There are inherent side effects in the use of these molecules 
because they also inhibit pathways necessary for functions of non-transformed cells 
(Abou-Jawde, Choueiri et al. 2003, Ruoslahti, Bhatia et al. 2010). This drawback has led 
to the emerging field of study involving the potential use of peptides to target tumour 
cells. A number of proteins have been discovered that show remarkable cytotoxic 
activities which are tumour specific (Murphy 2010, Boohaker, Lee et al. 2012). The 
cytotoxicity of these tumour specific killer proteins is independent of genetic changes 
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such as EGFR, p53 or pRB mutations and tumour type (Argiris, Panethymitaki et al. 
2011).  
 
Peptides have a seemingly endless array of advantages for use as therapeutic agents 
(Kasper and Reichert 2013). They are biodegradable, biocompatible, weakly 
immunogenic and provide selectivity in binding (Kopecek and Yang 2009, Goodwin, 
Simerska et al. 2012). Numerous functional and structural diversities can be designed and 
developed at the peptide monomer level (McGregor 2008). Peptides can be readily and 
conveniently synthesized by solid phase techniques due to the ease of commercial 
availability of natural and non-natural amino acid residues (Reichert 2010, Albericio and 
Kruger 2012). A number of bioconjugation strategies can be employed to elaborate the 
functionality of these peptides by conjugating them with biological ligands, lipids, other 
peptides and polymers. Peptide assemblies are those molecules where the bulk material 
itself acts as the therapeutic agent (Collier 2008). Peptide assemblies can show 
morphologies such as fibrillar networks, micelles, hybrid networks, worm like, etc. 
(Branco, Sigano et al. 2011)(Fig. 1.14). 
 
These assemblies actively engage in the intended biological targeting and exert the 
desired functional outcome, unlike the common application of peptides as drug delivery 
vehicles and extracellular matrix attachment and elaboration factors (Cui, Webber et al. 
2010). They can be modelled to adopt any desired structure such as α-helix, β-sheet or a 
peptide amphiphile with block or facial amphiphilicity. Multifunctionality can be brought 
about in a single assembly by the attachment of more than one bioactive moiety 
(Rajagopal and Schneider 2010). When monomeric peptides are introduced systemically, 
they are rapidly recognized by the members of the reticuloendothelial system, resulting 
in short circulation half-lives. They are also subjected to conformational denaturation by 
serum proteins such as albumin, whereas, the peptides within the assemblies have 
conformational stability and a longer serum half-life (Zhang, Marini et al. 2002). These 
highly ordered peptide structures with well-defined chemistry can be developed and 
applied for cellular recognition, targeting and internalization, paving a promising way 
towards the treatment of cancer and other human ailments (Zhang, Marini et al. 2002).  
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Fig. 1. 12. Synthesis and functionalization of peptides. Peptides have an endless array 
of advantages for use as therapeutic agents. They can be synthesized chemically on solid 
support and functionalized with other peptides, lipids, polymers and ligands by ligation 
chemistry. This enables functionality and control of folding and self-assembly. Self-
assembled peptides into micelles, fibrillar and hybrid networks can be engineered to 
display bio-functionality such as increased half-life, conformational stability, cell 
recognition and uptake enabling successful targeted applications. Adapted from Branco, 
Sigano et al. (2011). 
 
1.6.7 Alpha-lactalbumin as a therapeutic agent 
As discussed earlier in section 1.3.3.5, alpha-lactalbumin (LALBA) is the most abundant 
protein of human milk whey secreted by the mammary gland epithelium (Mossberg, 
Petterson et al. 2006). It is a 14 kDa protein and serves as a co-enzyme in lactose synthesis 
(Fitzgerald, Brodbeck et al. 1970). Lactalbumin is a globular protein with 122-123 amino 
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acids divided into 2 domains (Acharya, Ren et al. 1991). The small β domain has a triple 
stranded anti-parallel sheet and a small helix. The larger domain has 3 major α helices. 
The two domains are connected by a calcium binding loop and four disulphide bonds 
stabilize the native conformation of the protein (Schulman, Redfield et al. 1995). Protein 
unfolding is mostly associated with tissue destruction or disease, and considered a threat 
to tissue homeostasis (Kaufman 2002). Misfolding also accompanies normal protein 
synthesis, where a small portion of the synthesized peptide does not fold correctly and is 
removed by proteases. An interesting observation made many years ago is that alpha-
lactalbumin may undergo partial unfolding, bind to a fatty acid co-factor such as oleic 
acid and become tumoricidal (Fig. 1.15). Therefore, the addition of a lipid co-factor 
changed the biological activity of this protein (Mossberg and Svanborg 2010).  
 
Fig. 1. 13. Formation of HAMLET. Alpha-lactalbumin undergoes partial unfolding 
(with a depletion of calcium ions), binds to a fatty acid co-factor such as oleic acid and 
forms the tumoricidal complex HAMLET (Human Alpha-lactalbumin Made Lethal to 
Tumor cells). Adapted from Mossberg and Svanborg (2010). 
 
The native protein did not have any effect on tumor cell viability. It has been 
demonstrated that the folding change and the attachment of the lipid co-factor are both 
essential for the complex to attain the apoptotic function (Mok, Petterson et al. 2007). 
There is specificity in the type of lipid co-factor attaching to the partially unfolded protein 
which impacts directly on the function of the complex. It has been reported that 
attachment of only unsaturated C18 fatty acids in cis confirmation can bring about the 
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desired functional complex.  It has been found that the oleic acid binding site resides in 
the β domain of the protein (Anderson, Brooks et al. 1977). HAMLET (Human α-
lactalbumin made lethal to tumour cells) is a unique protein complex with interesting 
properties. It induces apoptosis in tumour and immature cells, but normal differentiated 
cells are resistant to its effects (Svanborg, Agerstam et al. 2003). Alpha-lactalbumin binds 
to lipid vesicles (negatively charged) in a pH-dependent manner (Halskau, Underhaug et 
al. 2005). The fatty acid co-factor, oleic acid, stabilizes the protein and helps maintain it 
in a confirmation suitable for interaction with the tumour cell membrane. The abnormal 
O-glycosylated mucine or the phosphatidylserine content in the cell membrane of cancer 
cells allows HAMLET to preferentially bind to them (Agasoster, Halskau et al. 2003). 
The trafficking of the complex is different in normal and cancer cells and this brings about 
the difference in responses. Translocation of the complex to the cytoplasm and formation 
of cytoplasmic aggregates is more efficient in the tumour cells than the normal cells. The 
translocated complex is redistributed to the perinuclear regions only in the tumour cells 
and accumulated in the tumour cell nuclei (Gustafsson, Hallgren et al. 2005). HAMLET 
shows high affinity binding to histone complexes – dimers H2A-H2B and tetramers H3-
H4. There is co-localization of the complex with histones in the nuclei, inducing changes 
in the chromatin structure. This marks the irreversible stage of tumor cell apoptosis as 
transcription is impaired and cell death is imminent. HAMLET disrupts the histone-DNA 
association and perturbs the structure and function of chromatin. As the complex enters 
the cell, it competes with the chaperones for histones, interacts with the newly synthesized 
histones and prevents the transport of histones to the nucleus (Duringer, Hamiche et al. 
2003). In the nucleus, the complex impairs the function of the nucleosomes by directly 
binding to them. Other targets of HAMLET are the mitochondria and proteasomes 
(Goldberg 2003) (Fig. 1.16). HAMLET causes mitochondrial membrane depolarization, 
cytochrome C release and activation of pro-apoptotic caspases (Kohler, Gogvadze et al. 
2001). Alpha-lactalbumin is structurally conserved among a number of species and 
HAMLET-like complexes are also formed by other species variants of α-lactalbumin. 
BAMLET is formed when bovine α-lactalbumin binds to oleic acid and this complex was 
also shown to have anti-tumour activity (Jensen and Pitas 1976).  
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Fig. 1. 14. The targets of HAMLET in the cell. HAMLET has several targets in the 
tumor cells: a) the mitochondria, b) the endoplasmic reticulum, c) the histones in the 
nucleus and d) the proteasomes. The mythological animal, the Lernaean Hydra is used as 
a metaphor for HAMLET, hence the name – the biological Hydra. If one head of the 
Hydra is cut off, new heads soon emerge. Similarly, HAMLET has multiple targets in the 
tumor cell. Adapted from Mok, Petterson et al. (2007). 
 
HAMLET is speculated to kill premalignant cells and virus transformed cells in the 
gastrointestinal tract of breast-fed children. The conditions in the stomach of breast fed 
children are ideal for the formation of the complex as the low pH triggers release of 
calcium and unfolding of the protein and oleic acid is released due to acid sensitive lipases 
hydrolyzing milk triglycerides. It has been postulated that this is the reason why breast-
fed children have less frequency of lymphoid malignancies than bottle fed children (Davis 
1998). HAMLET has also been reported to induce apoptosis in melanoma, leukemia, 
glioblastoma of the brain and cells from carcinoma of the kidney, colon, lung, prostrate, 
bladder, throat and ovaries (Gustafsson, Hallgren et al. 2005, Storm, Klausen et al. 2013).  
Alpha-lactalbumin has been found to increase levels of 5-HT (serotonin) in the brain and 
reduce sleep disturbances (Orosco, Rouch et al. 2004). Recently, alpha-lactalbumin has 
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been put to an interesting and different use where its administration has been associated 
with seizure control in patients with drug resistant epilepsy (Citraro, Scicchitano et al. 
2011). Topical application of the alpha-lactalbumin-oleic acid complex has also been 
used in the treatment of skin papilloma (Gustafsson, Leijonhufvud et al. 2004).  
  
Although, 14 kDa alpha-lactalbumin is the most abundant form of lactalbumin in the 
milk, a small amount of the rare dimer 28 kDa alpha-lactalbumin has also been reported 
to be present in milk. It has been shown that samples having the 14kDa form alone did 
not induce apoptosis, whereas the samples containing the 28kDa form induced significant 
apoptosis (Brennan , Sharp et al. 2008). Recent studies (in our laboratory) have shown 
that the alpha-lactalbumin dimer complexed with unsaturated fatty acids also has the 
capacity to program apoptosis in a variety of calls. These data may be consistent with the 
potential of other binding proteins dimerized with fatty acids also signalling apoptosis in 
cells. The apoptosis inducing 28 kDa alpha-lactalbumin is different from multimeric 
alpha-lactalbumin and HAMLET. It does not depend on bound or free calcium and 
induces apoptosis in a variety of cell types including healthy and tumour cells (Brennan , 
Sharp et al. 2008). The molecular basis of apoptosis induced pathways of the 28kD alpha-
lactalbumin and its therapeutic potential is an area of intensive research. 
 
1.6.8 Nanotechnology in peptide delivery 
Although peptides are interesting and promising therapeutic molecules, their delivery is 
highly challenging due to their restricted administration routes, large molecular size, 
sensitivity, chemical characteristics and poor bioavailability (Kilpelainen, Monkare et al. 
2011). Particulate drug delivery systems have been developed to overcome these 
drawbacks and aid in the following ways: control drug release and reduce associated side 
effects, increase the bioavailability of the drug or peptide by protecting it from 
degradation and by increasing its solubility and targeting of the therapeutic molecule to 
specific cells or tissues (Tan, Choong et al. 2010). The extensive and elaborated surface 
area of porous materials like silicon nanoparticles has the ability to carry a large amount 
of the payload within a small carrier mass. The particle surface, pore size and loading 
level affect the release profile (Salonen, Kaukonen et al. 2008). Porous silicon 
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nanoparticles are of great use as the loading of the drug can be done at any temperature 
and in any solution in which it is soluble, making this material one of the best choices for 
delivery of sensitive molecules like peptides (Prestidge, Barnes et al. 2007).  
 
1.7 Aims of this study 
Mammary gland involution is a physiological process associated with rapid apoptosis 
(programmed cell death) of the lactating mammary epithelial cells followed by 
remodelling of the mammary gland to a pre-pregnant state. Mammary gland involution 
in the mouse is a two-step process according to its reversibility. Early involution, 
occurring within the first 24-48 hours, is reversible and induced by local factors. The 
second phase, a remodelling programme initiated to return the gland to a pre-pregnant 
state, is irreversible and requires systemic factors. The loss of secretory alveolar 
epithelium is attributed to a number of factors such as mild ischemia as a result of milk 
engorgement and compression of vasculature, factors in milk that promote cell death, 
physical distension of the luminal epithelium and increased activity of the basement 
membrane degrading enzymes (matrix metalloproteinases). Therefore it is clear that the 
retention of milk plays an essential role in this process but, the initial trigger of involution 
is yet to be identified. 
The broad objective of this study is to investigate the regulation of mouse mammary gland 
involution, particularly the role of milk proteins, the extracellular matrix and the 
involvement of other cell types in the early signals of apoptosis, and the mechanisms of 
transition between the reversible and irreversible phases.  
 
The following specific aims are proposed: 
x To identify signals from the ECM and their effects on epithelial cells during 
involution 
The first aim of this project is to develop an in vitro model to study the effect of 
extracellular matrix extracted from both the phases of involution on the growth and 
proliferation of mammary epithelial cells.   
x To determine the role of milk proteins and other cell types in regulating the 
two phases of involution 
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The second aim of this project is to study the effect of involuting milk on the in vitro 
model established above (in the first aim) and the signalling between the mammary 
epithelial cells and other cell types, especially adipocytes, during involution 
 
x To develop a silicon based nanocarrier system to deliver a peptide based 
cytotoxic payload to cancer cells 
The third aim of this project is to synthesis and characterize silicon nanoparticles, load 
alpha-lactalbumin based complex and deliver to breast cancer cells to study their 
apoptotic potential and specificity. 
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Chapter 2: Effect of the extracellular matrix on the 
growth of mouse mammary epithelial cells during 
involution 
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2.1 Introduction 
The cells in multicellular organisms monitor their micro-environment through 
interactions with neighbouring cells and receptors for soluble and locally acting factors. 
In addition to providing signals for proliferation, differentiation and migration, these 
interactions are also essential for cell survival and in the absence of these interactions, 
cells undergo apoptosis (Farrelly, Lee et al. 1999, Oskarsson 2013). Studies using the 
mouse as a model system have shown that mammary epithelial cells depend on 
interactions with substratum for cytological and functional differentiation even in the 
presence of lactogenic hormones (Hall 1987). A complex substratum such as the 
extracellular matrix (ECM) is essential for maximal differentiation of cultured mammary 
epithelial cells. The ECM is an interconnected meshwork of secreted proteins that interact 
with the cell to form a functional unit (Bissell and Barcellos-Hoff 1987). It confers 
cellular functions including survival, apoptosis, polarity, cell adhesion, proliferation and 
differentiation through structural properties such as physical support and boundary 
constraints, by providing mechanosensory cue, and through classical signal transduction 
pathways (Butcher, Allison et al. 2009). It has been established that endocrine hormones 
control the morphological and biochemical differentiation of the mature mammary 
epithelium (Silberstein 2001) and in vitro studies have demonstrated the role of the ECM 
in maintaining the mammary epithelial cell glandular structure, viability and milk protein 
expression (Pullan, Wilson et al. 1996). If the ECM is involved in mediating the response 
of the epithelium to endocrine hormones, whether the mammary ECM protein 
composition and function are also endocrine regulated is a question that needs to be 
addressed. Data from Schedin et al, 2004 suggests that the responsiveness of rat 
mammary epithelium to systemic hormones is aided by concomitant modification of the 
mammary ECM (Schedin, Mitrenga et al. 2004). The ECM and the mammary epithelial 
cells follow a dynamic and reciprocal relationship with two way communication, where 
the ECM supports and instructs the cells and the cells in-turn build, shape and re-shape 
the ECM (Bissell, Hall et al. 1982). The mammary gland undergoes reductive 
remodelling following the removal of the suckling stimulus upon weaning, a process 
termed involution (Atwood, Ikeda et al. 1995). When there is an interruption in suckling, 
the mother temporarily reduces milk production, but involution is a two-step process 
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based on its reversibility (Pai and Horseman 2011). The first stage of involution is 
characterized by the appearance of apoptotic cells and down-regulation of milk protein 
production. This phase is reversible, lasts up to 48 hours and is triggered by local factors 
related to milk accumulation (Furth, Bar-Peled et al. 1997). The irreversible stage is 
characterized by decreased systemic hormone levels and proteinase activation (Lund, 
Romer et al. 1996). The alveoli begin to collapse and adipocytes re-fill the fat pad. 
Important regulators of this phase are the matrix metalloproteases (MMPs) and serine 
proteases that break down the ECM and activate plasminogen, respectively, resulting in 
apoptosis and tissue remodelling (Murphy and Nagase 2008, Kessenbrock, Plaks et al. 
2010, Watson and Kreuzaler 2011). MMPs are primarily expressed by the stromal cells 
and MMP2, MMP3, MMP9 and MMP11 are up-regulated during involution, and are 
involved in the remodelling of the ECM. MMPs cleave a variety of substrates including 
collagen IV, E-cadherin and chemokines, which lead to cell detachment (Watson and 
Kreuzaler 2011). Thus the MMPs have a dual role during the second phase of involution 
as initiators of apoptosis and re-modellers of the gland architecture (Watson 2006). Most 
MMPs are synthesized as pre-proenzymes and the removal of the signal peptide during 
translation generates the proMMPs. Thus, activation of the precursor zymogen regulates 
MMP activity (Nagase, Visse et al. 2005). The activity of MMPs is suppressed in early 
involution by the up-regulation of endogenous inhibitors, tissue inhibitor of 
metalloproteases (TIMPs), in order to maintain the reversibility of the first phase (Green 
and Lund 2005). The irreversible tissue remodelling follows near complete loss of the 
epithelial cell compartment returning the gland to a pre-pregnant state within 
approximately ten days in the mouse (Green and Streuli 2004). Although the core 
signalling programmes that regulate apoptosis are well understood, the roles of specific 
components of the apoptotic cellular machinery needs to be comprehensively addressed. 
The difference in the morphology of the apoptotic cells, the appearance of apoptotic 
markers such as caspases and the multiple different pathways involved (Watson 2006) in 
the first and second phases suggests that the apoptotic mechanisms are different in these 
phases. The experiments described in this chapter address the hypothesis that changes in 
the ECM during the second phase of murine mammary involution contribute to epithelial 
cell loss and mammary ECM isolated from actively involuting glands during the two 
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phases differ in the mammary epithelial cells response to forming milk producing 3-
dimensional acini structures.   
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2.2 Materials and methods 
2.2.1 Animals 
All experiments in this thesis were approved by the Deakin University Animal Ethics 
Committee and conformed to the National Health and Medical Research Council code of 
practice (NHMRC Australia, Australian code for the care and use of animals for scientific 
purposes 8th Edition 2013). 
C57BL/6J mice were obtained from Monash Animal Services, Melbourne, Australia. 
BALB/c mice were obtained from ARC (Animal Resources Centre), Western Australia. 
Mammary glands were dissected from day 12 pregnant C57BL/6J mice under sterile 
conditions after the animals were euthanized. Pups were removed from BALB/c mice at 
day 15 lactation (this was considered as day 0 involution) and the mothers were housed 
in the Deakin University animal centre for further experiments. Mammary gland was 
dissected from day 0 - day 4 involuting BALB/c mothers under sterile conditions 
following forced weaning at day 15 of lactation. The tissue was frozen and stored at -80̊ 
C. 
2.2.2 Preparation of mouse mammary epithelial cells from mammary glands 
Mammary gland dissected from day 12 pregnant C57BL/6J mice was placed in a petri 
dish containing 1x DMEM/F12 (1:1) (Dulbecco’s Modified Eagle Medium: Nutrient 
Mixture F- 12) medium (11320-082, Gibco, Life technologies, Victoria, Australia) with 
fungizone (15290-018, Gibco, Life technologies, Victoria, Australia) and 
penicillin/streptomycin (15140-122, Gibco, Life technologies, Victoria, Australia) to 
maintain sterile conditions. It was then transferred to digest medium containing 
DMEM/F12, 1% Fungizone, 1% Penicillin/Streptomycin, 35% Bovine Serum Albumin 
(BSA) (A0281, Sigma, Sydney, Australia) and 1 mg/mL Collagenase class III 
(Worthington, Scima, Victoria, Australia). The pH of the medium was maintained at 7.4. 
The tissue was minced using curved scissors to very small pieces and transferred to a 
pyrex 50mL flask with a stopper. Digest medium of volume 10 mL was used per gram of 
tissue obtained. The tissue was incubated at 37˚C in a Ratek orbital shaking incubator at 
195 rpm for 90 minutes with intermittent pipetting every 20 minutes. The contents were 
filter digested through a 150 μm mesh in a sterile filter unit. The filtered material was 
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centrifuged at 1000xg for 5 minutes. The fat layer was removed using transfer pipette and 
the supernatant discarded. The pellet containing the cells was re-suspended in wash 
medium made up of 1x DMEM/F12, 20 μg/mL DNase I (1284932, DNase I from bovine 
pancreas, Roche) and 0.1mg/mL Trypsin Inhibitor (T6522, Sigma, Sydney, Australia). 
The contents were centrifuged at 1000xg for 5 minutes. The cell pellet wash step was 
repeated once and the re-suspended cells in wash medium were filtered through a 50 μm 
mesh in a sterile filter unit. The filtrate was centrifuged at 1000xg for 5 minutes and the 
cell pellet was suspended in growth medium containing 1x DMEM/F12, 10% Fetal 
Bovine Serum (Australian origin, 10099141, Gibco, Life technologies, Victoria, 
Australia), 1% Penicillin/Streptomycin, 1 μg/mL bovine Insulin (I; I6634 Sigma, Sydney, 
Australia), 1 μg/mL Cortisol (F; H4001 Sigma, Sydney, Australia) and 10 ng/mL 
Epidermal Growth Factor (EGF; E4127, Sigma, Sydney, Australia). The contents were 
centrifuged at 1000xg for 5 minutes and the cells were cultured in growth medium at 37˚C 
in 5% CO2 incubator.  
2.2.3 Extraction of extracellular matrix from mouse mammary glands 
Extracellular matrix (ECM) was extracted from mammary tissue excised from BALB/c 
mothers at day 0 - day 4 of involution based on the protocol described in (O'Brien, 
Fornetti et al. 2010). Buffers 1, 2 & 3 were prepared and autoclaved (See composition of 
buffers below). 
Buffer 1 (high salt buffer): 3.4 M NaCl (S7653, Sigma, Sydney, Australia), 50 mM Tris-
HCl (pH 7.4) (H5131, Promega, Sydney, Australia), 4 mM EDTA-Na2 (#10093, Merck, 
Victoria, Australia) 
Buffer 2 (Urea extraction buffer): 0.2 M NaCl, 50 mM Tris-HCl (pH 7.4), 4 mM EDTA-
Na2, 2 M Urea (A817, Ajax finechem, Victoria, Australia) 
Buffer 3 (Tris dialysis buffer): 0.15 M NaCl, 50 mM Tris-HCl (pH 7.4) and 4 mM EDTA-
Na2 
Buffers 1 and 2 were stored at room temperature and buffer 3 at 4˚C. Fresh stock solutions 
of 200mM n-ethylmaleimide (NEM; E1271 Sigma, Sydney, Australia) and 15 mg/mL 
phenylmethylsulfonyl fluoride (PMSF; P7626 Sigma, Sydney, Australia) were prepared 
 71 
 
and stored throughout the 5 day isolation period at 4˚C and -20˚C respectively. The 
mammary tissue was kept frozen in liquid nitrogen to maintain the integrity of ECM 
proteins after removal from long term storage at -80˚C and prior to homogenization. The 
following protocol was used for 3 g of mammary tissue. The amount of starting tissue 
was weighed and the protocol was proportionately scaled with particular attention to 
homogenization times and buffer volumes.  
Day 1 
A pre-chilled mortar and pestle was used to pulverize the frozen mammary tissue to a fine 
powder in liquid nitrogen. The mammary tissue was maintained in a frozen state at all 
times and pulverized tissue from all the animals at a particular time point of involution 
were pooled together. Buffers 1 and 2 were pre-chilled on ice. Solutions for high salt 
washes 1 and 2 were prepared by placing 2 mL of buffer 1 per gram of tissue into two 50 
mL polypropylene tubes. Stock NEM, PMSF and protease inhibitor cocktail (PI; P 8340, 
Sigma, Sydney, Australia) were added to each tube to obtain the following working 
concentrations: 2 mM NEM, 200 μg/mL PMSF and 2xPI cocktail. This buffer was 
referred to as Buffer 1B.  
High Salt Wash 1: Approximately one third of the pulverized starting tissue was added 
to the 50 mL tube containing buffer 1B and homogenized on ice for 8 seconds using a 
Polytron tissue homogenizer (PT2100, Kinematica). Half of the remaining tissue was 
added and homogenized for another 8 seconds on ice. Final homogenization on ice of 2x8 
seconds was performed after the addition of the remaining tissue, for a total 
homogenization time of 4x8 seconds. In order to prevent tissue from warming, 5-10 
seconds was allowed between the homogenization steps. The homogenized tissue was 
transferred to polycarbonate centrifuge tubes (355603, Beckman, USA) and centrifuged 
at 100,000xg for 30 minutes at 4˚C in a Beckman Coulter ProteomeLab XL-A/XL-1 
ultracentrifuge. The top layer of lipid and supernatant were discarded.  
High Salt Wash 2: Half the volume of buffer 1B solution was added to the centrifuge tube 
containing the ECM-enriched pellet. The tissue was homogenised on ice for 5 seconds. 
The homogenized tissue was transferred to the 50 mL tube containing the remainder of 
buffer 1B and homogenized on ice for a further 5 seconds. The homogenized tissue was 
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transferred to a polycarbonate centrifuge tube and centrifuged at 100,000xg for 30 
minutes at 4˚C. The top layer of lipid and supernatant were discarded.  
Urea Extraction: Urea extraction solution was prepared by placing 1.8 mL of buffer 2 per 
gram of tissue into a 50 mL polypropylene tube. Stock NEM, PMSF and PI cocktail were 
added to achieve the following working concentrations: 2 mM NEM, 100 μg/mL PMSF 
and 2xPI cocktail. This buffer was referred to as buffer 2B. 
Half the volume of buffer 2B was added to the centrifuge tube containing the ECM-
enriched pellet. The tissue was homogenized on ice for 5 seconds. The homogenized 
tissue was transferred to the 50 mL tube containing the remainder of buffer 2B and 
homogenized on ice for a further 5 seconds. The homogenized tissue was transferred to a 
75 cm2 tissue culture treated polystyrene flask with a non-ventilated cap. The flask was 
kept shaking in an orbital shaker overnight at 4˚C.  
Day 2 
Preparation of Dialysis Tubing: Preparation of dialysis tubing and all subsequent steps 
were carried out under sterile conditions in a laminar flow hood. Regenerated cellulose 
dialysis tubing (MWCO 12-14 kDa, 132703, Spectrum laboratories) was cut using sterile 
scissors according to the sample volume plus 5-10 cm extra. The tubing was submerged 
in 100 mL of buffer 3 containing 25 μg/mL gentamicin for 3 hours at 4˚C. The ECM-
enriched sample was removed from the orbital shaker and transferred to a sterile 
centrifuge tube. A cell scraper was used to collect as much sample as possible including 
the liquid and particulate component of the sample from the flask. The contents were 
centrifuged at 26,000xg for 1 hour at 4˚C. The supernatant was retained for dialysis, 
whereas the pellet was discarded.  
Dialysis 1: The first dialysis solution was prepared by placing 70 mL of buffer 3 per gram 
of starting tissue into a measuring cylinder/Erlenmeyer flask. NEM and PMSF were 
added to achieve the following working concentrations: 2 mM NEM and 100 μg/mL 
PMSF. This was referred to as buffer 3B. The dialysis tubing was removed from 4˚C and 
a knot was tied at one end of the tubing. A dialysis tubing clip was placed inside of the 
knot. The supernatant following centrifugation was transferred into the dialysis bag. The 
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tubing was clamped using a second dialysis tubing clip and a knot was tied outside of the 
second clip. The dialysis bag was placed in the flask containing buffer 3B. A sterile stir 
bar was added and the flask was covered tightly with parafilm (PM 996, Bemis flexible 
packaging). The dialysis bag did not touch the inside of the flask and there was adequate 
liquid for liquid and solute exchange. It was dialysed at 4˚C for 24 hours with gentle 
stirring.  
Day 3 
Dialysis 2: Following dialysis 1, buffer 3B was discarded and replaced with 70 mL of 
buffer 3 per gram of starting tissue containing 100 μg/mL PMSF and 30 μg/mL 
gentamicin (buffer 3C). It was dialysed at 4˚C with gentle stirring for 10 hours.  
Dialysis 3: After 10 hours, buffer 3C was discarded and replaced with 70 ml buffer 3 per 
gram of starting tissue containing 30 μg/mL gentamicin (buffer 3D). This was dialysed 
overnight for 14 hours at 4˚C with gentle stirring.  
Day 4 
Dialysis 4: After 48 hours of total dialysis in buffer 3 solutions, the dialysis buffer was 
replaced with 40 mL serum free media M199/F12 (Gibco, Life technologies, Victoria, 
Australia) per gram of starting tissue containing 1 μg/mL gentamicin. This dialysis was 
carried out at 4˚C overnight (~24 hours) with gentle stirring.  
Day 5 
Following dialysis against culture medium, the extracellular matrix was transferred from 
the dialysis tubing to a polypropylene tube and stored at -20˚C for long term storage. The 
consistency of the final matrix was that of a viscous liquid and did not solidify at 37˚C 
unlike commercially available matrices.  
2.2.4 Tissue culture 
In order to study the effect of the extracellular matrix on the 3-dimensional structure of 
the mouse mammary epithelial cells, 40 μL of the viscous matrix was transferred to each 
well on a 96 well plate and incubated at 37˚C for 1 hour. Mammary epithelial cells were 
cultured on the different matrices (days 0 – 4 involuting ECM) in 1x DMEM/F12 medium 
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containing 2% Fetal Bovine Serum, 100 ng/mL Insulin, 50 ng/mL Cortisol and 1% 
Penicillin/Streptomycin. The mammospheres were observed using a Nikon eclipse TS100 
inverted light microscope and images captured using a DFC425C camera.  
2.2.5 Measure of cell proliferation/death 
Cell proliferation and cell death were analysed by MTS assay (Cell titer 96 AQueous non-
radioactive cell proliferation assay, G5421, Promega, Sydney, Australia). 20μL of the 
reagent solution containing a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an 
electron coupling reagent (phenazine ethosulfate; PES) was added to the wells in the 96 
well assay plate containing cells in 100 μL of culture medium. The plate was incubated 
at 37˚C for 1-4 hours in a humidified, 5% CO2 atmosphere. The absorbance was read at 
490 nm using a 96 well plate reader (Biorad xMarkTM microplate absorbance 
spectrophotometer). All samples were analysed in triplicate, where the experiment was 
repeated three times under the same conditions.  
2.2.6 Histology 
Mammary glands from day 12 and day 15 pregnant; day 3 lactating and day 0 – day 4 
involuting BALB/c mothers were excised and washed in 1x PBS  and immersed in 4% 
paraformaldehyde (PFA) overnight at 4˚C. The tissue was processed with increasing 
concentration of ethanol from 70 to 100% followed by soaking in histolene for an hour 
in a rotating shaker. The tissue was then embedded in paraffin (P3558, Sigma, Sydney, 
Australia). Sections were cut at 4 μm using low profile microtome blades from Extremus 
and placed carefully on Starfrost hydrophilic slides (ProScitech, Queensland, Australia). 
The sections were stained with Haematoxylin & Eosin (Gill’s, Amber Scientific) and 
mounted using DPX mountant (O6522, Sigma, Sydney, Australia). Sections were viewed 
on a Zeiss imager A1 inverted microscope. 
2.2.7 RNA extraction and reverse transcription PCR 
Total RNA was isolated from the mammospheres/cells on the different involuting 
matrices using TRIzol TriPure isolation reagent (#11667165001, Roche) as per the 
manufacturer’s protocol. Reverse transcription was performed on 1 μg of RNA using 
iScript cDNA synthesis kit (170-8841, Bio-Rad, NSW, Australia). The reaction was 
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placed in a Bio-Rad C1000 thermocycler at 25˚C for 5 minutes, 42˚C for 30 minutes 
followed by 85˚C for 5 minutes, and samples were then stored at -20˚C until further use.  
2.2.8 Quantitative polymerase chain reaction 
Quantitative polymerase chain reaction (qPCR) was performed on a Bio-Rad CFX96 Real 
time C1000 thermocycler using SsoFast Evagreen supermix (172-5200, Bio-Rad). The 
primer sequences and amplicon sizes are listed in Table 2.1, and were synthesized by 
Macrogen, Korea. The PCR reactions (20 μL) contained 1x SsoFast Evagreen supermix, 
forward and reverse primers at 10 μM concentrations and diluted cDNA. The qPCR 
thermal profile included an initial denaturation (95˚C for 3 minutes) and quantification 
for 40 cycles (denaturation at 95˚C for 30 seconds, annealing at 60˚C for 30 seconds, 
extension at 72˚C for 30 seconds) followed by a final extension at 72˚C for 5 minutes. 
All samples were assayed in triplicate and template free controls were included. The gene 
expression was normalized using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
as a housekeeping gene and relative expression was calculated using Bio-Rad CFX 
manager software, using the ΔΔCt normalized expression method. Melting curve analysis 
was performed to confirm the amplification of a single PCR product.  
2.2.9 Statistical analysis 
All statistical comparisons were made using a two-tailed t-test assuming unequal 
variances between means. Data were presented as mean ± standard error of the mean. In 
all statistical tests a p value of less than 0.05 was considered significant. 
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Table 2. 1. Primers used in qPCR 
Gene Forward Primer Reverse Primer Amplicon 
size (bp) 
Mus 
Beta 
Casein 
5'-
TGCACCTTCCTCAGTC
TCTG-3' 
5'-
GTGGAAGGAAGGGT
GCTACT-3' 
147 
Mus 
GAPDH 
5'-
CATCTTCCAGGAGCG
AGACC-3' 
5'-
GAAGGGGCGGAGAT
GATGAC-3' 
150 
Mus 
Afadin 
5'-
AGGGCAGCAGAACTC
ATGAC-3' 
5'-
GTTTACCTGAGCCAC
GACGA-3' 
148 
Mus 
Scribble 
5'-
CGGCTGCTAGAAGTG
AACCA-3' 
5'-
CAGACAAGCACGGTA
AGGGT-3' 
101 
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2.3 Results 
2.3.1 Histological features of the mammary gland during involution 
Mammary glands excised at different stages during the reproductive cycle; day 12 & day 
15 pregnancy, day 3 lactation, day 0 to day 4 involution were fixed in 4% PFA 
(paraformaldehyde), processed, sectioned and stained with hematoxylin & eosin to 
observe the morphological changes in the gland (Fig. 2.1). About 50% of the development 
of the mammary gland occurs during pregnancy from day 12 until term. Day 12 and day 
15 pregnant mammary tissue was characterized by the advanced development of acini 
and end buds. The onset of lactation was characterised by majority of the mammary 
stroma being populated with alveoli capable of milk secretion as seen in day 3 lactating 
mammary tissue. Upon weaning and during involution, there is loss of the secretory 
alveolar epithelium. Histologically, early involuting mammary gland showed distended 
alveoli and the large ducts filled with cells and apoptotic cell fragments. Alveolar lobules 
with degrading luminal epithelium were seen and interlobular adipocytes reappearing was 
apparent. During late involution (day 4 involution), an increase in adipocyte repopulation 
coincident with a decrease in size of alveolar lobules was observed.  
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Fig. 2. 1. Histological structures of paraffin embedded mammary glands from 
female BALB/c mice during pregnancy, lactation and involution. Mammary glands 
dissected at indicated stages and stained with hematoxylin and eosin. A) day 12 
pregnancy, B) day 15 pregnancy, C) day 3 lactation, D) day 15 lactation (day 0 
involution), E) day 1 involution, F) day 2 involution, G) day 3 involution and H) day 4 
A B 
C D 
E F 
H G 
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involution. A-D were photographed at 40x magnification and E-H were photographed at 
20x magnification.  
 
2.3.2 Effect of extracellular matrix extracted from different stages of involution on 
the 3-dimensional structure of mammary epithelial cells - An in vitro model 
The isolated primary mammary epithelial cells were cultured on ECM extracted from 
excised mammary tissue at day 0 (day 15 lactation), day 1 & day 2 involution (early 
involution matrices) and day 3 & day 4 involution (late involution) matrices. Day 0 
involution ECM was considered as a control for comparisons. The cells were cultured on 
these matrices for 7 days, then imaged using a Nikon inverted light microscope. The cells 
on day 0, day 1 and day 2 involution matrix clumped together to form a 3-dimensional 
acini structure as opposed to the cells on day 3 and day 4 matrices which lost their 
potential to form these acini-like structures (Fig. 2.2).   
                      
                                            
Fig. 2. 2. 3-dimensional structure of MMECs on involuting matrices. Mouse 
mammary epithelial cells (MMECs) from day 12 pregnant mothers were cultured on A) 
Day 0 involution ECM, B) Day 1 involution ECM, C) Day 2 involution ECM, D) Day 3 
involution ECM and  E) Day 4 involution ECM. All images were photographed at 40x 
magnification. 
A B C 
D E 
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Cell viability on all involution matrices was analysed by MTS cell proliferation assay at 
the end of 7 days in culture on their respective ECM. The % viability of cells on the 
involuting matrices was calculated relative to the cell viability on day 0 (day 15 lactating) 
involuting matrix (Fig. 2.3). Although the cells cultured on day 3 involuting matrix did 
not polarize and form acini, they remained viable, whereas the cells cultured on day 4 
involuting matrix, in addition to loss of polarity were also observed to have significantly 
reduced viability.  
 
 
Fig. 2. 3. Cell viability of MMECs cultured on involution matrices. % cell viability of 
mouse mammary epithelial cells cultured on day 1 to day 4 (D1-D4) involution matrices 
was calculated relative to the cell viability on day 0 involution matrix. All values are 
represented as mean ± SEM (n=3). *significantly different to D1 (p<0.05).  
 
Reduction in viability and cell death of the mammary epithelial cells when cultured on 
day 4 involuting matrix was also confirmed by morphological analysis. The cells when 
observed under a light microscope were rounded with shrunken nuclei, detached from the 
underlying surface and floating in the media (data not shown).  
The loss of polarity of cells when cultured on late involution matrices compared to the 3-
dimensional acini structures on early involuting matrices was analysed by observing the 
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changes in expression of genes coding for Afadin and Scribble, proteins that regulate cell 
polarity.  
There was a significant down-regulation in the expression of genes belonging to the apical 
and basolateral complex, Afadin and Scribble respectively, in cells cultured on day 3 
involution matrix when compared to the expression levels seen in early involution 
matrices (Fig. 2.4). Since most of the cells cultured on day 4 involuting matrix were found 
dead and floating in the media, enough RNA could not be obtained to test for polarity 
markers.  
 
 
Fig. 2. 4.  Gene expression analysis of polarity markers by qPCR. The gene expression 
of polarity proteins Afadin and Scribble of mouse mammary epithelial cells cultured on 
days 1, 2 & 3 involution matrix (D0, D1, D2 & D3) cultured for 7 days was analysed by 
qPCR. The normalized gene expression levels were calculated relative to expression 
levels seen on day 0 involution (D0). All values are represented as mean ± SEM (n=3). 
*significantly different to D0 Afadin (p<0.05) and #significantly different to D0 Scribble 
(p<0.05). 
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2.3.3 Hormone responsiveness of mammospheres 
The hormone responsiveness of the mammospheres formed on early involuting matrices 
and the cells cultured on late involuting matrices was analysed by measuring the level of 
expression of the beta casein gene after addition of insulin, cortisol and prolactin to the 
culture media. The cells were cultured on the respective matrices in media with insulin 
(100 ng/mL) and cortisol (50 ng/mL) for 4 days. The media was then replaced with fresh 
media containing insulin, cortisol and prolactin (1 μg/mL). Media with no prolactin was 
added to the control wells. Three days after the addition of prolactin, RNA was extracted 
from the mammospheres on early involution matrices and the cells on day 3 involution 
matrix. Reverse transcription was performed with 1μg of RNA and beta casein gene 
expression was measured by quantitative PCR (qPCR). All expression levels were 
normalized to the GAPDH gene and expressed relative to the normalized expression 
levels of the respective controls (Fig. 2.5).  
It was observed that there was a significant increase in the expression of beta casein when 
the mammospheres formed on early involuting matrices were cultured in media with 
prolactin. In contrast, when the cells on day 3 involuting matrix were cultured in media 
containing prolactin, there was no significant increase in beta casein expression indicating 
their non-responsiveness to prolactin induction.  
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Fig. 2. 5. Hormone dependent expression of beta-casein gene in mammospheres. Beta 
casein gene expression was measured after the mammospheres on day 0, 1 & 2 involution 
matrices (D0, D1 & D2) and cells on day 3 involution matrix (D3) were treated with or 
without prolactin (P; 1 μg/mL). The prolactin treated samples were compared to control 
samples in the presence of insulin (I) and cortisol (F). All values are represented as mean 
± SEM (n=3). *significantly different to D0 IF (p<0.05), **significantly different to D1 
IF (p<0.05) and #significantly different to D2 IF (p<0.05). Conditions: IF- Insulin, 
Cortisol only; IFP- Insulin, Cortisol and Prolactin 
 
2.3.4 Influence of the ECM on retention of polarity 
Mammospheres from mouse mammary epithelial cells formed on early involuting 
matrices (days 0, 1 &2 involuting ECM) were lifted and cultured on late involuting 
matrices (days 3 & 4 involuting ECM) to study the programming of the cells towards 
retaining their polarity (Fig. 2.6). In order to lift the mammospheres formed on early 
matrices, the media was discarded after 4 days and the mammospheres gently scraped off 
the bottom of the wells using pipette tips. Mammospheres lifted and cultured again on the 
same matrices were considered as the control in these experiments. After 3 days of culture 
on late involuting ECM, the wells were photographed and the % cell viability was 
measured. RNA was extracted from these cells and the expression of polarity proteins 
Afadin and Scribble was analysed.  
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Fig. 2. 6. Experimental design for lifting mammospheres formed on early involuting 
matrices and culturing on extracellular matrix from late involution. Mammospheres 
from mouse mammary epithelial cells formed on early involuting matrices (days 0, 1 & 
2 involuting ECM – D0, D1 & D2) were lifted after 4 days and cultured on late involuting 
matrices (days 3 & 4 involuting ECM- D3 & D4) for a further 3 days.  
 
It was found that when the mammospheres formed on day 0 ECM were cultured on day 
3 involuting matrix, they lost their polarity and the 3-dimensional structure was partially 
dismantled (Fig. 2.7). In addition to the loss of 3-dimensional structure, when the 
mammospheres were cultured on day 4 involuting matrix, they also lost viability (Fig. 
2.8). Similar results were obtained when mammospheres from day 1 and day 2 involuting 
matrices were cultured on day 3 and day 4 involuting ECM.  
 
 
 
 
 
D3/ D4 Involution ECM Mammospheres from D0/ 
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Fig. 2. 7. Mammospheres from early involuting matrices cultured on late involuting 
matrices. Mammospheres cultured for 4 days on early involuting matrices (days 0, 1 & 
2) were lifted and cultured on late involuting matrices (days 3 & 4) for a further 3 days. 
A) Mammospheres grown on Day 0 matrix transferred to day 3 matrix, B) 
Mammospheres grown on Day 1 matrix transferred to day 3 matrix, C) Mammospheres 
grown on Day 2 matrix transferred to day 3 matrix, D) Mammospheres grown on Day 0 
matrix transferred to day 4 matrix, E) Mammospheres grown on Day 1 matrix transferred 
to day 4 matrix, F) Mammospheres grown on Day 2 matrix transferred to day 4 matrix, 
G) Mammospheres grown on Day 0 matrix transferred to day 0 matrix, H) 
Mammospheres grown on Day 1 matrix transferred to day 1 matrix  & I) Mammospheres 
grown on Day 2 matrix transferred to day 2 matrix. G-I are the controls in the study. On 
day 3 matrix, the mammospheres dissociated. On day 4 matrix, in addition to dissociation 
there was also cell death observed. All images were photographed at 10x magnification.  
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Fig. 2. 8. MTS assay for cell viability. Cell viability was determined by MTS assay for 
the mammospheres formed on early involuting matrices (days 0, 1 & 2 involuting ECM 
– D0, D1 & D2) transferred to late involuting matrices (days 3 & 4 involuting ECM – D3 
& D4). Mammospheres cultured on their own matrices (i.e. Mammospheres formed on 
D0 involuting matrix transferred to D0 involuting matrix, etc.) were used as control and 
% cell viability was expressed relative to these mammospheres. All values are represented 
as mean ± SEM (n=3). *significantly different to ‘D0 to D3’ (p<0.05), **significantly 
different to ‘D1 to D3’ (p<0.05) and #significantly different to ‘D2 to D3’ (p<0.05). 
 
RNA extracted after 3 days of culturing the mammospheres initially grown on day 0, 1 
& 2 involution matrix and transferred to late involuting matrices was reverse transcribed 
to cDNA followed by qPCR analysis of gene expression of the polarity proteins Afadin 
and Scribble. There was significant down-regulation of gene expression of these markers 
when mammospheres were transferred to both day 3 and day 4 involuting matrices (Fig. 
2.9).  
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Fig. 2. 9. Gene expression analysis by qPCR. Expression of polarity markers Afadin 
and Scribble was measured by qPCR for the mammospheres formed on early involuting 
matrices (days 0, 1 & 2 involuting ECM – D0, D1 & D2) transferred to late involuting 
matrices (days 3 & 4 involuting ECM – D3 & D4). The expression was normalized 
against GAPDH and relative normalized expression was calculated relative to the 
respective controls (D0 to D0, D1 to D1 and D2 to D2). All values are represented as 
mean ± SEM (n=3). *significantly different to ‘D0 to D0’Afadin (p<0.05), #significantly 
different to ‘D0 to D0’Scribble (p<0.05), **significantly different to ‘D1 to D1’Afadin 
(p<0.05), ##significantly different to ‘D1 to D1’Scribble (p<0.05), #*significantly 
different to ‘D2 to D2’Afadin (p<0.05) and **#significantly different to ‘D2 to 
D2’Scribble (p<0.05). 
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2.3.5 Reversal of loss of polarity 
Viable epithelial cells which failed to form mammospheres on day 3 involuting matrix 
were lifted and cultured on early involuting matrices (days 0, 1 & 2) to see if the loss of 
polarity could be reversed (Fig. 2.10).  
 
 
                    
                    
 
 
Fig. 2. 10. Experimental design for lifting cells on day 3 involuting matrices and 
culturing on extracellular matrix from early involution. Mouse mammary epithelial 
cells cultured on day 3 involuting matrix (D3) were lifted after 4 days and cultured on 
early involuting matrices (days 0, 1 & 2 involuting ECM – D0, D1 & D2) for a further 3 
days.  
 
It was found that there was absence of formation of mammospheres following transfer of 
cells to matrix isolated from early involuting mammary gland. The cells cultured on day 
3 involuting matrix survived on the early involuting matrices, but they lost their 
polarization potential and this could not be reversed by transferring them on to early 
involuting matrices (Fig. 2.11). There was no difference in the percentage of cell viability 
when the cells from day 3 involuting matrix were cultured on day 0, 1 and 2 involuting 
matrices (Fig. 2.12), indicating that although the cells could not regain polarity they 
remained viable.                                 
Cells from D3 Involution 
ECM 
D0/D1/ D2 Involution ECM 
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Fig. 2. 11. Cells from day 3 matrix on early involuting matrices. Cells cultured on day 
3 involuting matrix that were viable were lifted and cultured on A) Day 0 involuting 
matrix, B) Day 1 involuting matrix , C) Day 2 involuting matrix & D) Day 3 involuting 
matrix (Control). There was no mammosphere formation observed under these 
conditions. All the images were captured at 4x magnification.  
 
 
Fig. 2. 12. MTS assay for cell viability. Cell viability was calculated by Promega MTS 
assay for the cells cultured on day 3 involuting matrix (D3) and transferred to early 
involuting matrices (days 0, 1 & 2 involuting ECM – D0, D1 & D2). Cells cultured on 
day 3 involuting matrix and transferred to day 3 involuting ECM (D3) were considered 
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as control and % cell viability was calculated relative to this. All values are represented 
as mean ± SEM (n=3). No significant changes in cell viability were observed.  
 
RNA extracted from these cells was reverse transcribed to cDNA and the gene expression 
levels of polarity proteins Afadin and Scribble were analysed. Again, there was no 
difference in expression levels of these polarity markers when compared to the control 
(day 3 cells on day 3 matrix) (Fig. 2.13).  
 
 
 
Fig. 2. 13. Gene expression analysis by qPCR. Gene expression of polarity markers 
Afadin and Scribble was measured by qPCR when cells cultured on day 3 involuting 
matrix (D3) for 4 days were transferred to days 0, 1 & 2 involution matrices (D0, D1 & 
D2) and cultured for further 3 days. Cells cultured on day 3 involuting matrix and 
transferred to day 3 involuting ECM (D3) were considered as control. The expression 
was normalized against GAPDH and relative normalized expression was calculated 
relative to expression levels on control. All values are represented as mean ± SEM (n=3). 
No significant changes in expression levels were observed. 
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2.4 Discussion 
When a sexually mature mouse becomes pregnant, the mammary gland begins a cycle of 
lobulo-alveolar development and maturation which results in fully functional and 
differentiated secretory epithelium producing milk during lactation. The morphological, 
ultra-structural and biochemical changes in the mammary gland after cessation of 
lactation are equally remarkable (Lund, Romer et al. 1996). The mammary gland thus 
completes a cycle of growth, functional differentiation and involution with each 
successive pregnancy. These processes illustrate how proliferation, differentiation and 
apoptosis are integrated into the organization of a complex three-dimensional tissue unit, 
whose function changes with time (Gordon, Binas et al. 2000). Each of these stages of 
development are hormonally regulated and the necessity for the complex structural and 
hormonal interactions provide a challenge for development of an in vitro model to 
accurately study the differentiation and death of mammary epithelial cells (Brisken and 
O'Malley 2010). The majority of in vitro experiments used to study the regulation of 
genes and molecular pathways involved in apoptosis and involution have been cell culture 
based models. However, whole organ culture and mammary explants have also been used 
to investigate mammary involution (Atwood, Ikeda et al. 1995). We developed an in vitro 
model, the mammosphere model (Romagnolo and DiAugustine 1994, Debanth, 
Muthuswamy et al. 2003), to study the extracellular matrix-cell interactions, and the 
effects of milk-borne factors and hormones that govern the organization of mammary 
epithelium during the two phases of involution. The mammosphere is a three dimensional 
in vitro model comprised of polarized epithelial cells having similar functionality to 
secretory alveoli (Mailleux, Overholtzer et al. 2008) and they develop on an ECM. 
Mammary epithelial cells cultured on ECM form a hollow lumen and upon lactogenic 
hormone induction synthesize milk proteins and secrete them into the lumen (Mailleux, 
Overholtzer et al. 2008).  
2.4.1 Mammosphere formation on early involution matrices 
Earlier studies using microarray analysis have shown an increase in the expression of 
apoptotic transcripts as early as 12 hours after the onset of involution (Clarkson, Wayland 
et al. 2004). Involution is thought to be initiated by mammary derived signals and milk 
stasis is likely to be the primary trigger in inducing involution (Li, Liu et al. 1997, Marti, 
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Feng et al. 1997). The build-up of secreted pro-apoptotic factors in milk which are 
normally removed by nursing, and mechanical stretch of the alveolar epithelium due to 
milk retention causing the activation of stretch receptors and altering the cell-matrix 
interactions, are some theories suggesting how milk stasis might initiate involution 
(Green and Streuli 2004, Quaglino, Salierno et al. 2009). We dissected the model of 
involution and studied the effect of an individual component, namely the ECM, on the 
proliferation, functional differentiation, capability to respond to hormones and produce 
milk proteins, and cell death of mammary epithelial cells. The cells were cultured on 
involuting matrices in media devoid of epithelial growth factor (EGF). EGF belongs to a 
family of proteins which act as survival factors for mammary epithelial cells and its 
expression peaks during lactation and dramatically decreases during involution in the 
mammary gland (Wirl, Hermann et al. 1995). Production of milk proteins is known to be 
induced in vitro by the synergistic interactions of insulin, prolactin and glucocorticoids, 
while it is inhibited by EGF and progesterone (Borellini and Oka 1989). Since EGF has 
an anti-apoptotic effect on the epithelial cells, it was added only to maintain the cells in 
culture and not used in the experimental conditions (Romorini, Coso et al. 2009). We 
know that ECM-cell interaction in the mammary gland regulates cell polarity and milk 
protein gene expression with the induction of lactogenic hormones (Topper and Freeman 
1980, Aggeler and Bissell 1987). In our study, when epithelial cells were laid on early 
involuting matrices from day 0, 1 and 2 of involution, there was no cell death and these 
cells polarized to form mammospheres and remained viable in culture. The ability of the 
cells to polarize was measured by the gene expression of two signature proteins that 
regulate polarity, namely Afadin and Scribble. Normal cell architecture is established by 
the orientation cues provided by these polarity proteins (Chatterji, Seifried et al. 2012, 
Godde, Sheridan et al. 2014). The regulators of cell polarity in epithelial cells are grouped 
as members of the apical and basolateral complex (Macara and Mili 2008). The apical 
complex includes the following proteins: Afadin/AF6, Crumbs, Junctional adhesion 
molecules (JAMs), PATJ, PALS, atypical Protein Kinase C (aPKC), Partitioning 
defective complex members Par3, Par6, etc. The basolateral complex members include 
Scribble, Lethal giant larvae (lgl) and Discs large (Dlg) (Macara and Mili 2008). It has 
been shown that disruption of polarity proteins, Scribble, Dlg1 and Af6/Afadin along with 
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ErbB2 activation primes epithelial cells to cooperate with oncogenes to promote invasive 
behaviour (Chatterji, Seifried et al. 2012). Literature shows evidence for the role of the 
ECM and its components in regulating milk protein gene expression in mouse, such as 
WAP (Lin, Dempsey et al. 1995) and β-casein (Li, Aggeler et al. 1987, Streuli, Bailey et 
al. 1991). Introduction of the lactogenic hormone cocktail of insulin, prolactin and 
glucocorticoids in the media resulted in an up-regulation of β-casein gene expression. 
This indicated that the mammospheres formed when mammary epithelial cells were 
cultured on extracellular matrices obtained from days 0, 1 & 2 of involution formed 3-
dimensional acini structures, polarized and capable of expressing milk protein genes upon 
hormone induction, thus conferring the reversibility of the process during early 
involution. It has been shown in earlier studies that when a single mammary epithelial 
cell is in contact with a basement membrane gel, it is capable of synthesizing β-casein, 
implying that the signals emanating from the ECM alone were sufficient and necessary 
for tissue specific gene expression (Roskelley, Desprez et al. 1994).  
2.4.2 Mammosphere formation on late involution matrices 
In contrast, when cells were cultured on day 3 involuting matrix, they did not come 
together to form 3-dimensional acini structure/mammospheres. Although there was a 
reduction in cell viability seen in the MTS assay, there was no significant cell death 
observed. In order to determine if this was due to loss of ability of the cells to form 3-
dimensional acini structures or a loss of polarization signal from the ECM, the expression 
of genes coding for polarity proteins, Afadin and Scribble were analysed. There was 
significant down-regulation of the expression of genes encoding these polarity proteins, 
implying a loss of polarity of the cells when laid on this matrix. Since the ECM-cell 
interaction is known to regulate cell polarity (Topper and Freeman 1980, Aggeler and 
Bissell 1987), we can conclude that the matrix remodelling happening during the second 
phase of involution (Kessenbrock, Plaks et al. 2010, Watson and Kreuzaler 2011) 
contributes to the loss of polarity signals and hence the irreversibility to form polarized, 
milk producing mammospheres during late involution.  
Lactogenic hormone induction saw no up-regulation of milk protein genes like β-casein, 
confirming the non-responsiveness of these cells to hormones. Evidence from the 
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literature states that a small amount of apoptosis occurs during the start of the second 
phase of involution and by late involution, apoptosis is well underway within the gland 
accompanied by matrix remodelling (Green and Lund 2005). Matrix remodelling is 
primarily induced by the matrix metalloproteinases (MMPs) through cleaving substrates 
such as collagen IV, chemokines and E-cadherins, facilitating cell detachment (Pullan, 
Wilson et al. 1996, Watson and Kreuzaler 2011). Apoptosis in the later stage of involution 
appears to be influenced by constituents contained within the ECM as seen in our study 
when the mammary epithelial cells were cultured on day 4 involuting matrix. In addition 
to the loss of polarity, there was significant cell death observed. The second phase of 
involution also sees adipocyte differentiation to re-populate the fat pad in order to return 
the gland to a pre-pregnant state (Lund, Romer et al. 1996, Lu, Weaver et al. 2012). This 
adipocyte re-population was seen in our histological analysis of the tissue collected 
during the second phase of involution.  
2.4.3 ECM contribution to the reversibility of mammary involution 
Post-lactational involution is divided into two distinct phases: an early, reversible phase 
characterized by engorgement of the gland with milk, and initial apoptosis of mammary 
epithelial cells and a second, irreversible phase characterized by extensive apoptosis and 
tissue remodelling (Strange, Li et al. 1992). The reversibility of the first phase was 
demonstrated when teat sealing experiments were conducted in mice (Li, Liu et al. 1997), 
but not in in vitro culture studies. In order to further understand the reversibility of the 
involution process, polarized mammospheres capable of expressing β-casein upon 
lactogenic hormone induction, formed on early involuting matrices were lifted and 
cultured on late involuting matrices. The complete loss of the 3-dimensional acini 
structure and polarity, shown by significant down-regulation of genes for the polarity 
proteins and loss of milk protein gene expression (β-casein) revealed a role for the 
extracellular matrix in the switch between the reversible and irreversible phases of 
involution. It has been shown in earlier studies that during early involution, laminins and 
type IV collagen are destroyed, whereas tenascin is deposited (Roskelley, Srebrow et al. 
1995). The addition of this latter ligand to differentiated mammary epithelial cells in 
culture down-regulates endogenous β-casein gene expression (Chammas, Taverna et al. 
1994, Jones, Boudreau et al. 1995). Thus, although the mammary epithelial cells were 
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driven to polarize and become functional, expressing milk protein genes, when cultured 
on early involuting ECM, the signals from the late involuting matrices overrode this 
functionality and caused depolarization of the mammospheres. The cells become no 
longer capable of polarization to form a milk producing structure at this stage. The second 
phase of involution is characterized by an irreversible loss of mammary epithelial cells 
and when pups are returned back to the mother at this stage, the mother can no longer re-
initiate lactation (Stein, Morris et al. 2004, Watson 2006). In our in vitro model, this was 
studied by lifting viable cells on day 3 involuting matrix and culturing them on early 
involuting matrices. The irreversible loss of polarity and ability to synthesize milk 
proteins upon lactogenic hormone induction indicates that the ECM signals the mammary 
epithelial cells to irreversibly lose their ability to form secretory structures capable of 
producing milk. Thus the extracellular matrix and its components contribute to 
maintaining the reversibility of the two step involution process and play an important role 
in the involution switch.   
2.5 Conclusion 
To conclude, 
i. The ECM controls the ability of mammary epithelial cells to form 3-dimensional 
structures resembling the secretory alveoli in the mammary gland and their milk 
producing ability upon lactogenic hormone induction. 
ii. The ECM does not contribute to the initial apoptotic signals seen at the onset of 
involution. 
iii. The ECM signals apoptosis during late involution and this is attributed to changes 
in the matrix following activation of matrix metalloproteinases (MMPs) and tissue 
remodelling. 
If the initial apoptotic signals are not originating from the extracellular matrix, where do 
they come from? This question will be addressed in the following section of our study 
where we investigated the effect of stromal factors and milk contributing to apoptosis 
during involution.  
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Chapter 3: The role of milk and adipocytes in regulating 
the two phases of murine mammary gland involution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 97 
 
3.1 Introduction 
Milk has a significant role in providing nutrition to the newborn as well as playing a role 
in regulating mammary gland growth and death (Brennan, Sharp et al. 2007b, Sharp, 
Lefevre et al. 2008, Topcic, Auguste et al. 2009, Nicholas, Sharp et al. 2012). It has the 
potential to signal development of the neonate and also helps in protecting the mammary 
gland from infection (Kwek, De Longh et al. 2009, Tomasinsig, De Conti et al. 2010, 
Wanyonyi, Sharp et al. 2011, Watt, Sharp et al. 2012, Morgan, Riley et al. 2014). 
Lactation is the result of two processes: the synthesis and secretion of milk into the lumen 
and the subsequent removal of milk from the mammary gland (Holmes, Brookes et al. 
2002). The number of mammary secretory cells and their activity influence the level of 
milk production, with a daily milk production range of 1-2 mL per gram of mammary 
tissue across all species (Holmes, Brookes et al. 2002). The two important components 
regulating maintenance of lactation are galactopoietic hormones and the removal of 
accumulated milk from the gland (Delouis, Dijiane et al. 1980, Tucker 1985, Rillema 
1994, Wilde, Knight et al. 1999).  
Cessation of milk removal leads to significant and rapid changes in the mammary tissue 
and initiates the process of involution (Hurley 1989). Mammary involution is 
characterized by loss of tissue function and degeneration of alveolar structure along with 
massive loss of mammary secretory epithelial cells and down-regulation of differentiated 
gene expression (Walker, Bennett et al. 1989, Strange, Li et al. 1992, Marti, Feng et al. 
1997). According to its reversibility, murine mammary involution has two distinct stages 
– the reversible and irreversible phases. During the first phase, lactation can be re-
established if pups are returned back to the mother within 48 hours enabling the mammary 
epithelial cells (MECs) which have entered the initial non-committed apoptosis stage, to 
return to an active secretory state in response to milk removal (Jaggi, Marti et al. 1996, 
Li, Liu et al. 1997, McMahon, Farr et al. 2004). This phase is assumed to be initiated by 
local signals since the addition of galactopoietic hormones (glucocorticoids) does not 
affect apoptosis at this stage (Li, Liu et al. 1997). However, the addition of prolactin has 
been demonstrated to inhibit involution of the mouse mammary gland for up to 4 days 
(Flint, Boutinaud et al. 2006). The cell survival effects of prolactin are in turn inhibited 
by IGFBP-5, by inhibiting phosphorylation of STAT5, a downstream signalling molecule 
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of prolactin (Tonner, Barber et al. 2002, Flint, Boutinaud et al. 2006). Thus, local intra-
mammary death signals dominate over the protective effects of systemic survival signals 
during phase I of involution (Quarrie, Addey et al. 1996, Li, Liu et al. 1997, Marti, Feng 
et al. 1997). Phase II murine mammary involution is characterized by ECM remodeling 
and collapse of lobulo-alveolar structures by ECM-degrading proteases, returning the 
gland to a pre-pregnant state. Addition of galactopoietic hormones delays and prevents 
the onset of this stage, suggesting the dominance of systemic control of phase II 
involution (Talhouk, Bissell et al. 1992, Lund, Romer et al. 1996, Sorenson and Knight 
1997).  
Composition changes in mammary secretions during early involution indicate changes in 
the normal mechanisms of milk synthesis and secretion (Linzell and Peaker 1971, Peaker, 
Jones et al. 1975, Hurley and Rejman 1986, Khalil, Digby et al. 2008). These composition 
changes include a rapid decline in the concentration of lactose, indicating a decline in 
lactose synthesis and associated water transport mechanisms following cessation of milk 
removal. There is an increase in total protein concentration in early involution, partly due 
to water resorption from the milk and due to increased concentration of serum albumin, 
lactoferrin and immunoglobulins (Hurley 1987). The synthesis of lactoferrin is increased 
during involution, in contrast to a decrease in synthesis of milk specific proteins such as 
caseins (Nicholas and Hartmann 1991, Hurley and Rejman 1993, Aslam, Jimenez-Flores 
et al. 1994). Our study also analyzed milk composition changes during the early and late 
involution phases.  
Numerous studies have been conducted to investigate the profile of gene expression 
during mouse mammary gland involution (Baik, Lee et al. 1998, Marti, Lazar et al. 1999, 
Clarkson and Watson 2003, Clarkson, Wayland et al. 2004, Stein, Morris et al. 2004, 
Stephen and Lewis 2004, Zhou, Gong et al. 2014). The most comprehensive study carried 
out by Clarkson, Wayland et al. (2004) revealed the prominence of genes involved in 
DNA damage and apoptosis, metabolism, cellular protection and inflammation during 
involution. Another study using gene pathway networks highlighted lipid synthesis, 
metabolism, tissue morphology and architecture, mechanical stress and cell survival and 
immune response and protection during involution (Blanchard, Shiu et al. 2007). The 
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early involuting gland thus provides a resource of genes that are critical to mammary 
tissue regression and programmed cell death, and delineation of the roles of these genes 
will have implications for breast cancer management (Blanchard, Shiu et al. 2007). The 
second phase of involution is characterized by up-regulation of genes involved in ECM 
breakdown, especially proteases, and down-regulation of their inhibitors, TIMPs 
(Strange, Li et al. 1992, Talhouk, Bissell et al. 1992, Li, Strange et al. 1994, Lund, Romer 
et al. 1996).  
Although historical observation and different research groups agree that accumulation of 
milk is fundamental for the onset of involution (Talhouk, Bissell et al. 1992, Lund, Romer 
et al. 1996, Quarrie, Addey et al. 1996, Li, Liu et al. 1997), the explicit signal and initial 
trigger for mammary epithelial cell apoptosis remains unclear. The trigger for the switch 
from reversible to irreversible involution also remains an area to be investigated.  
Milk stasis has been identified as a likely trigger for the onset of mammary involution 
(Marti, Feng et al. 1997, Green and Streuli 2004). The accumulation of milk in the 
mammary gland as a result of cessation of suckling allows factors within milk to regulate 
the function of mammary epithelium causing down-regulation of milk protein gene 
expression and involution by apoptotic cell loss (Li, Liu et al. 1997). A milk protein, 
feedback inhibitor of lactation (FIL) has been shown to act specifically on the apical 
surface of mammary epithelial cells to reduce secretory efficiency by inhibiting the 
movement of proteins and is sensitive to the frequency and completeness of milk removal 
from the gland (Wilde, Addey et al. 1995, Hendry, Simpson et al. 1998). The study of 
involution in the fur seal has been proposed as an interesting model to study the factors 
that trigger the apoptotic phase, and those that separate the two phases of involution 
(Sharp, Lefevre et al. 2008). During foraging at sea in the absence of suckling, fur seal 
mammary glands produce 80% less milk than when lactating on land and there is decrease 
in milk protein gene expression (Arnould and Boyd 1995, Sharp, Cane et al. 2006), both 
of which are characteristics of initiation of involution (Lund, Romer et al. 1996). 
However, in contrast to other mammals, the fur seal mammary gland does not undergo 
involution comprising apoptosis (mammary epithelial cell death) and remains active to 
continue nursing the young upon return to land (Sharp, Cane et al. 2006). These animals 
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display resistance to mammary involution and apoptosis although there is milk 
accumulated in the gland (Sharp, Lefevre et al. 2008). It has been shown that this absence 
of mammary involution in the fur seal mammary gland is due to the absence of alpha-
lactalbumin (LALBA) in fur seal milk (Sharp, Lefevre et al. 2008). This work on fur seal 
enlightens us about the potential role of alpha-lactalbumin in involution in other species.  
It has been well documented that breast milk contains bioactive components and recent 
studies have been directed towards identifying the bioactive peptides in milk (Lonnerdal 
2003, Baldi, Ionnis et al. 2005, D'Alessandro, Scaloni et al. 2010, Lonnerdal 2010, 
Sedaghatia, Ezzatpanaha et al. 2014). The milk cryptome or peptidome consists of 
peptides that are formed through the proteolytic digestion of proteins to release latent 
bioactive peptides (Meisel 2004, Autelitano, Rajic et al. 2006, Pimenta and Lebrun 2007). 
The catalytic activity of systemic protease enzymes and protease inhibitors play an 
important role in the proteolysis of milk proteins (Shen and Chou 2009). Milk contains a 
number of bioactive proteins with a multitude of functions and considerable work has 
been done on peptides derived from bovine milk proteins such as alpha-lactalbumin, β-
casein, κ-casein, α-casein, lactoferrin and β-lactoglobulin (Meisel and Fitzgerald 2000, 
Meisel 2004, Meisel 2005, Kanda, Hisayasu et al. 2007, Schmelzer, Schops et al. 2007). 
The bioactive milk peptides have been shown to possess a number of functions including 
antimicrobial (Liepke, Zucht et al. 2001, Gifford, Hunter et al. 2005, Dallas, Guerrero et 
al. 2013a), proliferative (Kanda, Hisayasu et al. 2007, Morgan, Riley et al. 2014), 
immunomodulatory (Qian, Xing et al. 2011, Adel-Patient, Nutten et al. 2012), 
antithrombotic (Fiat, Migliore-Samour et al. 1993, Chabancea, Jollesa et al. 1995), opioid 
stimulation (Koch, Wiedemann et al. 1985, Migliore-Samour, Floc'h et al. 1989, 
Teschemacher, Koch et al. 1997) and as ACE inhibitors (Wu, Pan et al. 2013). 
Understanding the role of proteases that are secreted in milk and the potential effects of 
peptides in milk will help provide new insights into mammary gland function and 
development. Typical methods to digest milk proteins and study the activity of proteases 
in releasing bioactive peptides has involved incubating milk or individual milk proteins 
with proteases found in the gut like pepsin, trypsin and chymotrypsin (Kitazawa, 
Yonezawa et al. 2007, Schmelzer, Schops et al. 2007, Eriksen, Holm et al. 2010, 
Picariello, Ferranti et al. 2010, Morgan, Riley et al. 2014). There has been limited analysis 
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of proteases found in milk and the bioactive peptides released as a result of their 
proteolytic activity (Kitazawa, Yonezawa et al. 2007). We aimed to address this limitation 
by incubating mouse milk isolated at the onset of involution for 1-4 days to study the 
effect of proteases accumulated in milk during involution on the milk proteins and 
subsequent release of bioactivity intrinsic to these proteins. Changes in expression of milk 
proteases during the lactation cycle has been previously reported (Riley, Zubair et al. 
2006, Albenzio, Santillo et al. 2009). The current study aims to identify if changes in 
expression of genes for proteases secreted into milk are important for the transition from 
phase 1 to phase 2 of involution. It is important to study their action within the mammary 
gland as it is a process that primarily (but not exclusively) leads to regulation of mammary 
function as opposed to the studies using gut proteases.  
Stromal fibroblasts and adipocytes in the mammary gland are known to influence 
mammary gland development and differentiation (Levine and Stockdale 1985, Polyak 
and Kalluri 2010). Co-culturing experiments where MECs demonstrated growth 
promoting activity due to interaction with adipocytes confirms the role of cell-cell 
interactions in mammary gland regulation and function (Levine and Stockdale 1984, 
Hovey and Aimo 2010).The caveolin family of proteins, expressed specifically by 
myoepithelial cells and adipocytes, have been implicated in lactation in the mouse (Park, 
Lee et al. 2001, Park, Lee et al. 2002). The expression of caveolin 1 and 2 genes in mouse 
mammary gland was shown to be elevated before and during early pregnancy, down-
regulated during lactation and subsequently up-regulated with the onset of involution at 
levels similar to the non-pregnant state (Park, Lee et al. 2001). Interestingly, the 
expression of caveolins was found to be localized to the myoepithelial cells and 
adipocytes, and not the secretory epithelial cells. Paracrine regulation due to cell-cell 
interactions between the mammary epithelial cells, adipocytes and myoepithelial cells is 
mediated by a complex interplay of hormones (Sotgia, Casimiro et al. 2009, Kuruppath, 
Sharp et al. 2014). The current study investigates the role of caveolins and the influence 
of cell-cell interaction on mammary epithelial cells during involution. For example, is 
caveolin 1 secreted from other cell types to impact on the mammary epithelial cells or is 
it potentially driving a response in these cells that leads to the secretion of paracrine 
signals is an area that needs to investigated in detail. The mammary gland is concurrently 
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regulated by peripheral hormones and growth factors, by milk and by the surrounding 
cells/tissue. This regulation is complex with considerable changes occurring in the tissue 
as the gland proceeds through the lactation cycle, particularly from galactopoesis to 
involution. This study examines the way adipocytes (and particularly caveolins) 
contribute to this complex regulation of the mammary gland.  
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3.2 Materials and methods 
3.2.1 Animals  
BALB/c mice were obtained from ARC (Animal Resources Centre), Western Australia. 
Pups were removed from the mice at day 15 lactation (this was considered as day 0 
involution) and the mothers were housed in the Deakin University animal center for 
further experiments. The mothers were milked on days 0-3 of involution. 
3.2.2 Milking procedure 
Five mothers were used for each time point of involution and each mouse was used only 
once for milking. For day 0 involution milk collection, the pups were removed from the 
dam 4 hours prior to the milking procedure. The mice were anaesthetized using doses of 
isoflurane (CDS019936, Sigma, Sydney, Australia) that complied with the Committee 
for Animal Welfare regulations. Following this, each mouse received 50 μL (0.5 IU/mL) 
of oxytocin (Ilium Syntocin, synthetic oxytocin, 50435, Troy laboratories, New South 
Wales, Australia), a 9 amino acid peptide with an extremely short half-life, injected 
intraperitoneally using a 29 gauge needle attached to a 0.5 mL Terumo syringe. Milking 
was initiated within 1 minute of administration of oxytocin by applying Vaseline to the 
teats, massaging the gland and manually milking the mouse. Milk was collected in 0.2 
mL PCR tubes and samples were kept on ice immediately and stored at -80˚C for long 
term use.  
3.2.3 Analysis of milk composition  
Skim milk was used for analyzing the total carbohydrate and protein composition, 
whereas neat milk samples were used for lipid analysis. The collected milk samples were 
centrifuged at 1000g for 5 minutes at 4˚C. The upper layer of fat was removed and the 
centrifugation step was repeated for complete removal of fat. The skim milk was diluted 
according to the sensitivity of the assay.  
3.2.3.1 Total protein estimation 
The total protein content was measured by using the Thermo Scientific Pierce Micro BCA 
protein assay kit (23235, Thermo Fisher Scientific, Victoria, Australia). This assay is 
based on bicinchoninic acid formulation for colorimetric detection and quantitation of 
total protein (Brown, Jarvis et al. 1989). The milk samples were diluted 1000 fold in 
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autoclaved double distilled water. BSA protein standards were prepared in the range of 
0.5 μg/mL to 200 μg/mL in triplicate. 75 μL of each standard, water (blank) and the 
diluted milk samples (in triplicate) were pipetted into microplate wells. 75 μL of working 
reagent consisting of Micro BCA reagents A, B & C in the ratio 25:24:1 was added to the 
wells and the plate was shaken for 30 seconds on a plate shaker. The plate was then 
incubated at 37 ˚C for 2 hours. Following this, the plate was cooled to room temperature 
and the absorbance was measured at 562 nm using a plate reader (Biorad xMarkTM 
microplate absorbance spectrophotometer). 
3.2.3.2 Carbohydrate estimation 
The carbohydrate concentration was determined using the phenol-sulfuric acid method in 
micro-plate format (Masuko, Minami et al. 2005). The milk samples were diluted 1000 
fold with autoclaved double distilled water. Glucose (783, Ajax Finechem, Victoria, 
Australia) solutions were prepared in the range of 5 μg/mL to 100 μg/mL and used as 
standards for the assay. 50 μL of glucose standards, blank (water) and diluted milk 
samples (in triplicate) were placed in microfuge tubes. 150 μL of concentrated sulfuric 
acid (Merck, Victoria, Australia) and 30 μL of 5% phenol (P9346, Sigma, Sydney, 
Australia) was added. The tubes were incubated at 90 ˚C for 5 minutes. The tubes were 
cooled to room temperature for 5 minutes and the contents were transferred to a 96 well 
plate, and absorbance was measured at 490 nm using a plate reader (Biorad xMarkTM 
microplate absorbance spectrophotometer).  
3.2.3.3 Lipid estimation 
The lipid concentration in the milk samples was determined by colorimetric method in 
micro-plate format (Atwood and Hartmann 1992). Milk samples without dilution were 
used for this assay. Triolein (T7140, Sigma, Sydney, Australia) solutions prepared in the 
range of 5 mg/mL to 200 mg/mL with chloroform (CA038, Chemsupply, South Australia) 
and methanol (MA004, Chemsupply, South Australia) (2:1) mixture were used as 
standards. 2.5 μL of blank (chloroform: methanol: 2:1), standards and milk samples (in 
triplicate) were transferred to microfuge tubes. 600 μL of ethanol (EA043, Chemsupply, 
South Australia) was added to each tube followed by the addition of 100 μL of 2 M 
hydroxylamine hydrochloride (379921, Sigma, Sydney, Australia). The contents of the 
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tube were then vortexed. 100 μL of 3.5M Sodium hydroxide (NaOH, Merck, Victoria, 
Australia) was added to each tube, vortexed and the tubes were incubated at room 
temperature for 20 minutes. 100 μL of 4 M hydrochloric acid (HCl, Merck, Victoria, 
Australia) was added to the tubes followed by the addition of 100 μL of 0.37 M ferric 
chloride (157740, Sigma, Sydney, Australia) made up with 0.1 M HCl. The tubes were 
vortexed and 250 μL of the contents were transferred to a 96 well plate. The absorbance 
was measured at 540 nm using a plate reader (Biorad xMarkTM microplate absorbance 
spectrophotometer).  
3.2.4 SDS-PAGE  
For qualitative analysis, 2 μL of 10 times diluted skim milk samples from the 4 time 
points of involution were used for analysis by SDS PAGE (Boumahrou, Andrei et al. 
2009). Day 0 involution milk with 0.01% sodium azide (S8032, Sigma, Sydney, 
Australia) to prevent bacterial contamination, was incubated at 37 ˚C with 150 rpm in a 
Thermoline Scientific orbital shaker incubator for 4 days. A small amount of the sample 
was collected every day and diluted 10 times to be run on the gel. 2 μL of the diluted milk 
samples were mixed with 15 μL of 2x SDS loading buffer containing 250 mM Tris HCl 
(H5131, Promega, Sydney, Australia) at pH 6.8, 10% Sodium dodecyl sulfate (SDS, 
L3771, Sigma, Sydney, Australia), 30% glycerol (242, Ajax finechem, Victoria, 
Australia), 5% β-mercaptoethanol (M6250, Sigma, Sydney, Australia) and 0.02% 
bromophenol blue (B0126, Sigma, Sydney, Australia). The tubes were incubated at 95˚C 
for 5 minutes followed by cooling at room temperature. The samples were then 
electrophoresed at 200V for 50 minutes using a 12% SDS-polyacrylamide gel (TGX 
Criterion gels, 567-1043, Biorad, Sydney, Australia). The running buffer was made up of 
25mM Tris, 192mM glycine (G8898, Sigma, Sydney, Australia) and 0.1% SDS. Seeblue 
plus2 prestained protein standard (LC5925, Invitrogen, Life Technologies, Victoria, 
Australia) was used as marker. The gel was stained in 0.05% Coomassie brilliant blue 
(CBB, B7920, Sigma, Sydney, Australia) solution made up with 40% methanol (MA004, 
Chemsupply, South Australia) and 10% acetic acid (AA009, Chemsupply, South 
Australia). This was followed by destaining in 40% methanol and 10% acetic acid 
solution.  
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Another set of the samples were run on a different gel and silver stained for enhanced 
visualization of the bands. In order to examine casein breakdown and whey proteins in 
the samples, the casein and whey fraction were separated and run individually on the gels. 
The skim fraction of the milk samples were centrifuged at 10,000xg for 10 minutes at 
4˚C. The whey fraction (supernatant) and the casein pellet were separated. The 
centrifugation step was repeated to ensure complete separation of casein and whey 
fractions. The casein pellet was suspended, vortexed and finally dissolved in 50 mM 
NaOH (Merck, Victoria, Australia). The samples were then electrophoresed at 200 V for 
50 minutes using a 12% SDS-polyacrylamide gel. Silver staining is an ultrasensitive, low 
background staining system. A Pierce silver stain kit (24612, Thermo Fisher Scientific 
Inc., Victoria, Australia) was used to stain the gels. The gel was placed on a clean staining 
try (glass or plastic) and all steps were carried out with constant gentle shaking. The gel 
was washed twice for 5 minutes each in ultrapure water. This was followed by the fixing 
step, where the gel was immersed in 30% ethanol:10% acetic acid solution (6:3:1 
water:ethanol:acetic acid) and placed on a shaker for 15 minutes. This step was repeated 
with fresh fixing solution for another 15 minutes. The gel was then subjected to washing 
in 10% ethanol twice for 5 minutes each followed by washing in ultrapure water for 5 
minutes each twice. The gel was incubated in sensitizer working solution (1 part silver 
stain sensitizer with 500 parts ultrapure water- 50μL sensitizer+25mL water) for exactly 
one minute followed by washing with two changes of ultrapure water for one minute 
each. The sensitizing step was followed by the staining step, where the gel was incubated 
in stain working solution (1 part silver stain enhancer with 50 parts silver stain – 0.5mL 
enhancer + 25mL silver stain) for 30 minutes. The gel was quickly washed with two 
changes of ultrapure water for 20 seconds each. The developer working solution (1 part 
silver stain enhancer with 50 parts silver stain developer – 0.5mL enhancer + 25mL 
developer) was added immediately and the gel was incubated until the appearance of 
protein bands (2-3 minutes). When the desired band intensity was reached, the developer 
solution was replaced with stop solution (5% acetic acid solution). The gel was washed 
briefly in the stop solution. It was then replaced with fresh stop solution and incubated 
for 10 minutes. This was followed by a wash in ultrapure water and imaging using a Bio-
Rad ChemiDocTM XRS Gel documentation system. Images were acquired via a CCD 
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camera and analyzed using accompanying Bio-Rad Quantity one software. Sufficient 
volume of solutions were used such that the gel was covered. All solutions except the 
fixing, ethanol and stop solutions were prepared immediately before use.  
3.2.5 In-gel trypsinization and mass spectrometry  
After the coomassie brilliant blue staining protocol, the bands of interest were excised 
and subjected to in-gel tryptic digestion (Shevchenko, Tomas et al. 2006). The gel bands 
were cut into 1x2 mm pieces with a clean scalpel blade and transferred to 1.5 mL 
polypropylene tubes. The gel pieces were washed with 200 μL of 100 mM ammonium 
bicarbonate (28509-9, Aldrich, Sydney, Australia) for 5 minutes and the supernatant was 
discarded after pulse centrifugation. The Coomassie stain was removed by incubating the 
gel pieces in 200 μL of 100 mM ammonium bicarbonate and 50% acetonitrile 
(Chemsupply, South Australia) solution (1:1) for 30 minutes in a sonicating water bath. 
The supernatant was discarded after pulse centrifugation. This process was repeated until 
the gel pieces appeared clear and transparent. 200 μL of acetonitrile was added to the gel 
pieces and incubated for 10 minutes until they reduced in size, turned white and 
accumulated together. The supernatant was discarded following pulse centrifugation. The 
shrunken gel pieces were dried down in a vacuum centrifuge for 10 minutes. This was 
followed by re-swelling of the gel pieces with 150 μL of freshly prepared 10 mM DTT 
(D9779, Sigma, Sydney, Australia) in 100 mM ammonium bicarbonate (15.4 mg 
DTT/10mL) and incubated at 56 ˚C for 1 hour to reduce the proteins. The samples were 
allowed to cool to room temperature and the supernatant was discarded following pulse 
centrifugation. Again, 200 μL of acetonitrile was added and incubated for 10 minutes 
until the gel pieces shrunk and the supernatant was discarded after pulse centrifugation. 
The cysteines were alkylated with 150 μL of freshly prepared 50 mM Iodoacetamide 
(I1149, Sigma, Sydney, Australia) in 100 mM ammonium bicarbonate (92.5 mg 
iodoacetamide/10 mL) and incubated in the dark at room temperature for 20 minutes. The 
samples were centrifuged and the supernatant discarded. The wash step was repeated with 
200 μL of 100 mM ammonium bicarbonate for 10 minutes followed by removal of the 
supernatant by centrifugation in order to remove the excess iodoacetamide. The reduction 
and alkylation step was followed by the in-gel tryptic digestion step involving the addition 
of 200 μL of acetonitrile, incubation for 10 minutes and removal of supernatant from the 
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shrunken gel pieces. The gel pieces were then dried using a vacuum centrifuge for 20-30 
minutes to remove as much liquid as possible. Sufficient enzyme solution (freshly 
prepared trypsin at 10 μg/mL in 10 mM ammonium bicarbonate containing 5% 
acetonitrile) was added to just cover the gel pieces. This was incubated at 4˚C for 30 
minutes and extra enzyme solution was added if needed to fully re-swell the gel pieces. 
The samples were then incubated overnight at 37˚C. Peptide extraction was performed 
the next day by adding 150 μL of 50% acetonitrile and 0.1% trifluoroacetic acid (TFA, 
299537, Sigma, Sydney, Australia). The samples were incubated in a sonicating water 
bath for 30 minutes. The contents were spun and the supernatant containing the extracted 
peptides were transferred to fresh 1.5 mL microfuge tubes. This step was repeated and 
the extracts were pooled together. The volume of the pooled extracts was reduced by 
vacuum centrifugation in order to reduce the volume to approximately 30 μL. The 
samples were sent to the Mass Spectrometry and Proteomics facility at Bio21, University 
of Melbourne, Australia to be analysed using an Orbitrap EliteTM Hybrid Ion Trap- 
Orbitrap mass spectrometer (Thermo Fisher Scientific). The analysis of the acquired 
peptide profile was performed using a mouse transcriptome database 
(/raid1/www/sequences/mouse/mouse.fasta).  
3.2.6 Milk treatment of mammary epithelial cells cultured on involuting matrices 
The skim milk obtained from involuting mice and the day 0 (day of pup removal) milk 
incubated for 1-4 days was added to the culture media (1x DMEM/F12 with 1% FBS, 
100 ng/mL I, 50 ng/mL F and 1 % P/S) at a concentration of 10% (vol/vol) on mouse 
mammary epithelial cells cultured on mammary gland matrix extracted from tissue 
collected at days 0 to 4 involution. Cells were incubated at 37˚C, 5% CO2 for 2 days. 
Following this incubation, the cell viability was determined by MTS assay according to 
manufacturer’s instructions.  
3.2.7 Bioinformatics analysis 
Publicly available microarray databases published by (Rudolph, McManaman et al. 
2003), (Clarkson and Watson 2003) and (Stein, Morris et al. 2004) were used in an R 
script to perform analysis (Appendix 1). Affymetrix Mu74Av2 microarray chips were 
used in all these 3 experiments. RNA extracted from the mammary gland of mice at 
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different stages of the mammary cycle were used in these experiments. R version 3.0.2, 
Frisbee sailing, and Bioconductor package version 2.14 were used to identify differential 
expression of genes between various time points during pregnancy, lactation and 
involution. The normalization of the 12,488 transcripts was performed using RMA. RMA 
from the Affymetrix package was used to pre-process Affymetrix arrays and the limma 
package was used for assessing differential expression. Multiple testing correction 
methods including Bonferroni correction, Benjamini-Hochberg standard false discovery 
rate correction, Benjamini-Hochberg Adaptive Procedure and Qvalue procedure were 
used in the script to obtain a vector of adjusted p values. A p-value of 0.05 was used as a 
filter for the elimination process. DAVID (The Database for Annotation, Visualization 
and Integrated Discovery) software version 6.7 was used to identify secreted proteins in 
the list generated from the R script (Huang da, Sherman et al. 2009). The functional 
annotation clustering tool of the program with medium classification stringency was used. 
An enrichment score of above 2.5 was considered significant in all analyses.  
3.2.8 Differentiation of 3T3L1 fibroblasts into adipocytes 
3T3L1 mouse embryonic fibroblasts obtained from ATCC (American Type Culture 
Collection) were a kind gift from Prof. Ken Walder’s lab (School of Medicine, Deakin 
University, Geelong, Australia). The fibroblasts were successfully differentiated to 
adipocytes based on the protocol described in Zebisch, Voigt et al. (2012). The fibroblasts 
were cultured in Dulbecco’s modified eagle medium (DMEM, 11995-073, Gibco, Life 
Technologies, Victoria, Australia) with 4mM L-Glutamine, 1mM sodium pyruvate, 4.5 
g/L glucose, 1.5 g/L sodium bicarbonate, 10% heat inactivated fetal bovine serum (FBS, 
10099141, Gibco, Life technologies, Victoria, Australia) and 1% Penicillin/Streptomycin 
(P/S, 15140-122, Gibco, Life technologies, Victoria, Australia).  
Fibroblasts were densely confluent prior to differentiation. In order to ensure maximal 
confluency, differentiation was initiated 2-3 days after the cells reached confluency. The 
cells were cultured in differentiation media for 3 days before changing to post-
differentiation media. The differentiation media was made up of DMEM, 10% heat 
inactivated FBS, 1% P/S, 0.4 μM (2 μg/mL) final concentration of insulin, 0.25 μM 
dexamethasone (D1756, Sigma, Sydney, Australia) and 500 μM 3-isobutyl-1-
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methylxanthine (IBMX, I5879, Sigma, Sydney, Australia). Following 3 days of culture 
in differentiation media, post-differentiation media containing DMEM, 10% heat 
inactivated FBS, 1% P/S and 0.4 μM insulin was added. The cells were incubated at 37˚C 
for 3 days during which the media was changed once. Thereafter, the adipocytes were 
replenished with DMEM and further treatments were performed. The fully differentiated 
adipocytes were cultured in DMEM/F12 media with different hormone combinations- no 
hormone (NH), insulin alone (I) at 100 ng/mL, insulin at 100 ng/mL+ cortisol at 50 ng/mL 
(IF) and insulin at 100 ng/mL+ cortisol at 50 ng/mL+ prolactin at 1 μg/mL (IFP) media 
to check for caveolin 1 expression in each of these treatments.   
3.2.9 Culturing mouse mammary epithelial cells on day 0 involution matrix in 
conditioned media from adipocytes 
After the complete differentiation of 3T3L1 fibroblasts to adipocytes, the adipocytes were 
cultured in DMEM/F12 with 2% FBS, 1% P/S, 100 ng/mL insulin (I) and 50 ng/mL 
cortisol (F). Another set of adipocytes in different wells were cultured in a similar media 
with the addition of 1 μg/mL of prolactin (P). RNA was extracted from both sets of cells 
(3.2.11) and checked for caveolin 1 gene expression. The conditioned media from the 
adipocytes cultured in IF and IFP was taken after 2 days and mouse mammary epithelial 
cells (MMECs) were cultured on day 0 involution matrix in these media.  
3.2.10 Addition of anti-caveolin 1 antibody to conditioned media from adipocytes in 
MMECs culture 
Caveolin 1 antibody (Polyclonal Rabbit Anti Caveolin, 610059, BD Transduction 
laboratories, Sydney, Australia) was added to the IFP conditioned media in a 1:100 
dilution and MMECs were cultured in this media. The control media, IFP conditioned 
media without the antibody was diluted with an aqueous buffered solution of BSA, 
glycerol and ≤ 0.09% sodium azide (1:100 – buffer: media).  
3.2.11 RNA extraction and reverse transcription PCR  
Total RNA was isolated from the 3T3L1 fibroblasts, differentiated adipocytes in NH (No 
Hormone), I (Insulin alone), IF (Insulin and Cortisol) and IFP (Insulin, Cortisol and 
Prolactin) media, MMECs cultured in normal, IF and IFP DMEM/F12 media, MMECs 
cultured in IF and IFP conditioned media from adipocytes and MMECs in IFP 
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conditioned media containing anti-caveolin 1 antibody using TRIzol TriPure isolation 
reagent (#11667165001, Roche) as per the manufacturer’s protocol. Reverse transcription 
was performed from 1 μg of RNA using iScript cDNA synthesis kit (170-8841, Bio-Rad, 
NSW, Australia). The reaction was placed in a Bio-Rad C1000 thermocycler at 25˚C for 
5 minutes, 42˚C for 30 minutes followed by 85˚C for 5 minutes and samples were stored 
at -20˚C until further use.  
3.2.12 Quantitative polymerase chain reaction 
Quantitative polymerase chain reaction (qPCR) was performed on a Bio-Rad CFX96 Real 
time C1000 thermocycler using SsoFast Evagreen supermix (172-5200, Bio-Rad). The 
primer sequences and amplicon sizes are listed in Table 3.1 and were synthesized by 
Macrogen, Korea and Sigma, Sydney, Australia. The PCR reactions (20 μL) contained 
1x SsoFast Evagreen supermix, forward and reverse primers at 10 μM concentrations and 
diluted cDNA. The qPCR thermal profile included an initial denaturation (95˚C for 3 
minutes) and quantification for 40 cycles (denaturation at 95˚C for 30 seconds, annealing 
at 60˚C for 30 seconds, extension at 72˚C for 30 seconds) followed by a final extension 
step at 72˚C for 5 minutes. All samples were assayed in triplicates and template free 
controls were included. The gene expression was normalized using glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) housekeeping gene and relative expression was 
calculated using Bio-Rad CFX manager software, ΔΔCt normalized expression method. 
Melting curve analysis was performed to confirm the amplification of a single PCR 
product.  
3.2.13 Statistical analysis 
All statistical comparisons were performed using a two-tailed t-test assuming unequal 
variances between means. Data were presented as mean ± standard error of the mean. In 
all statistical tests a p value of less than 0.05 was considered significant. 
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Table 3. 1. Primers used in qPCR 
Gene Forward Primer Reverse Primer Amplicon 
size (bp) 
Mus Beta- 
Casein 
5'-
TGCACCTTCCTCAGTC
TCTG-3' 
5'-
GTGGAAGGAAGGGTG
CTACT-3' 
147 
Mus 
GAPDH 
5'-
CATCTTCCAGGAGCG
AGACC-3' 
5'-
GAAGGGGCGGAGATG
ATGAC-3' 
150 
Mus 
Caveolin 1 
5'-
TTGCCATTCTCTCCTT
CCTG-3' 
5'-
TCTCTTTCTGCGTGCT
GATG-3' 
177 
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3.3 Results 
3.3.1 Milk composition analysis 
3.3.1.1 Total protein concentration 
The total protein in milk isolated from days 0 to 3 involuting mice was estimated using a 
micro BCA kit. The concentration of total protein declined from 53.5 mg/mL to 51.4 
mg/mL after the pups and dam had been separated for a day but thereafter the 
concentration increased to 59.0 mg/mL at day 3 of involution (Fig. 3.1), however there 
was no significant increase in the concentration of total protein in the involuting milk 
samples.  
 
 
Fig. 3. 1. Total protein concentration. Protein concentration in milk collected from mice 
at day 0 to day 3 of involution estimated by micro BCA kit. All values are represented as 
mean ± SEM (n=5). 
 
3.3.1.2 Carbohydrate concentration 
The carbohydrate concentration of milk samples obtained from day 0 to day 3 (D0-D3) 
involuting mice was estimated using the phenol-sulfuric acid method. The carbohydrate 
0
10
20
30
40
50
60
70
D0 D1 D2 D3
To
ta
l P
ro
te
in
 (m
g/
m
L)
Involution (Day)
 114 
 
concentration markedly reduced (p<0.05) from 34.6 mg/mL on the first day of removal 
of pups from dam to 17.4 mg/mL on day 3 of involution (Fig. 3.2).  
 
 
Fig. 3. 2. Carbohydrate estimation. Carbohydrate concentrations in milk from mice 
from days 0-3 (D0-D3) of involution was analyzed by phenol-sulfuric acid method. All 
values are represented as mean ± SEM (n=5). *significantly different to D0 (p<0.05).  
 
3.3.1.3 Lipid concentration 
The concentration of lipid in milk isolated from day 0 to day 3 involuting mice was 
estimated by a colorimetric method in micro-plate format. The concentration of lipid in 
milk collected after 3 days of cessation of suckling did not change significantly from the 
concentration at day 0 of involution (day 15 of lactation), the day the pups were removed 
from the dam (Fig. 3.3).  
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Fig. 3. 3. Lipid concentration.  Lipid concentrations in milk collected from mice from 
day 0 to day 3 (D0-D3) involution was estimated by a colorimetric method. All values 
are represented as mean ± SEM (n=5). 
 
3.3.2 Milk treatment of MMECs cultured on involuting matrices 
Milk contains a number of bioactive proteins and when incubated for a period of time, 
peptides are released that contain additional bioactive properties (Autelitano, Rajic et al. 
2006, Dallas, Guerrero et al. 2013a, Dallas, Guerrero et al. 2013b). In order to determine 
the putative role that both proteins and peptides play on mammary epithelial cells during 
involution, the in vitro model of mammary epithelial cells cultured on ECM extracted 
from days 0 to day 4 (D0-D4) involuting mouse mammary glands was employed (see 
chapter 2). Milk collected from day 0 involution was incubated at 37 ˚C for a period of 
1-4 days prior to addition to the cells while milk collected from day 0-4 was added to the 
cells without treatment. Specifically, mouse mammary epithelial cells were cultured on 
matrices extracted from day 0 to day 4 involuting mammary gland in media containing 
10% skim milk obtained from involuting mice (days 0, 1, 2 & 3) and day 0 involuting 
milk incubated for 1-4 days. The cells were allowed to remain in culture for 2 days 
following which the MTS assay was performed to assess cell viability. It was observed 
that milk collected from day 1 to day 3 involuting mice mammary glands significantly 
reduced (p<0.05) the viability of cells cultured on early involuting matrices within 24 
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hours (Fig. 3.4 A-C). On D0 involution matrix, the cell viability was significantly reduced 
(p<0.05) to 70% when treated with milk from day 3 involuting mice within 24 hours (Fig. 
3.4A). A significant reduction (p<0.05) in cell viability to 68% and 66% was observed 
when day 3 involution milk was treated on cells cultured on D1 and D2 involution 
matrices respectively (Fig. 3.4 B&C). Since the late involuting matrices promoted cell 
death even in the absence of milk (Chapter 2 section 2.3.2), the role of milk in 
contributing towards the loss of cell viability independently could not be observed (Fig 
3.4 D & E). It was also observed that incubation of milk collected from day 0 involuting 
mouse mammary glands (i.e. day 15 lactation) significantly reduced (p<0.05) the viability 
of cells cultured on all matrices, and that the amount of cell viability decreased as the 
length of milk incubation increased. On D0 involution matrix, the cell viability 
significantly reduced (p<0.05) to 95%, 88%, 81% and 71% when treated with days 1-4 
incubated milk respectively (Fig. 3.4A) MMECs cultured on involuting matrices in the 
absence of milk were used as controls in this study and cell viability was calculated 
relative to the respective controls. All assays were performed in triplicate.   
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Fig. 3. 4 A - E. Cell viability of MMECs cultured on involuting matrices treated with 
milk. % cell viability of mammary epithelial cells cultured on A) Day 0, B) Day 1, C) 
Day 2, D) Day 3 and E) Day 4 involuting matrices treated with 10% skim milk from 
involuting mice collected on days 0-3 (D0-D3 milk) and D0 milk incubated for 1-4 days 
(D1-D4 incubated milk) estimated by MTS assay after 2 days in culture. Cell viability 
was calculated relative to D0 milk for each matrix. All values are represented as mean ± 
SEM (n=3). *statistically significant to D0 milk on respective matrices (p<0.05). 
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3.3.3 SDS-PAGE and mass spectrometry of involuting milk samples 
Skim fractions of milk collected from days 0 to 3 of involution and day 15 lactating (day 
0 involution) incubated for 1-4 days was run on 12.5% SDS-PAGE gels. For clear 
visualization of bands, the casein fraction of the samples were run on the gel and silver 
stained while the skim fraction of the same samples were run on a gel and stained with 
coomassie brilliant blue (CBB). The CBB stained gel was imaged and the bands were 
excised from the CBB stained gel and analyzed using mass spectroscopy (Fig. 3.5, table 
3.2 and appendix 2).  
 
 
              
 
Fig. 3. 5. CBB stained 12.5 % SDS polyacrylamide gel showing skim milk samples 
from involuting mice and incubated milk samples. Skim fraction of milk samples 
collected from A) Day 15 lactation (day 0 involution), B) Day 1 involution, C) Day 2 
involution and D) Day 3 involution, E) Day 0 milk incubated for 1 day, F) Day 0 milk 
incubated for 2 days, G) Day 0 milk incubated for 3 days and H) Day 0 milk incubated 
for 4 days. The numbers 1-15 represent the band number that was excised from the gel.   
 2 
1 
3
Band 
Number  
4
5 
6 
7 
8 
9 
11 
13 
14 
15 
12 
10 
Bands  A        B        C        D            E          F        G        H 
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Table 3. 2. Proteins in bands 1, 2, 3 and 4 identified by mass spectrometry 
Day Band Protein identified by mass spectrometry 
D0 involution 1 WAP (precursor) 
D1 involution 1 WAP (precursor), Glutaredoxin 
D2 involution 1 WAP (precursor) 
D3 involution 1 WAP (precursor), Glutaredoxin 
D0 milk incubated for 1 day 1 WAP (precursor) 
D0 milk incubated for 2 days 1 WAP (precursor) 
D0 milk incubated for 3 days 1 WAP (precursor) 
D0 milk incubated for 4 days 1 WAP (precursor) 
D0 involution 2 Transthyretin, Profilin, Cystatin C, Fatty 
acid binding protein, α-lac, Hemoglobin 
subunit beta-1, Hemoglobin subunit 
beta-2, Hemoglobin subunit alpha 
D1 involution 2 Transthyretin, Profilin, Cystatin C, Fatty 
acid binding protein, α-lac, Prolactin 
induced protein isoform CRA 
D2 involution 2 Profilin, Cystatin C, Fatty acid binding 
protein, α-lac, Prolactin induced protein 
isoform CRA, Hemoglobin subunit beta-
1, Hemoglobin subunit beta-2 
D3 involution 2 WAP, Cystatin C, Prolactin induced 
protein isoform CRA, α-lac, Fabp4 
protein, Hemoglobin subunit beta-1, 
Hemoglobin subunit beta-2 
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D0 milk incubated for 1 day 2 Profilin, Cystatin C, Fatty acid binding 
protein, α-lac, Prolactin induced protein 
isoform CRA, Hemoglobin subunit beta-
2 
D0 milk incubated for 2 days 2 Profilin, Cystatin C, Fatty acid binding 
protein, α-lac, Transthyretin, Prolactin 
induced protein isoform CRA, 
Hemoglobin subunit beta-1, 
Hemoglobin subunit beta-2 
D0 milk incubated for 3 days 2 Cystatin C, Prolactin induced protein 
isoform CRA, α-lac, Transthyretin 
D0 milk incubated for 4 days 2 Cystatin C, Prolactin induced protein 
isoform CRA, Fatty acid binding 
protein, Profilin, α-lac, Hemoglobin 
subunit beta-1, Hemoglobin subunit 
beta-2 
D0 involution 3 Alpha S2 casein like B, Peptidyl-prolyl 
cis-trans isomerase, Cofilin-1, ADP-
ribosylation factor 3 
D1 involution 3 Alpha S2 casein like B, Casein alpha S2 
like A, Peptidyl-prolyl cis-trans 
isomerase 
D2 involution 3 Alpha S2 casein like B, Casein alpha S2 
like A, Peptidyl-prolyl cis-trans 
isomerase, ADP-ribosylation factor 3, 
Major urinary protein 8 
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D3 involution 3 Alpha S2 casein like B, Casein alpha S2 
like A, Peptidyl-prolyl cis-trans 
isomerase, ADP-ribosylation factor 3 
D0 milk incubated for 1 day 3 Casein alpha S2 like A, ADP-
ribosylation factor 3, Peptidyl-prolyl cis-
trans isomerase, ADP-ribosylation 
factor 4, ADP-ribosylation factor 2 
D0 milk incubated for 2 days 3 Alpha S2 casein like B,  Peptidyl-prolyl 
cis-trans isomerase, ADP-ribosylation 
factor 3 
D0 milk incubated for 3 days 3 ADP-ribosylation factor 3 
D0 milk incubated for 4 days 3 Peptidyl-prolyl cis-trans isomerase, 
ADP-ribosylation factor 3 
D0 involution 4 Casein alpha S2 like A, Glutathione 
peroxidase 3. Beta casein, Csnk protein 
D1 involution 4 Casein alpha S2 like A, Neutrophil 
gelatinase associated lipocalin, Beta 
casein 
D2 involution 4 Casein alpha S2 like A, Neutrophil 
gelatinase associated lipocalin, Beta 
casein, Clusterin (Fragment), Protein Trf 
(Fragment) 
D3 involution 4 Casein alpha S2 like A, Neutrophil 
gelatinase associated lipocalin, Ras 
related protein 1b, Peroxiredoxin-2, 
Beta casein 
D0 milk incubated for 1 day 4 Beta casein 
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D0 milk incubated for 2 days 4 Glutathione peroxidase 3 
D0 milk incubated for 3 days 4 Casein alpha S2 like A, Glutathione 
peroxidase 3 
D0 milk incubated for 4 days 4 Casein alpha S2 like A, Glutathione 
peroxidase 3, Beta casein 
List of proteins identified in bands 1, 2, 3 and 4 excised from CBB stained 12.5% SDS-
PAGE gels using an Orbitrap EliteTM Hybrid Ion Trap- Orbitrap mass spectrometer. A 
significance threshold of p< 0.05 was used in the searches.  
 
There was an increase in concentration of band 1 and decrease in concentration of band 
2 as involution progressed. These were identified as whey proteins from the mass 
spectrometry data. Band 1 was identified as WAP precursor (15267 Da) and band 2 had 
whey fractions cystatin C (15749 Da), alpha-lactalbumin (16762 Da), fatty acid binding 
protein (14810 Da) and prolactin induced protein isoform (17098 Da). There was also a 
decrease in concentration of band 3 and 4 as seen in the gel and were identified to contain 
predominantly casein proteins from the mass spectrometry data. Band 3 was identified to 
contain alpha S2 casein like B (16957 Da) along with peptidyl-cis-trans isomerase (18131 
Da) and band 4 was identified to contain casein alpha S2 like A (21258 Da). The D0 milk 
incubated for 1-4 days showed a profile similar to the milk collected from involuting 
mouse mammary glands. Appendix 2 shows the list of all the proteins identified in the 15 
different excised bands using mass spectrometry.  
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Fig. 3. 6. Casein fraction of incubated milk examined using 12.5% SDS PAGE (silver 
stained). D1 to D4 represent the skim milk from day 15 involution mice incubated for 4 
days. Lane 1- Seeblue plus2 prestained protein standard. The numbers on the left 
correspond to the molecular weight of the Seeblue plus 2 protein standard. The caseins 
on the right were identified by comparison to literature and mass spectroscopy data.  
 
Casein fraction of incubated milk shows the breakdown of caseins. Different caseins were 
broken down at different rates (Fig. 3.6). A similar profile was seen in the casein fraction 
of milk isolated from mice at days 0 to 3 of involution (Appendix 2). The caseins were 
identified using their molecular mass as run on the gel in comparison with the literature 
(Boumahrou, Andrei et al. 2009) and the mass spectrometry data. All caseins decreased 
in concentration, but it was observed that γ casein and κ casein decreased in concentration 
more rapidly than α casein and β casein.  
The excised bands from the CBB stained gel enabled us to identify the proteins 
corresponding to each band on the gel (Table 3.2 & Appendix 2). It was found that band 
1 (Fig. 3.5), which started increasing as involution progressed in samples obtained 
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directly from involuting mice and as the incubation days progressed was WAP precursor 
(Whey Acidic Protein precursor). On the other hand, band 2 appeared to decrease towards 
late involution and this region primarily had the whey fractions- cystatin C, alpha-
lactalbumin, fatty acid binding protein and prolactin induced protein isoform. There was 
also breakdown of the casein fractions and for better visualization of these bands, the 
casein fractions run on the gel were silver stained (Fig. 3.6). It was found that as 
involution progressed, each casein was broken down at different rates. It was observed 
that γ casein and κ casein decreased in concentration more rapidly than α casein and β 
casein. The casein breakdown was also evident in the incubated milk samples indicating 
that the stromal environment had less influence on the breakdown of milk constituents 
during involution since the day 0 involuting milk incubated for 1-4 days was devoid of 
stromal factors and still showed a similar profile to the milk sample obtained from 
involuting mice (Appendix 2).  
 
3.3.4 Milk factors responsible for phase II mammary involution 
A script was written in R to identify the differentially expressed genes between involution 
day 2 and day 3 to identify potential factors responsible for the second phase of mammary 
involution (Appendix 1). Particularly, this analysis was performed to identify genes 
coding for secreted proteins that might play a role in the transition from the reversible to 
irreversible phase of mammary involution in mice. This time point was chosen over other 
time points during involution since it has been shown in the literature that involution 
progresses to an irreversible phase after 48 hours of forced weaning (Lund, Romer et al. 
1996, Li, Liu et al. 1997). A P value cut-off of 0.05 was used in the script. DAVID 
functional annotation software tool was used to identify genes coding for secreted 
proteins in this list of differentially expressed genes. The list yielded 471 distinct genes 
coding for secreted proteins (as shown in table 3.3). These genes were grouped into 
different categories using the functional annotation chart function in DAVID (Table 3.3).  
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Table 3. 3. Functional annotation chart of 471 differentially regulated genes coding 
for secreted proteins between involution days 2 and 3 identified using DAVID 
Category Number of 
genes 
Percentage 
(Involved 
genes/total 
genes) 
P value Fold 
enrichment 
Secreted 471 100 0.0E0 12.6 
Extracellular region 460 97.7 0.0E0 7.3 
Signal peptide 443 94.1 3.0E-294 5.7 
Disulfide bond 326 69.2 6.6E-172 5.0 
Extracellular matrix 104 22.1 1.4E-71 16.7 
Defense response 64 13.6 7.7E-28 5.2 
Cytokine  57 12.1 4.4E-45 12.2 
Hormone activity 46 9.8 1.2E-40 14.5 
Growth factor 
activity 
46 9.8 1.3E-35 11.6 
Peptidase activity 43 9.1 1.5E-7 5.1 
Protease 39 8.3 8.1E-9 5.1 
Enzyme inhibitor 
activity 
35 7.4 7.0E-15 5.1 
Pathways in cancer 31 6.6 2.9E-7 2.8 
ECM-receptor 
interaction 
28 5.9 2.9E-20 9.9 
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Regulation of 
apoptosis 
28 5.9 2.5E-3 1.9 
Protease inhibitor  26 5.5 5.7E-17 9.0 
Regulation of growth 26 5.5 3.3E-8 3.7 
Cell-cell signalling 24 5.1 4.5E-6 3.0 
ECM structural 
constituent 
22 4.7 1.6E- 26 26.1 
Serine protease 
inhibitor 
22 4.7 1.8E-15 10.2 
Serine protease 22 4.7 2.2E-9 5.1 
Immune response 16 3.4 1.1E-4 3.8 
Regulation of cell 
growth 
13 2.8 7.1E-6 5.2 
Inflammatory 
response 
12 2.5 5.9E-6 7.2 
Metallopeptidases 6 1.3 5.8E-4 3.1 
Milk protein  4 0.8 9.2E-4 19.0 
The category column is the enriched term associated with the gene list of 471 genes 
uploaded in DAVID. The P value is a modified Fisher Exact P value, EASE score for 
gene enrichment analysis ranging from 0 to 1. Fisher exact P value = 0 represents perfect 
enrichment. P value smaller than 0.05 is considered strongly enriched gene list.  
 
 
Some of the significantly (p<0.05) up-regulated and down-regulated genes based on the 
enrichment scores are shown in Table 3.4 and Table 3.5 respectively. 
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Table 3. 4. Down-regulated genes coding for secretory proteins on day 3 compared 
to day 2 of involution. Log FC = log fold change compared with day 2. 
Gene name LogFC P value Annotation cluster 
casein alpha s2-like B -4.89982 4.4E-07 Milk Protein 
casein kappa -1.24987 0.019172 Milk Protein 
similar to alpha-
lactalbumin; lactalbumin, 
alpha 
-4.74866 
 
4.35E-06 
 
Milk Protein 
lactotransferrin -3.21656 4.35E-06 Milk Protein 
prolactin -0.5336 0.000542 Hormone activity 
whey acidic protein -3.80474 0.000291 
 
Protease/Peptidase inhibitor 
activity and Milk Protein 
tissue inhibitor of 
metalloproteinase 2 
-0.84004 
 
4.17E-05 
 
Protease/Peptidase inhibitor 
activity 
serine (or cysteine) 
peptidase inhibitor, clade 
F, member 2 
-0.81169 
 
0.002162 
 
Protease/Peptidase inhibitor 
activity 
serine protease inhibitor, 
Kunitz type 1 
-0.68104 
 
0.022381 
 
Protease/Peptidase inhibitor 
activity 
serine (or cysteine) 
peptidase inhibitor, clade 
A, member 5 
-0.5251 
 
0.011296 
 
Protease/Peptidase inhibitor 
activity 
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serine (or cysteine) 
peptidase inhibitor, clade 
A, member 6 
-0.47305 
 
0.003759 
 
Protease/Peptidase inhibitor 
activity 
serine (or cysteine) 
peptidase inhibitor, clade 
A (alpha-1 antiproteinase, 
antitrypsin), member 10 
-0.47001 
 
0.008703 
 
Protease/Peptidase inhibitor 
activity 
serine (or cysteine) 
peptidase inhibitor, clade I, 
member 1 
-0.43293 
 
0.000684 
 
Protease/Peptidase inhibitor 
activity 
secretory leukocyte 
peptidase inhibitor 
-0.42509 
 
0.038124 
 
Protease/Peptidase inhibitor 
activity 
WAP four-disulfide core 
domain 12 
-0.40541 
 
0.003363 
 
Protease/Peptidase inhibitor 
activity 
serine (or cysteine) 
peptidase inhibitor, clade 
B, member 2 
-0.38271 
 
0.026087 
 
Protease/Peptidase inhibitor 
activity 
cystatin F (leukocystatin) -0.3728 
 
0.003664 Protease/Peptidase inhibitor 
activity 
serine (or cysteine) 
peptidase inhibitor, clade 
A (alpha-1 antiproteinase, 
antitrypsin), member 12 
-0.29733 
 
0.04693 
 
Protease/Peptidase inhibitor 
activity 
serine (or cysteine) 
peptidase inhibitor, clade 
A, member 3M 
-0.33813 
 
0.001977 
 
Protease/Peptidase inhibitor 
activity 
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Cystatin 9 -0.21345 0.019161 
 
Protease/Peptidase inhibitor 
activity 
SCO-spondin -0.49366 0.002976 
 
Protease/Peptidase inhibitor 
activity 
alpha-2-macroglobulin -0.35012 0.005574 
 
Protease/Peptidase inhibitor 
activity 
alpha-2-HS-glycoprotein -0.2866 0.037895 
 
Protease/Peptidase inhibitor 
activity 
 
It was clear that genes coding for milk protein genes and hormones were down-regulated 
during involution and as involution progressed to the irreversible phase, the protease 
inhibitors were seen to be down-regulated enabling the MMPs to degrade the ECM and 
prepare the gland for tissue remodeling.  
 
Table 3. 5. Up-regulated genes coding for secretory proteins on day 3 compared to 
day 2 of involution. Log FC = log fold change compared with day 2. 
Gene name LogFC P value Annotation cluster 
Von Willebrand factor 
homolog 
0.759151 
 
0.006058 
 
Response to wound 
healing 
calcitonin/calcitonin-related 
polypeptide, alpha 
2.731418 
 
2.04E-05 
 
Response to wound 
healing 
chemokine (C-C motif) 
ligand 11 
0.884468 
 
0.000499 
 
Response to wound 
healing 
 131 
 
complement factor D 
(adipsin) 
1.313757 
 
1.14E-05 
 
Response to wound 
healing/ Acute 
inflammatory 
response 
complement factor properdin 0.670211 0.036738 
 
Response to wound 
healing/ Acute 
inflammatory 
response 
orosomucoid 1 1.71683 0.003831 
 
Response to wound 
healing/ Acute 
inflammatory 
response 
protein S (alpha) 0.932188 0.003036 
 
Response to wound 
healing 
complement component 1, q 
subcomponent, alpha 
polypeptide 
0.854219 
 
0.022357 
 
Acute inflammatory 
response 
complement component 1, q 
subcomponent, beta 
polypeptide 
1.34239 
 
0.001014 
 
Acute inflammatory 
response 
AE binding protein 1 0.909881 5.8E-05 
 
Metallopeptidase 
activity 
a disintegrin-like and 
metallopeptidase (reprolysin 
type) with thrombospondin 
type 1 motif, 1 
0.336486 
 
0.008305 
 
Metallopeptidase 
activity 
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arginyl aminopeptidase 
(aminopeptidase B) 
0.221999 
 
0.04125 
 
Metallopeptidase 
activity 
carboxypeptidase E; similar 
to carboxypeptidase E 
1.08729 
 
0.01142 
 
Metallopeptidase 
activity 
carboxypeptidase X 1 (M14 
family) 
1.122224 
 
7.44E-07 
 
Metallopeptidase 
activity 
matrix metallopeptidase 3 0.997603 0.038072 
 
Metallopeptidase 
activity 
immunoglobulin superfamily 
containing leucine-rich repeat 
0.968326 
 
0.000292 
 
Immunoglobulin like 
immunoglobulin superfamily, 
member 10 
0.371149 
 
0.017327 
 
Immunoglobulin like 
collagen, type I, alpha 1 1.510125 0.001552 
 
ECM structural 
constituent 
collagen, type I, alpha 2 1.734016 0.000598 
 
ECM structural 
constituent 
collagen, type III, alpha 1 1.75248 9.61E-05 
 
ECM structural 
constituent 
collagen, type V, alpha 2 1.809328 
 
0.00275 
 
ECM structural 
constituent 
collagen, type VI, alpha 2 1.270065 0.000322 
 
ECM structural 
constituent 
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collagen, type XV, alpha 1 1.527359 0.0001 
 
ECM structural 
constituent 
elastin 0.814391 0.014886 
 
ECM structural 
constituent 
fibrillin 1 1.066465 0.011763 
 
ECM structural 
constituent 
laminin B1 subunit 1 0.88635 0.003117 
 
ECM structural 
constituent 
microfibrillar associated 
protein 5 
1.093189 0.016771 
 
ECM structural 
constituent 
Insulin-like growth factor 
binding protein-like 1 
0.351055 0.038195 Regulation of cell 
growth 
Insulin-like growth factor 
binding protein 2 
0.886041 0.005361 Regulation of cell 
growth 
Insulin-like growth factor 
binding protein 3 
0.488868 0.046931 Regulation of cell 
growth 
Insulin-like growth factor 
binding protein 5 
1.134575 1.4E-06 Regulation of cell 
growth 
Insulin-like growth factor 
binding protein 6 
0.923585 0.002521 Regulation of cell 
growth 
Insulin-like growth factor 
binding protein 7 
0.314266 0.013032 Regulation of cell 
growth 
cysteine rich protein 61 0.438098 0.006023 Regulation of cell 
growth 
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growth arrest specific 6 1.121714 0.001699 Regulation of growth 
 
It was found that genes coding for the extracellular matrix structural components such as 
collagen, laminins and fibronectin were upregulated during the second phase of 
involution, due to tissue remodelling. The existing ECM proteins are degraded by 
proteases, reflected by up-regulation in the expression of metallopeptidases, thus, 
requiring production of new ECM components in the remodeling process. Also, the 
immune factors and proteins involved in wound healing and the acute inflammatory 
response were seen to be up-regulated. The second phase of involution is associated with 
removal of cell debris due to extensive apoptosis occurring in the gland. This is assisted 
by macrophages and there is autophagy seen in the gland during this stage (Gajewska, 
Zielniok et al. 2013). In order to prevent uncontrolled infection at the site, the anti-
inflammatory factors and immune components are recruited. This is seen by the up-
regulation of genes coding for these immune components. Phase 2 involution is 
associated with increase in expression of genes coding for regulation of cell growth, such 
as IGF-binding protein 5 (Igfbp 5), Igfbp 6, growth arrest specific 6 etc. The delayed 
expression of inhibitors of cell survival like IGF-binding protein 5 is thought to induce 
apoptosis pathways during second phase of involution (Marshman, Green et al. 2003, 
Clarkson, Wayland et al. 2004) acting as potential triggers for phase II involution.  
 
We also analysed the publicly available databases to identify differentially regulated 
genes coding for secreted proteins between lactation (time points used - days 0, 1, 2, 3, 5, 
7, 9 & 10) and involution (time points used - days 0.5, 1, 2, 3 & 4). Table 3.6 gives the 
list of some of the genes coding for secreted proteins based on enrichment scores.  
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Table 3. 6. Genes coding for secretory proteins during involution compared to 
lactation. Log FC = log fold change compared with lactation. 
Gene name LogFC P value Annotation 
cluster 
Enrichment 
Casein beta -3.08265 4.44E-08 Milk protein 44.3 
Casein alpha s1 -2.46222 7.11E-08 Milk protein 44.3 
Casein alpha 
s2-like A 
-3.01191 2.19E-07 Milk protein 44.3 
Casein kappa -1.00174 0.004937 Milk protein 44.3 
Whey acidic 
protein 
-1.79063 0.020835 Milk protein, 
proteinase 
inhibitor 
44.3 
Insulin-like 
growth factor 
binding 
protein-like 1 
0.136967 0.015856 IGFBP related 48.7 
Extracellular 
proteinase 
inhibitor 
-1.04663 0.000812 Proteinase 
inhibitor 
70.8 
Interleukin 6 0.086991 0.032133 Immuno-
regulation 
53.1 
Interleukin 5 0.155809 0.03219 Immuno-
regulation 
53.1 
Interleukin 1 
alpha 
0.140577 0.018171 Immuno-
regulation 
53.1 
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secretory 
leukocyte 
peptidase 
inhibitor 
-1.02804 0.014176 Peptidase 
inhibitor 
31.8 
Orosomucoid 1 1.591436 4.5E-08 Acute phase 
response 
23.7 
regenerating 
islet-derived 3 
gamma 
0.158726 0.007045 Acute phase 
response 
23.7 
serine (or 
cysteine) 
peptidase 
inhibitor, clade 
E, member 2 
-0.26961 0.0086 Serine 
proteinase 
inhibitor 
20.2 
Caveolin 1 0.291425 0.00996927 Integrin 
signalling 
pathway 
11.0 
Caveolin 3 0.11151 0.009326 Integrin 
signalling 
pathway 
11.0 
collagen, type 
IV, alpha 1 
-0.52997 0.017707 ECM structural 
constituent 
18.4 
laminin, alpha 
1 
-0.3922 2.26E-05 ECM structural 
constituent 
18.4 
 
Of the many differentially regulated genes coding for secreted proteins between lactation 
and involution, we were interested in the caveolin family of genes. It was observed that 
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there was a significant up-regulation of caveolin 1 and caveolin 3 genes as the gland 
progressed from lactation to involution. In order to investigate the role of caveolin 1 in 
mammary gland involution and its regulation, we made use of the 3T3L1 adipocytes 
model (Section 3.3.5).  
 
3.3.5 Role of different cell types in regulating mammary gland involution  
While milk protein genes are expressed by the mammary epithelial cells, caveolins are 
expressed by myoepithelial cells and adipocytes which reside in the mammary gland 
(Park, Lee et al. 2002, Sotgia, Casimiro et al. 2009, Polyak and Kalluri 2010, Kuruppath, 
Sharp et al. 2014). In order to study the role of caveolins and adipocytes in regulation of 
the mammary gland, we utilized an in vitro model involving the 3T3L1 mouse embryonic 
fibroblasts that were differentiated to become adipocytes. The differentiated adipocytes 
were confirmed by observing the cell morphology and the presence of fat globules which 
is consistent with the literature (Felmer and Clark 2004) (Fig. 3.7).  
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Fig. 3. 7. 3T3L1 fibroblasts and adipocytes. A) 3T3L1 fibroblasts imaged at 4x 
magnification. B) Differentiated 3T3L1 adipocytes imaged at 4x magnification and C) 
40x magnification.  
 
RNA was extracted from 3T3L1 fibroblasts and adipocytes and reverse transcribed to 
cDNA to measure caveolin 1 gene expression. It was found that caveolin 1 was not 
expressed in fibroblasts, but was expressed after differentiation into adipocytes (Fig. 3.8).  
 
A B 
C 
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Fig. 3. 8. Caveolin 1 expression in 3T3L1 cells. RT-PCR analysis of caveolin 1 gene 
expression in 3T3L1 fibroblasts (Fib-lanes 2 and 4) and 3T3L1 differentiated adipocytes 
(Adi-lanes 3 and 5) run on 1% agarose gel. Lane 1 is the 1kb plus DNA ladder. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the housekeeping 
gene in the study. Caveolin 1 was found to run at 177 bp and GAPDH at 150 bp.   
 
3T3L1 fibroblasts do not express caveolin 1 but upon differentiation to adipocytes, they 
constitutively express caveolin 1. Previous studies have shown that prolactin negatively 
regulates caveolin 1 gene expression in the mammary gland during lactation (Park, Lee 
et al. 2001). Thus, prolactin has a negative correlation with milk protein gene expression 
in the mammary gland. We investigated whether prolactin had a similar effect on caveolin 
1 gene expression in the 3T3L1 adipocytes. The differentiated adipocytes were cultured 
in media with no hormone (NH), insulin (I) alone, insulin + cortisol (IF) and insulin + 
cortisol + prolactin (IFP). RNA was extracted from these cells to analyze for caveolin 1 
gene expression. RNA extracted from day 12 pregnant mouse mammary tissue expressing 
100 
200 
300 
        Fib  Adi  Fib  Adi 
400 
Cav 1 GAPDH 
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caveolin 1 was used as a positive control in the study. There was no effect of prolactin on 
the expression of Caveolin 1 in differentiated adipocytes. This was confirmed by qPCR 
analysis (Fig. 3.9).  
 
 
Fig. 3. 9. Gene expression analysis of caveolin 1 in 3T3L1 fibroblasts and adipocytes 
by qPCR. Caveolin 1 gene expression in 3T3L1 fibroblasts and differentiated adipocytes 
in different hormone treatments [NH - No hormone, I - insulin alone (100 ng/mL), IF - 
insulin (100 ng/mL) + cortisol (50ng/mL) and IFP – insulin (100ng/mL) + cortisol (50 
ng/mL) + prolactin (1 μg/mL)] was analyzed by qPCR. The expression level in day 12 
pregnant (12P mouse) mouse mammary tissue was used as positive control in the study. 
The normalized gene expression levels were calculated relative to 3T3L1 fibroblasts. All 
values are represented as mean ± SEM (n=3). *significantly different to caveolin 1 gene 
expression in 3T3L1 fibroblasts (p<0.05). Hormone conditions: NH- No hormone, I- 
Insulin alone, IF- Insulin, Cortisol, IFP- Insulin, Cortisol and Prolactin. 
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3.3.5.1 Culturing mouse mammary epithelial cells on day 0 involution matrix in 
conditioned media from adipocytes 
In order to understand the regulation between different cell types through putative 
paracrine signalling factors in the mammary gland, we wanted to study the signaling 
between adipocytes and epithelial cells in the mammary gland. For this, the conditioned 
media (CM) from adipocytes cultured in the presence and absence of prolactin was taken 
and mouse mammary epithelial cells were cultured in this media on day 0 involution 
matrix. MMECs cultured on day 0 involution matrix (D0) in normal media in the presence 
and absence of prolactin (IFP and IF respectively) were used as controls in this study. 
The concentration of hormones, insulin, cortisol and prolactin was the same in the normal 
media in control treatments and in the conditioned media. RNA was extracted from these 
MMECs after 5 days in culture and analyzed for beta-casein expression. In the controls, 
beta-casein gene expression was seen in the cells cultured in the presence of prolactin 
(IFP media) as opposed to the cells cultured in the absence of prolactin (IF media). It was 
observed that there was a reduced beta-casein gene expression in MMECs cultured in IFP 
conditioned media from the adipocytes compared with control IFP media. There was no 
increase in beta-casein gene expression when the cells were cultured in the conditioned 
media from adipocytes lacking prolactin [IF(CM)]. This was confirmed by qPCR analysis 
(Fig. 3.10). All samples were assayed in triplicate. The expression levels were normalized 
to GAPDH and expressed relative to the expression levels found when MMECs were 
cultured in IF media on day 0 involution matrix (D0 IF).  
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Fig. 3. 10. Gene expression analysis of beta-casein by qPCR. Beta-casein expression 
in MMECs cultured in normal media in the presence and absence of prolactin (D0 IF and 
D0 IFP) and in adipocyte conditioned media (CM) in the presence and absence of 
prolactin [IF(CM) and IFP(CM)] was analyzed by qPCR. The normalized gene 
expression levels were calculated relative to D0 IF. All values are represented as mean ± 
SEM (n=3). *significantly different to D0 IF (p<0.05). 
 
3.3.5.2 Regulation of beta-casein gene expression by caveolin 1 
In order to confirm the activity of caveolin 1 in down-regulating beta casein gene 
expression through prolactin signaling, the addition of anti-caveolin1 antibody to the 
conditioned media was examined. The controls were MMECs cultured in on D0 
involution matrix in IF and IFP media. There was significant increase in beta-casein gene 
expression in IFP control (Fig. 3.11). It was observed that when the mouse mammary 
epithelial cells were cultured on day 0 involution matrix in conditioned media from 
adipocytes containing insulin (I), cortisol (F) and 1μg/mL of prolactin, there was a 
decrease in expression of beta-casein gene, whereas when the cells were cultured in 
conditioned media containing IFP along with a 1:100 dilution of anti-caveolin1 antibody, 
there was no significant difference in beta-casein gene expression compared to the control 
(MMECs cultured in IFP media on day 0 involution matrix (Fig. 3.11).  
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Fig. 3. 11. Gene expression analysis of beta-casein regulation by caveolin 1. Beta-
casein gene expression in MMECs cultured on normal media in the presence and absence 
of prolactin (D0 IF and D0 IFP) and in conditioned media (CM) IFP in the presence and 
absence of 1:100 dilution of anti-caveolin 1 antibody [IFP (CM) and Anti-cav IFP (CM)] 
was analyzed by qPCR. The expression levels were normalized to GAPDH and expressed 
relative to the expression levels found when MMECs were cultured in IF media on day 0 
involution matrix (D0 IF). All values are represented as mean ± SEM (n=3). 
*significantly different to D0 IF (p<0.05). 
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3.4 Discussion 
The mammary gland undergoes cyclical periods of proliferation, differentiation and post-
lactational regression throughout its life cycle (Bertucci, Quaglino et al. 2010). Lactation, 
the process of nourishment of the new born with a copious amount of milk secreted by 
the mammary gland, is the most defining characteristics of mammals (Pond 1977). The 
milk composition varies among different species and is driven by the developmental 
requirements of the neonate, the reproductive strategy and other environmental factors 
(Nicholas, Wilde et al. 1995). Two significant factors maintain milk synthesis and 
secretion, the suckling/milking stimulus and the removal of milk. Milk that is stored in 
the lumen of the mammary gland, either in the secretory alveoli or ductal system is 
removed by suckling of the young one (Holmes, Brookes et al. 2002). When there is 
complete cessation of milk removal, involution is initiated. Involution is characterized by 
engorgement of gland due to milk accumulation, cessation of milk production, apoptosis 
of mammary secretory epithelia and remodelling of the gland (Lund, Romer et al. 1996). 
Composition analysis of the milk isolated from involuting mice showed a rapid decline 
in the concentration of carbohydrate during the first 3 days following cessation of 
suckling. This is due to the removal of lactose and K to the extracellular fluid by a 
paracellular mechanism involving the influx of Na and Cl through the leaky tight 
junctions and is consistent with previous findings (Wheelock, Smith et al. 1967, 
Hartmann and Kulski 1978, Peaker 1983, Nicholas and Hartmann 1991). A reciprocal 
relationship between lactose and salt concentrations has been known to exist in a number 
of species (Peaker 1975, Davies, Holt et al. 1983). We observed that the loss of lactose, 
a major osmole of milk, was accompanied by the increase in concentration of total protein 
during involution. Literature has evidence for the increase in concentration of caseins and 
whey proteins as involution progresses (Nicholas and Hartmann 1991, Gors, Kucia et al. 
2009). There was no significant correlation between the concentration of fat and 
carbohydrate in the milk samples during involution. Murine mammary gland involution 
has two distinct phases- reversible and irreversible phases. A number of factors have been 
identified as triggers of involution (Green and Streuli 2004). Local mammary derived 
signals are thought to initiate the decline in milk secretion and the progressive induction 
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of apoptosis of the mammary epithelial cells and involution in response to an extended 
period of milk accumulation (Li, Liu et al. 1997).  
3.4.1 Milk as a primary trigger for phase 1 involution 
Different theories have been proposed regarding the mechanisms involved in the initial 
trigger of mammary gland involution, although it seems to be an interplay between 
different pathways. One suggested mechanism is related to the accumulation of chemical 
inhibitory or pro-apoptotic factors in the milk which are normally removed during 
suckling (Wilde, Addey et al. 1998, Shamay, Shapiro et al. 2002). This theory was 
supported by our study. When milk collected from involuting mice was added to 
polarized mammary epithelial cells formed on lactating and early involuting matrices, 
cell death was observed. When day 0 involuting milk was incubated in the absence of 
influence from stromal factors, it induced similar cell death. This indicates that the 
accumulation of milk borne pro-apoptotic factors in the gland acts as a trigger for 
involution. Some of these accumulated milk borne factors also act upon other milk 
proteins and help in their breakdown. The plasmin system is a major milk protease 
(enzyme) system whose activity is increased during involution and helps in the 
breakdown of milk caseins (Aslam and Hurley 1998). The onset of involution is also 
characterized by cessation of milk production and secretion, causing down regulation of 
milk protein genes such as caseins and alpha-lactalbumin (Marti, Lazar et al. 1999). This 
was also seen in the gene expression analysis we performed in our study using publicly 
available microarray databases. Although, there is down-regulation of these milk protein 
genes and cessation of their production, the accumulated proteins in milk are broken down 
by proteases. It has been shown that the serine protease plasmin is the predominant 
protease in milk that produces peptides from β-casein and αS1 and αS2 caseins (Politis 
1996). The inactive form of plasmin, plasminogen, is converted to its active form by 
plasminogen activators (Politis 1996). This activator-plasminogen-plasmin (PPS) system 
plays an important role in the control of milk secretion and tissue remodeling during 
involution (Ossowski, Biegel et al. 1979). Accumulation of milk in the gland causes stress 
which in turn is thought to activate the PPS system (Silanikove, Shamay et al. 2000, 
Shamay, Shapiro et al. 2002) and thus help in the breakdown of caseins. Casein 
hydrolyzates (CNHs) are milk-borne factors that cause disruption of tight junction 
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integrity, inducing involution and the serine proteases in them break down caseins 
(Shamay, Shapiro et al. 2002, Shamay, Shapiro et al. 2003). This is also evident from our 
study, where the incubated milk in the absence of systemic and stromal factors, showed 
a similar profile to involuting milk, with casein breakdown. The proteases aiding in this 
breakdown come from the accumulated milk and this also contributes to the initial trigger 
for the onset of involution. The method of incubating milk or individual milk proteins 
with proteases in order to study the activity of proteases in releasing bioactive peptides 
has been employed in earlier studies (Kitazawa, Yonezawa et al. 2007, Schmelzer, 
Schops et al. 2007, Eriksen, Holm et al. 2010) and we made use of this concept to incubate 
milk collected from involuting mice to study the effect of proteases accumulated in milk 
on the milk proteins and release of potential bioactive peptides. We observed the activity 
of these proteases by the breakdown of milk proteins but the measure of bio-activity of 
the resulting peptides needs further investigation. It is proposed to isolate the peptides 
from the protein gels and assess their bio-activity for better understanding. Other potential 
chemical regulators accumulated in milk that have been shown to stimulate apoptosis 
include α-lactalbumin (Hakansson, Zhivotovsky et al. 1995, Hakansson, Andreasson et 
al. 1999, Sharp, Lefevre et al. 2008), TGF-β1 (Letterio, Geiser et al. 1994, Atwood, Ikeda 
et al. 1995, Kordon, McKnight et al. 1995), IGFBP-5 (Tonner, Barber et al. 1997, Tonner, 
Barber et al. 2002, Marshman, Green et al. 2003) and IGFBP7 (Chatterjee, Bacopulos et 
al. 2014). The absence of apoptosis and initiation of involution in the fur seal during its 
long foraging trips to the sea attributed to the lack of alpha-lactalbumin (LALBA) in its 
milk throws light on the role of LALBA as a milk-borne factor that feeds back on the 
mammary gland to regulate involution. It has been demonstrated that although LALBA 
is absent in the milk of fur seal, LALBA-mediated apoptotic pathway remains intact as 
there is evidence of bovine alpha-lactalbumin (bLALBA) causing apoptosis of fur seal 
primary mammary cells in culture (Sharp, Lefevre et al. 2008).  As a result of milk stasis 
and accumulation at weaning, LALBA levels increase in the milk. When it reaches a 
critical concentration and undergoes a conformational change, it is speculated that 
exposure of mammary epithelial cells to LALBA triggers mammary gland involution 
fortifying the role of milk-borne factors in triggering mammary involution.  
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3.4.2. Role of proteases and other factors in phase 2 involution 
The second stage of mammary involution is characterized by extensive tissue remodelling 
by ECM degrading proteases, resulting in collapse of the lobulo-alveolar structures. This 
stage prepares the gland to return to a pre-pregnant state, in preparation for the next cycle 
of lactation (Talhouk, Bissell et al. 1992, Lund, Romer et al. 1996, Li, Liu et al. 1997). 
There is up-regulation of matrix metallopeptidases (MMPs) such as gelatinase, 
stromelysin (Harvey, Leco et al. 1995, Lefebvre, Regnier et al. 1995), serine proteinase 
like plasminogen activator (Teesalu, Blasi et al. 1996, Zhang, Shu et al. 1996) and 
cysteine proteinases such as cathepsins (Hamilton, Bruns et al. 1990, Hamilon, Bruns et 
al. 1991) during this phase, and down-regulation of their inhibitors (tissue inhibitors of 
metalloproteinases, TIMPs). This is observed in gene expression studies along with the 
up-regulation of immune components and anti-inflammatory factors (Clarkson, Wayland 
et al. 2004, Stein, Morris et al. 2004). The cystatin superfamily of proteins control 
cysteine proteinases during lactation and early involution from ECM degradation. This 
superfamily of proteins includes intracellular (cystatin A and cystatin B) and secreted 
(cystatin C) forms (Abrahamson, Barrett et al. 1986, Tavera, Prevot et al. 1990, Huh, 
Nagle et al. 1995). Cystatin C is an inhibitor of cathepsin B and cathepsin L, that aid in 
tissue remodelling (Barrett, Davies et al. 1984, Abrahamson, Barrett et al. 1986). Mass 
spectrometry analysis of the milk samples conducted in our study identified secreted 
cystatin C in milk and possible down-regulation of this protein as involution progressed. 
Cystatin C is expressed and secreted in the milk during early involution to prevent ECM 
degradation by cysteine proteinases, and is broken down by milk-borne factors during 
late involution to enable tissue remodeling (Barrett, Davies et al. 1984). Thus it 
contributes to the switch from reversible to irreversible involution. The second phase of 
involution is also thought to be controlled by systemic hormones such as glucocorticoids. 
It has been shown that administration of artificial glucocorticoids during weaning 
prevents cell death (Bertucci, Quaglino et al. 2010). Glucocorticoids when administered 
within 48 hours of involution (reversible phase of involution) delays the onset of phase 2 
involution and the use of dexamethasone (DEX) during this period has also been shown 
to inhibit apoptosis induction. DEX delays STAT5a inactivation and degradation and 
delays STAT3 activation, both of which play an important role in epithelial cell apoptosis 
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induction (Bertucci, Quaglino et al. 2010). This leads to preservation of gene expression 
of target genes such as beta-casein and prolactin induced protein (pip), both of which 
were down-regulated in our study. Our mass spectrometry analysis shows possible down-
regulation of both prolactin induced protein and caseins during involution, indicating the 
involvement of transcription factors such as STAT5 and STAT3 in the process of 
mammary involution. Since the proteins identified in our mass spectrometry analysis such 
as cystatin C and prolactin induced protein, are part of the excised band that also includes 
alpha-lactalbumin, a major milk protein, their decreased expression as seen in the gel 
cannot be completely confirmed. Quantitative assessment of the different proteins in each 
band needs to be performed for better understanding of the expression levels of these 
proteins as involution progresses. In addition to these, glucocorticoids play an essential 
role in the involution switch. Teat sealing experiments have revealed that when one set 
of teats are tied off in a mouse, it leads to involution only in the associated mammary 
glands and the other pairs of glands remain unaltered in function (Feng, Marti et al. 1995, 
Li, Liu et al. 1997). This argues the role of systemic factors contributing to involution 
and remains an area that needs to be extensively investigated. It has been postulated that 
milk accumulation leading to mechanical stretching and shape change of mammary 
epithelial cells causes increased tight junction permeability and induction of mechano-
transduction signaling pathways resulting in decline in milk yield (Stelwagen, Farr et al. 
1997, Davis, Farr et al. 1999). In vitro studies have shown that the increase in production 
of reactive oxygen species within the involuting mammary gland and increase in 
antioxidant genes in early involution acts as triggers for apoptosis (Silanikove, Shapiro et 
al. 2005). Thus, multiple mechanisms related to oxidative stress has been postulated to 
play an important role in mammary gland involution and apoptosis (Singh, Davis et al. 
2008).  
We reanalyzed publicly available microarray databases to identify potential factors in the 
transition from reversible to irreversible phase of murine mammary gland involution. 
Specifically, we aimed to identify the changes in the expression level of genes coding for 
secreted proteins between days 2 and 3 of involution. Our analysis confirmed the 
previously reported down-regulation of milk protein genes like alpha-lactalbumin and 
caseins and the protease inhibitors during phase I involution (Clarkson, Wayland et al. 
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2004, Green and Streuli 2004). Mammary epithelial cell death by anoikis during phase II 
involution is primed by the loss of attachment-dependent survival signals contributed by 
the breakdown of ECM components and tissue remodeling (Talhouk, Bissell et al. 1992, 
Boudreau, Sympson et al. 1995, Lund, Bjorn et al. 2000, Baxter, Neoh et al. 2007). We 
also confirmed the up-regulation of genes coding for metalloproteases for tissue 
remodelling and proteins involved in wound healing and the immune cascade during 
phase II involution (Schedin, Strange et al. 2000, Clarkson and Watson 2003). Although 
much is known about the target genes that are induced by the involution switch such as 
STAT3 and NFκB (Clarkson and Watson 2003), the role of milk protein candidates and 
milk borne factors in regulating the transition from phase 1 to phase 2 involution remains 
unknown. Our analysis of the microarray data generated a list of differentially regulated 
genes coding for secreted proteins complying with literature but failed to yield specific 
factors that trigger phase II involution. Possible triggers include the secreted proteins that 
are involved in the regulation of cell growth such as the insulin like growth factor binding 
proteins.           
3.4.3. Role of WAP in phase 1 and phase 2 involution 
Another interesting finding from our study was the accumulation of WAP (Whey Acidic 
Protein) in the milk samples as involution progressed (band 1 seen in our gel and mass 
spectrometry results). Both the milk samples obtained from the involuting mice and the 
day 0 involuting milk incubated for 4 days showed a similar profile. It has been reported 
that one of the initial events following weaning is a rapid decline in the expression of 
milk protein genes such as WAP and β-casein (Strange, Li et al. 1992). This is also 
consistent with our bioinformatics analysis. We also noted a significant decrease in the 
expression of alpha-lactalbumin in our analysis. These milk protein genes are highly 
expressed during lactation but diminish during involution (Talhouk, Bissell et al. 1992). 
Their expression in the mammary gland becomes almost undetectable by days 5-6 of 
involution (Schwertfeger, Richert et al. 2001). The down-regulation of the expression of 
the genes of these secreted proteins was also seen in the microarray analysis presented in 
this thesis. Although, this data related to changes at the RNA level, the proteins that are 
accumulated in the milk are not removed due to cessation of suckling. We observed that 
the proteases in milk appear to process the casein proteins to smaller fragments. WAP is 
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the principal whey protein in rodent milk and it contains a cysteine rich motif identified 
in some protease inhibitors and proteins that are involved in tissue remodeling 
(Hennighausen and Sippel 1982b, Campbell, Rosen et al. 1984, Simpson, Ranganathan 
et al. 2000, Simpson and Nicholas 2002). It has been observed in earlier studies that WAP 
acts as a dispensable protease inhibitor to maintain the stability of secreted proteins in 
milk (Triplett, Sakamoto et al. 2005). Although WAP might not act as a general protease 
inhibitor, it has been hypothesized that it might function as a specific inhibitor of certain 
unidentified milk proteases (Simpson and Nicholas 2002). It is also evident that other less 
abundant protease inhibitors have been shown to have similar activities (Triplett, 
Sakamoto et al. 2005). WAP domain containing protease inhibitors such as SLPI 
(secretory leukocyte protease inhibitor) and elafin (elastase specific inhibitor) have been 
shown to possess antimicrobial properties (Idoji, Watanabe et al. 2008). These WAP 
domains have been known to play pivotal roles in anti-protease and antimicrobial 
activities (Fitch, Roghanian et al. 2006). It has been predicted that most of the mammalian 
N-terminal WAP domains derived from SLPIs and WFDC12s (WAP four-disulfide core 
domain 12) possess antimicrobial activities, whereas the C-terminal domains derived 
from SLPIs and elafins possess anti-protease activities (Idoji, Watanabe et al. 2008). 
Microarray analysis performed by Stein, Morris et al. (2004) showed that the anti-
inflammatory WAP domain protein SLPI was elevated during involution, contributing to 
the acute phase response (APR) pathways. The antibacterial WAP motif protein 2 also 
showed a strong increase in expression during involution (Stein, Morris et al. 2004). Thus, 
we hypothesize that the increase in concentration of the WAP observed in the milk 
analysis during late involution could contribute towards the anti-inflammatory and 
antimicrobial activities, whereas the WAP accumulated in milk during lactation and early 
involution are involved more in the anti-protease activities. In vitro culture studies using 
WAP isolated from the SDS-PAGE gel during early and late involution and testing for 
anti-microbial, anti-bacterial and anti-protease properties will provide better 
understanding of the function of this protein during the two phases of involution. 
Although, neither rat nor mouse WAP proteins exhibited protease inhibitory activity 
when assayed against a number of known proteases (Dandekar, Robinson et al. 1982, 
Burdon, Wall et al. 1991), it is suggested that the putative inhibitory function may be 
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highly specific of an as yet unknown mammary or milk protease. It has also been shown 
that the purified tammar wallaby WAP protein failed to inhibit chemotrypsin and trypsin 
(Simpson, Ranganathan et al. 2000). WAP has been identified in the milk of only a few 
species such as mouse (Hennighausen and Sippel 1982b), rat (Campbell, Rosen et al. 
1984), camel (Beg, von Bahr-Lindstrom et al. 1986), rabbit (Devinoy, Hubert et al. 1988), 
pig (Simpson, Bird et al. 1996, Simpson, Bird et al. 1998), platypus, echidna (Simpson, 
Ranganathan et al. 2000), brushtail possum (Demmer, Stasiuk et al. 2001) and tammar 
wallaby (Simpson, Ranganathan et al. 2000). However, despite intensive study, it has not 
been found in the human or ruminants milk (Hajjoubi, Rival-Gervier et al. 2006). The 
absence of WAP in the milk of species such as humans and ruminants and the loss of 
functionality of the gene in ruminants weakens the hypothesis about the biological role 
of WAP in involution.    
3.4.4 Adipocytes contribute to the regulation of mammary gland through caveolins 
Stromal fibroblasts and adipocytes play pivotal roles in regulating mammary gland 
development and the function of mammary epithelial cells (Levine and Stockdale 1984, 
Levine and Stockdale 1985). The cell-cell interaction between these cell types regulates 
milk protein gene synthesis and thus regulation of mammary gland function (Levine and 
Stockdale 1984, Levine and Stockdale 1985, Polyak and Kalluri 2010). These cell types 
have been shown to exert paracrine control by generating signals for regulation of the 
secretory epithelium (Knight 1995). We investigated this paracrine regulation and the 
cell-cell interaction through the caveolin proteins. It has been shown earlier that the 
expression of caveolin 1 and 2 in mouse mammary gland was elevated during pregnancy, 
down-regulated during lactation and subsequently upregulated with the onset of 
involution (Park, Lee et al. 2001, Park, Lee et al. 2002, Sotgia, Casimiro et al. 2009). Our 
microarray analysis also confirmed the up-regulation of caveolin 1 from lactation to 
involution and was found to be secreted. These caveolins were found to be localized in 
myoepithelial cells and adipocytes, but not in the secretory epithelial cells (Hue-Beauvais, 
Pechoux et al. 2007). Thus a negative correlation between the expression of caveolin 
genes and milk protein genes like β-casein regulated by lactogenic hormones suggests a 
paracrine regulation of the cell-cell interaction in the mammary gland. We made use of 
the transformation of 3T3L1 adipocytes in this study. Caveolin mRNA and protein are 
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known to be strongly induced during adipogenesis, the process of differentiation of 
3T3L1 fibroblasts to adipocytes (Scherer, Lisanti et al. 1994). This occurs in response to 
insulin induction. We observed that upon insulin induction and conversion to fully 
differentiated adipocytes, 3T3L1 adipocytes constitutively express caveolin 1. Prolactin 
has previously been shown to negatively regulate caveolin 1 expression (Park, Lee et al. 
2001). This is not seen in fully differentiated 3T3L1 adipocytes, as treatment with 
prolactin in these adipocytes showed no reduction in the expression of caveolin 1. 
Prolactin binds to its receptor (PRLR, Prolactin receptor) and activates the Ras-p42/44 
MAP kinase pathway down-regulating the expression of caveolin 1. During adipocyte 
differentiation, the prolactin receptor is highly expressed only during the early 
differentiation stages and declines after the cells achieve a fully differentiated state 
(McAveney, Gimble et al. 1996). Thus, prolactin has no effect on caveolin 1 expression 
in fully differentiated 3T3L1 adipocytes due to the lack of PRLR expression. We made 
use of this observation and the fact that prolactin stimulates β-casein expression to study 
the potential effects of secreted caveolin 1 on milk protein genes. When conditioned 
media from 3T3L1 adipocytes constitutively expressing caveolin 1 was used to treat 
functional mammospheres (capable of expressing β-casein) in the presence of prolactin, 
there was a down-regulation of β-casein expression. This phenomenon was reversed 
when anti-caveolin1 antibody was added to the media, suggesting that caveolin 1 could 
be secreted into the mammary gland during the onset of involution to switch off milk 
protein gene expression. We observed in the analysis of our microarray data that caveolin 
1 appeared in the list of differentially expressed genes coding for secreted proteins that 
were up-regulated during involution, fortifying the use of anti-caveolin 1 antibody in our 
experiment. The secretion of caveolin 1 needs to be confirmed by assessing whether the 
gene codes for a signal peptide for caveolin 1 and this forms a major part of our future 
study. We hypothesize that during lactation, lactogenic hormones such as prolactin, that 
are produced primarily by tissues other than the mammary gland, down-regulate the 
expression of caveolin 1 and with the onset of involution, when lactogenic hormones 
cease to exist in the mammary gland, caveolin 1 gets up-regulated and secreted into the 
gland, and in a paracrine fashion causes a decline in the expression of milk protein genes. 
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Thus, the adipocytes and myoepithelial cells control mammary secretory epithelium 
function by paracrine signalling and help in mammary gland development.  
3.5 Conclusion 
To conclude, the two phases of involution and its regulation can be summarized from this 
study as follows: 
i. During the first 2 days after the cessation of lactation (days 1 and 2 of involution), 
we observed that the mammary ECM supported alveolar differentiation by the 
formation of mammospheres and hormone responsiveness by the expression of 
milk protein genes like beta-casein.  
ii. During the subsequent 2 days of involution (days 3 and 4 of involution), the 
mammary ECM did not support alveolar structure and function seen by the 
absence of mammosphere formation, cell death and absence of expression of beta-
casein. This suggests the programming of irreversible apoptosis of existing 
differentiated mammary structures to negate the reversibility of the process. 
iii. Caveolin 1 was upregulated after the onset of involution as seen in the microarray 
studies and milk synthesis in mammospheres was down regulated by paracrine 
signalling from caveolin 1 due to the decreased expression of beta-casein.  
The activity of new proteases most likely processes milk proteins to bioactive peptides to 
initiate the first phase of apoptosis. At this stage milk production is down regulated but 
involution is reversible. Although, specific bioactive peptides in milk that could 
potentially drive apoptosis and act as triggers for involution were not identified in this 
study, we hypothesize that proteases secreted in milk process proteins to produce these 
bioactive peptides. To extend this concept, specific peptide fractions isolated from 
involuting milk and incubated milk samples identified by mass spectrometry analysis can 
be used to treat MECs in culture for apoptotic activity. Another approach would be the 
teat sealing experiments that could also contribute to processing milk to bio-actives which 
can be further isolated to understand their role in regulating involution.   
 
 
 154 
 
 
 
Chapter 4: A silicon nanocarrier system for the delivery 
of a milk protein based cytotoxic payload to cancer cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 155 
 
4.1 Introduction 
Cancer is a term used to describe diseases in which abnormal cells divide uncontrollably 
and are capable of spreading to other parts of the body through the blood and lymphatic 
systems (Ehdaie 2007). Cancer is an extremely complex disease to study and understand 
as it involves multiple cellular physiological systems such as cell signalling and apoptosis 
(Hanahan and Weinberg 2000). Hence, the most common conventional treatments are 
limited to chemotherapy, radiation and surgery. Most of the treatment paradigms rely on 
whole body treatment with chemotherapy agents, thus exposing the patient to medications 
that kill rapidly dividing cells in the body non-specifically leading to debilitating side-
effects (Mousa and Bharali 2011). Conventional treatments for cancer fail to overcome 
the problems of side effects of the drug, poor specificity and inefficient delivery of the 
therapeutic agent  to the tumour (Camphausen and Lawrence 2008). Nanotechnology has 
the potential to overcome the obstacles in cancer therapy due to the unique size of the 
nanoparticles (1-100 nm) and their large surface-to-volume ratio (McNeil 2005). Nano-
oncology has the versatility to uniquely overcome some of the most challenging 
impediments to successful treatment of cancer.     
Breast cancer is the most common type of cancer among women in the western world, 
affecting approximately one out of every 8 women over their lifetime (Torre, Bray et al. 
2015). With the increase in the availability of screening programs allowing early 
detection and treatment of primary breast cancers, there is still increasing incidences of 
relapse with metastases after successful primary tumor treatment/removal (Tharkar, 
Madani et al. 2015). Since the natural course of breast cancer is extremely variable even 
after metastasis, with a wide range of prognostic and tumor characteristics, the number 
of available treatments is also manifold (Fumoleau, Seidman et al. 1997). Some of the 
current therapies include radiation therapy, surgeries such as lymphadenectomy and 
mastectomy, adjuvant combination chemotherapy using drugs including doxorubicin, 
cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone, taxanes, 
paclitaxel and docetaxel, and hormone therapy using tamoxifen (Cummings and Saba 
1997). With the need to overcome the drawbacks of conventional therapies, 
nanotechnology offers a promising and powerful tool for fighting breast cancer.  
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Successful nanoparticle based breast cancer therapy includes the use of organic 
nanocarriers including dendrimers, micelles and liposomes, and inorganic nanoparticles 
such as iron and gold to deliver anti-cancer reagents (Park 2002, Hofheinz, Gnad-Vogt et 
al. 2005, Svenson and Tomalia 2005, Yezhelyev, Yacoub et al. 2009). The 
pharmacological properties of tamoxifen encapsulated in stealth nanoparticle molecules 
such as polyethylene glycol (PEG) and loaded in poly-caprolactone nanospheres have 
been studied in vitro (Shenoy and Amiji 2005). Recently, thiol modified gold 
nanoparticles were engineered for microRNA transfection into breast cancer cells (Ekin, 
Karatas et al. 2014). When magnetic nanoparticles are conjugated with a tumor targeted 
ligand, they can be used for selective thermal ablation of the tumor. An antibody against 
a glycoprotein overexpressed in breast cancer was coupled a with PEG-iron oxide 
impregnated dextral nano-molecule for selective targeting of breast cancer (DeNardo, 
DeNardo et al. 2007).  
Nanoparticle based targeted therapies involve the concept of active and passive tumor 
targeting (Gao, Cui et al. 2004, Sinha, Kim et al. 2006). Active targeting involves the use 
of a linker against an antigen that is overexpressed or exclusively expressed on the surface 
of cancer cells (Amin, Sutradhar et al. 2014). Active targeting has its own disadvantages. 
For example, the drug may lose its potential when linked to a targeting moiety, the 
targeting linker may not be stable and the payload may not be cleaved off correctly at the 
target site (Moghimi, Hunter et al. 2001). Identifying an ideal antigen specifically 
expressed on tumor cells with no variation and mutation is another major challenge (Desai 
2012). Passive targeting is based on the enhanced permeability of the tumor vasculature 
(Maeda and Matsumura 1989). Macromolecules that permeate normal microvascular in 
intact tissues are known to demonstrate significant diffusion into tumor areas. 
Nanoparticles of approximately 100 nm in size can easily penetrate through the leaky 
capillary systems of the tumor, whereas they cannot pass through the intact endothelium 
into normal tissues (Yezhelyev, Yacoub et al. 2009). The retention of these nanoparticles 
is aided by the inadequate lymphatic drainage in the tumor. Tumor specific targeting 
through enhanced permeation and retention (EPR) effect can be achieved by making use 
of the biochemical and physiological properties of the tumor microenvironment (Maeda 
2010).     
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Elucidating the molecular pathogenesis of cancer has led to the development of targeted 
therapies for cancer (Ruoslahti, Bhatia et al. 2010). Compounds are designed to act on 
specific targets which are involved in the development and progression of cancer. 
However, there are inherent side effects in the use of these molecules as they also inhibit 
pathways that are necessary for the function of non-malignant cells (Abou-Jawde, 
Choueiri et al. 2003, Ruoslahti, Bhatia et al. 2010). This drawback calls for the need to 
develop new therapies that uses biological molecules such as peptides to target tumor 
cells. Naturally occurring factors such as those found in breast milk form an important 
class of preferential candidates due to the expected low occurrence of side effects. 
Accumulation of milk in the mammary gland due to cessation of suckling results in a 
process termed involution, where factors present in milk that are normally removed 
during nursing cause down-regulation of milk protein gene expression and mammary 
gland remodeling by cell death (Li, Liu et al. 1997). When such a process of apoptosis 
occurs within tissues, it invokes an immune response (Hochreiter-Hufford and 
Ravichandran 2013). However, the mechanisms that are employed by the involuting 
mammary gland involves induction of distinct apoptosis pathways and stimulation of 
immunomodulatory signals that suppress the potentially damaging effects of a cellular 
inflammatory response during the transition from lactation to involution (Chapman, 
Lourenco et al. 1999, Gordon, Binas et al. 2000, Clarkson, Wayland et al. 2004). 
Harnessing this apoptotic machinery in the absence of an immune response is important 
for cancer therapy where reduced immune response is favorable.  
Milk stasis is likely to be the primary trigger for the onset of mammary involution (Marti, 
Feng et al. 1997, Green and Streuli 2004). One such factor that is responsible for this 
trigger is the 14 kD milk protein, alpha-lactalbumin (LALBA). LALBA based complexes 
have been shown to have apoptotic potential and some forms, chemically induced forms 
such as multimeric LALBA (MAL), human alpha-lactalbumin made lethal to tumor cells 
(HAMLET) and bovine alpha-lactalbumin made lethal to tumor cells (BAMLET) have 
shown specificity to cancer cells, while sparing healthy cells (Svanborg, Agerstam et al. 
2003). The apoptosis inducing component was a folding variant that underwent a 
conformational change towards a molten globule-like state and was stabilized by the 
incorporation of a fatty acid co-factor such as oleic acid (Kohler, Gogvadze et al. 2001). 
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Earlier studies in our laboratory have shown the apoptotic effect of bLALBA (Bovine 
LALBA) on primary seal mammary epithelial cells (Sharp, Lefevre et al. 2008). In 
addition to the presence of 14kD LALBA in milk, a small amount of 28kD LALBA 
protein has also been shown to be present in milk which accumulates at weaning. Studies 
done in our laboratory have shown that this 28kD form, that is distinct from MAL and 
HAMLET, is capable of inducing apoptosis in a broad range of cell types including 
healthy and cancer cells leading to its potential use as a therapeutic agent against tumors 
(Brennan , Sharp et al. 2008).  
The aim of this study was to load the peptide-fatty acid complex, alpha-lactalbumin-oleic 
acid into biocompatible, biodegradable, inorganic silicon nanoparticles and study their 
apoptotic potential and specificity on breast cancer cells. The uptake and specificity of 
the nanoparticles loaded with therapeutic agents in vitro in normal and tumour cells 
remains unclear, but would provide new paradigms relating to specificity of nanoparticles 
and nanoparticles loaded with a cytotoxic agent and their potential as a therapeutic with 
application in vivo.    
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4.2 Materials and methods 
4.2.1 Synthesis of silicon nanoparticles 
Silicon nanoparticles were synthesized using a ball milling procedure. The internal 
cascading effect between the material and the grinding media (usually the balls) reduces 
the material to a fine powder. Silicon wafers with crystal orientation (100) were used. 
The wafers were cut using a diamond pencil. Two different types of milling were used - 
vibratory milling and planetary milling. The vibratory ball mill (Fritsch, analysette 3 
Spartan pulverisette 0, John Morris Scientific Pty Ltd., Sydney, Australia) has a container 
vibrating along the axis such that the balls impact upon the powder inside the container 
(Fig. 4.1 A). Planetary ball mills (Planetary Micro mill Pulverisette 7 premium line, 
Fritsch, John Morris Scientific Pty Ltd., Sydney, Australia) are smaller and grind the 
sample to very small size in less time. A planetary ball mill owes its name to the planet-
like movements of the vial (Fig. 4.1 B).  The vessel rotates around the mill’s central axis 
and around its own axis in the opposite direction (Russo, Colangelo et al. 2011). The 
grinding balls are thus subjected to superimposed rotational movements, or coriolis forces 
(Balaz 2008). 
The synthesis parameters were optimized and best results were obtained under the 
following conditions: 
Vibrating mill: The milling was done at an amplitude of 0.5 mm at 200 kPa Argon 
pressure for 10 hours. The samples were collected, sonicated for an hour and centrifuged 
at 13,000 g for one hour.  
Planetary mill: Synthesis was carried out in atmospheric pressure at a mill speed of 600 
rpm for 2 hours.  
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Fig. 4. 1. Working principle of ball milling. A) Vibratory ball milling. B) Planetary ball 
milling (Balaz 2008). 
 
4.2.2 Characterization of nanoparticles - morphology observation  
The size, shape and surface morphologies of the silicon nanoparticles were analyzed by 
Scanning Electron Microscopy (SEM) (Carl Zeiss Supra 55VP FEG SEM, Deakin 
University, Australia) operating at 3 kV accelerating voltage and 8 mm working distance. 
The synthesized silicon nanoparticle powder was dispersed in a small amount of water 
and fixed on a heated arsenic doped silicon wafer, which was then fixed on a stub. A 
carbon coater (VG/Polaron SC 7620 sputter coater) was used to coat a thin carbon layer 
on the samples. The samples were stored in a vacuum chamber and imaged under a Zeiss 
Supra FE-SEM (Field Emission Scanning electron Microscope). SEM works on the 
A 
B 
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principle of detecting electrons (supplied by the electron beam) that are reflected from 
the samples.  
4.2.3 Structure characterization  
The structure of the prepared nanoparticles was characterized using a Panalytical X’Pert 
PRO MRD XL X-ray Diffractometer (40kV, 30mA) with Cu-Kα radiation (λ=0.154 nm) 
from 20˚ to 80˚ at a scanning rate of 0.02˚ s-1. A high score plus 3.0x software was used 
to analyze the lattice parameters. The diffraction data was compared against a database 
maintained by the International Centre for Diffraction Data.  
4.2.4 Serum stability 
The stability of the synthesized nanoparticles in a typical biological medium was assessed 
by dispersing them in 1x Phosphate Buffered Saline (PBS, E404, Amresco, Astral 
scientific, Victoria, Australia) with 1% Fetal Bovine Serum (FBS, 10099141, Gibco, Life 
technologies, Victoria, Australia), incubated at 37˚C and measuring their size at regular 
intervals of time (1 hour, 2 hours, 3 hours, 4 hours, 1 day up to 7 days) using a Dynamic 
Light Scattering (DLS) particle sizer (Malvern Zetasizer Nano ZS ZEN3600). DLS is a 
laser scattering-based size detection technology used to measure the particle sizes of 
nanoparticles depending on their Brownian movement.  
4.2.5 Alpha-lactalbumin-oleic acid complex formation 
A stock solution of alpha-lactalbumin (bovine alpha-lactalbumin, L5385, Sigma, Sydney, 
Australia) (20 mg/mL) was prepared in 1x PBS (e.g.: 5mg LALBA in 250 μL 1x PBS). 
To this, 120 molar equivalents (11.25 μL) of oleic acid (O1383, Sigma, Sydney, 
Australia) in ethanol were added. The mixture was subjected to heating at 60˚C on a heat 
block for 5 minutes (Kamijima, Ohmura et al. 2008). The reaction mix was cooled and 
centrifuged at 5000xg at 4˚C for 10 minutes to remove any unbound oleic acid. Any pellet 
formed was re-suspended and the centrifugation step was repeated to remove any residual 
unbound oleic acid. The pellet formed after this stage was removed, as cells treated with 
this showed toxic effects on the cultured cells. The protein concentration of the complex 
was estimated using Pierce Micro BCA protein assay kit (23235, Thermo Fisher 
Scientific, Victoria, Australia).  
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4.2.6 Adsorption of the complex onto nanoparticles 
Different concentrations of the alpha-lactalbumin-oleic acid complex, with protein 
concentration ranging from 125 μg/mL to 5.0 mg/mL, were prepared. The synthesized 
nanoparticles were added to the protein-fatty acid solutions and stirred overnight at 37˚C 
for 5 hours or 24 hours, then subjected to centrifugation at 3000xg for 10 minutes. The 
supernatant was collected and the concentration of un-adsorbed protein was estimated 
using Micro BCA protein assay kit. Time dependent and concentration dependent 
adsorption of the complex onto the nanoparticles was determined.  
4.2.7 Release of the adsorbed complex from the nanoparticles 
Time dependent release of the complex from the encapsulated nanocarriers in 1x PBS at 
37˚C was determined. The nanoparticles with the adsorbed protein-fatty acid complex 
were stirred in 1 x PBS at a temperature of 37˚C. At regular intervals (0, 5, 10, 15, 30, 60 
minutes, 2 hours, 3 hours, 4 hours and 5 hours), the supernatant was collected and equal 
volume of 1x PBS was replaced. The supernatant was estimated for protein concentration 
in the complex using Micro BCA protein assay kit. 1x PBS, stirring and 37˚C were 
maintained to mimic biological conditions.  
4.2.8 Internalization of nanoparticles into the cells 
Internalization of the nanoparticles into MCF-7 breast cancer cells was imaged using 
SEM. The cells (5000 cells) were plated on a polycarbonate transwell permeable 
membrane with pore size of 3 μm and an insert diameter of 24 mm and allowed to grow 
overnight (incubation at 37ºC, 5% CO2, humidified) in 1xDMEM media (11995-073, 
Gibco, Life Technologies, Victoria, Australia) with 10% Fetal bovine serum (FBS), 1% 
L-Glutamine (200mM L-Glutamine (100x), 25030-81, Gibco, Life Technologies, 
Victoria, Australia) and 1% P/S (Penicillin/Streptomycin, 15140-122, Gibco, Life 
Technologies, Victoria, Australia). After 3 hours of treatment with silicon nanoparticles, 
the cells were fixed with 4% paraformaldehyde for 2 hours and dehydrated with 
increasing grades of ethanol (60 to 100%). The polycarbonate membrane with the cells 
was fixed on a stub and imaged under a Zeiss Supra FE-SEM (Field Emission Scanning 
Electron Microscope). 
 163 
 
4.2.9 Cell culture  
The breast cancer cell line MCF-7 was cultured as described in the ATCC (American 
Type Cell Culture) data sheet in 1x DMEM (11995-073, Gibco, Life Technologies, 
Victoria, Australia) with 10% Fetal bovine serum (FBS, 10099141, Gibco, Life 
Technologies, Victoria, Australia), 1% P/S (Penicillin/Streptomycin, 15140-122, Gibco, 
Life Technologies, Victoria, Australia) and 1% L-Glutamine (200mM L-Glutamine 
(100x), 25030-81, Gibco, Life Technologies, Victoria, Australia) at 37º C in 5% CO2.  
4.2.10 Alpha-lactalbumin-oleic acid complex and alpha-lactalbumin-oleic acid 
complex loaded nanoparticle treatment of MCF-7 cells 
The alpha-lactalbumin-oleic acid complex at concentrations of 0.5, 1, 2 and 3 mg/mL was 
added to 5000 cultured MCF-7 cells in different wells of a 96 well plate in media (1x 
DMEM with 1% L-glutamine and 1% P/S) in the absence of serum for 4 hours and 24 
hours at 37º C in 5 %CO2 incubator. The cell culture treatments were conducted in the 
absence of FBS in the media as FBS was found to strip oleic acid from the complex and 
render the molecule inert. The protein concentration corresponding to the concentration 
of the complex with the desired kill activity was determined to be 2 mg/mL. The complex 
loaded nanoparticle at 2 mg/mL was used to treat the 5000 cultured MCF-7 cells in 1x 
DMEM with 1% L-glutamine and 1% P/S in the absence of serum at 37º C in 5% CO2. 
After 15 minutes of treatment, the media was replaced with fresh media and left for a 
further 4 hours or 24 hours. The cells were imaged using a Nikon eclipse TS100 inverted 
light microscope and images captured using DFC425C camera.  
4.2.11 Cell viability 
Cell death was estimated by use of the MTS assay kit (Cell titer 96 AQueous non-
radioactive cell proliferation assay, G5421, Promega, Sydney, Australia) according to 
manufacturer’s instructions. 20 μL of the reagent solution containing a tetrazolium 
compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an electron coupling reagent 
(phenazine ethosulfate; PES) was added to the wells in the 96 well assay plate containing 
cells in 100 μL of culture medium. The plate was incubated at 37˚C for 1-4 hours in a 
humidified, 5% CO2 atmosphere. The absorbance was read at 490 nm using a 96 well 
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plate reader (Biorad xMarkTM microplate absorbance spectrophotometer). All samples 
were analyzed in triplicate.  
4.2.12 Statistical analysis 
All statistical comparisons were made using a two-tailed t-test assuming unequal 
variances between means. Data were presented as mean ± standard error of the mean. In 
all statistical tests a p value of less than 0.05 was considered significant. 
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4.3 Results  
4.3.1 Size and shape of nanoparticles 
SEM images of the nanoparticles synthesized using vibratory and planetary ball milling 
confirmed the formation of nano-dimensional silicon particles (Fig. 4.2). Irregularly 
shaped nanoparticles less than 100 nm in size were obtained using both vibratory and 
planetary milling. However, reduction in the size of nanoparticles to less than 50 nm and 
better size distribution (homogeneous size distribution) was evident after planetary 
milling (Fig. 4.2 A).  
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Fig. 4. 2. SEM images of nanoparticles. Scanning electrograph images of nanoparticles 
synthesized by A) Planetary ball milling and B) Vibratory ball milling. The images were 
taken using Carl Zeiss Supra 55VP FEG Scanning Electron Microscope.  
A 
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4.3.2 X-Ray diffraction 
The X-ray diffraction spectrum showed 2θ peaks corresponding to silicon (Fig. 4.3). The 
diffraction data was compared against a database of diffraction patterns maintained by 
the International Centre for Diffraction Data. Peak broadening in the sample obtained 
from planetary milling showed reduction in size of the particles (Fig. 4.3 A). This 
confirmed the formation of smaller nanoparticles less than 50 nm in size after planetary 
milling.  
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Fig. 4. 3. XRD spectrum of silicon nanoparticles. The X-ray Diffraction spectrum of 
silicon nanoparticles synthesized by A) Planetary ball milling and B) Vibratory ball 
milling. The 2θ peaks in the spectrum correspond to the peaks of silicon. This data was 
obtained from the database of diffraction patterns maintained by the International Centre 
for Diffraction Data. The peak broadening seen in A) planetary milling shows the 
A 
B 
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formation of smaller size nanoparticles (< 50 nm) than the ones obtained using vibratory 
milling.   
 
4.3.3 Serum stability of the synthesized nanoparticles 
Stability of the silicon nanoparticles in serum was determined using Dynamic Light 
Scattering (DLS). The nanoparticles were dispersed in 1x PBS containing 1% Fetal 
Bovine Serum (FBS), incubated at 37 ºC and their size was measured using DLS at 
regular time intervals as shown below. The study showed that there was aggregation of 
the particles in serum with time and no visible degradation of the particles in serum (Fig. 
4.4). This experiment was performed to determine the stability of the nanoparticles in the 
biological medium. 
 
Fig. 4. 4. Serum stability of nanoparticles. In order to study the stability of the 
synthesized silicon nanoparticles in biological medium, the nanoparticles were dispersed 
in 1x PBS containing 1% FBS and their size measured by DLS for 7 days.  
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4.3.4 Internalization of nanoparticles into the cells 
Interaction of silicon nanoparticles with MCF-7 cells was examined using Scanning 
Electron Microscopy indicating the uptake of these nanoparticles after 3 hours of 
incubation (Fig. 4.7 B). This analysis will help to determine the uptake of the 
nanoparticles by the tumour cells at different time intervals and thus help in developing 
a model based on time dependent release of the therapeutic to the tumour cells.  
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Fig. 4. 5. Internationalization of silicon nanoparticles into MCF-7 cells. A) MCF-7 
cells on polycarbonate membrane prior to treatment. The blue arrow indicates the cells 
cultured on the membrane. B) Internalization of Si nanoparticles into the cells. The red 
arrow indicates the internalization of the nanoparticles into MCF-7 cells. The yellow 
arrow indicates the already internalized nanoparticle into the cell. The green arrow 
indicates a pore of the polycarbonate membrane.  
B 
A 
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4.3.5 Adsorption of alpha-lactalbumin-oleic acid complex onto nanoparticles  
The adsorption efficiency of the complex on the nanoparticles at two different stirring 
times was determined based on the concentration of un-adsorbed LALBA in the 
supernatant. The adsorption efficiency of the alpha-lactalbumin-oleic acid complex on 
the nanocarriers in 1x PBS at 37 ºC was carried out at 2 different stirring times – 5 and 
24 hours and it was found that the longer stirring time resulted in better adsorption 
efficiency (Fig. 4.5). Concentration dependent enhancement with maximum efficiency 
was shown up to a concentration of 2.5 mg/mL LALBA. This study was carried out to 
determine the optimum and best conditions required for maximum adsorption of protein-
fatty acid complex onto the nanoparticles and it showed increased adsorption efficiency 
at the longer stirring time.   
 
 
Fig. 4. 6. Adsorption efficiency of alpha-lactalbumin-oleic acid complex on 
nanoparticles. The adsorption efficiency of the complex on the nanoparticles at two 
different stirring times was calculated based on the concentration of un-adsorbed LALBA 
in the supernatant. The samples were assayed in triplicate and all values are represented 
as mean ± SEM (n=3).  
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4.3.6 Release of the complex from the nanoparticles 
The adsorbed alpha-lactalbumin-oleic acid complex on the nanoparticles showed an 
initial 80% release within half an hour, followed by sustained release for 5 hours at 37˚C 
(Fig. 4.6). This study was carried out to determine the probable release kinetics of the 
complex that is envisioned to be seen in the biological system. This would guide us in 
modifying the carrier in a way that ensures the best and desired temporal release of the 
protein-fatty acid complex in the tumour cells.   
 
Fig. 4. 7. Release of the complex from the nanoparticles. The release kinetics of the 
complex from the surface of the nanoparticles showed a sustained release up to 5 hours. 
All samples were assayed in triplicate and the values are represented as mean ± SEM 
(n=3).  
 
4.3.7 Treatment of alpha-lactalbumin-oleic acid on MCF-7 cells 
The effects of the synthesized LALBA-oleic acid complex were first examined by 
incubation with cultured MCF-7 cells using varying concentrations of the complex in 
order to identify the desired concentration with maximum cytotoxic activity. The final 
concentration of the complex in the media ranged from 0.5 mg/mL to 3 mg/mL. Oleic 
acid and alpha-lactalbumin concentrations corresponding to the concentration of these 
molecules in the complex were used to compare effects on cell death. In order to avoid 
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the toxicity from the complex, the media was changed 30 minutes after treatment with 
the complex. The measure of cell death/cell proliferation was estimated by MTS assay at 
two time intervals - 4 hours and 24 hours after treatment (Fig. 4.8). The absorbance at 
492 nm gives a measure of the live cells after treatment. There was significant reduction 
in cell viability with treatments using both 2 and 3 mg/mL complex after 4 and 24 hours. 
Reduction in cell viability was also seen in oleic acid treatments corresponding to 2 and 
3 mg/mL after 24 hours, although no cell death was observed in the 4 hour treatments. 
LALBA alone at 3 mg/mL reduced cell viability after 24 hours. The cells with treatments 
of 2 mg/mL of the complex were also imaged at 0, 4 and 24 hours after treatment (Fig. 
4.9). MCF-7 cells only and 2 mg/mL LALBA treatment alone after 24 hours showed no 
apparent cell death (Fig. 4.9 A&B). Oleic acid treatment at 2 mg/mL and 3 mg/mL 
concentrations showed cells aggregated and floating in the media (Fig. 4.9 C&D). The 
complex treatment at 2 mg/mL concentration showed cell death at 4 and 24 hours (Fig. 
4.9 F&G).  
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Fig. 4. 8. Alpha-lactalbumin-oleic acid treatment on MCF-7 cells. The effects of 
LALBA-Oleic acid complex, LALBA alone and oleic acid alone were examined 
following addition to media of MCF-7 cells. The complex was examined at 
concentrations from 0.5 to 3 mg/mL (final concentration). MTS assay was used to analyze 
cell viability. There was significant reduction in cell viability with treatments of 2 and 3 
mg/mL complex after 4 and 24 hours. Oleic acid treatments corresponding to this 
concentration (2 and 3 mg/mL) showed significant reductions in cell viability after 24 
hours, but not after 4 hours. LALBA alone treatment at 3 mg/mL showed a significant 
reduction in cell viability after 24 hours treatment. All samples were assayed in triplicate 
and the values are represented as mean ± SEM (n=3). *significantly different to control 
at 4 hours (p<0.05) and #significantly different to control at 24 hours (p<0.05). 
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Fig. 4. 9. Complex treatment on MCF-7 cells. A) Control (MCF-7 cells only) after 24 
hours, B) LALBA only treatment at 2 mg/mL after 24 hours, C) Oleic acid only treatment 
at 2 mg/mL after 24 hours, D) Oleic acid only treatment at 3 mg/mL after 24 hours, E) 
2mg/mL LALBA-oleic acid complex treatment at 0 hours, F) 2 mg/mL LALBA-oleic 
acid complex treatment after media change at 4 hours, G) 2mg/mL LALBA-oleic acid 
complex treatment at 24 hours. All images were captured at 4x magnification. 
 
4.3.8 Treatment of complex loaded nanoparticles on MCF-7 cells 
Since the nanoparticles had adsorption efficiency at 2.5 mg/mL of the complex (Section 
4.3.4) and the complex had cytotoxic activity at 2 mg/mL (Section 4.3.7), that 
concentration (2 mg/mL) was used subsequently for experiments to examine the effects 
of the complex loaded onto the nanoparticles on cultured MCF-7 cells. The cell 
proliferation/ cell death was measured by MTS assay at 4, 8 and 24 hours after treatment 
(Fig. 4.10). Cells cultured alone (untreated cells) were used as control. All samples were 
assayed in triplicate. 
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Fig. 4. 10. The effect of complex loaded nanoparticles on MCF-7 cells. Complex (2 
mg/mL) was loaded onto the nanoparticles used to treat MCF-7 cells (complex loaded 
NP). Activity was compared to the same concentration of complex treated directly on the 
cells (Complex alone). Cells alone and nanoparticles without the adhered complex (NP 
alone) were used as control. It was found that there was no reduction in cell viability when 
the nanoparticles alone were treated on the cells indicating their biocompatibility. All 
samples were assayed in triplicate and the values are represented as mean ± SEM (n=3). 
*significantly different to control (cells alone and NP alone) at 4 hours (p<0.05), 
**significantly different to control (cells alone and NP alone) at 8 hours (p<0.05) and 
#significantly different to control (cells alone and NP alone) at 24 hours (p<0.05).  
 
Cells when treated with complex loaded nanoparticles (with a final complex 
concentration of 2 mg/mL) showed sustained release of the payload after 4 and 8 hours 
compared to the complex treated directly on the cells. The effect of the nanoparticles was 
also assessed by treating cells with nanoparticles alone showing there was no significant 
decrease in cell numbers from the control.  
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4.4 Discussion 
Synthesis of silicon nanoparticles can be broadly classified into two categories - top-down 
approach and bottom-up approach (Klabunde 2001, Reverchon and Adami 2006). The 
top-down approach is characterized by reduction in dimension of the product’s original 
size by special size reduction techniques, involving vacuum deposition and high 
temperature techniques. This is the physical synthesis route. Bottom-up is the chemical 
approach involving production from atomic or molecular scale (Rahman and Padavettan 
2012). We used the physical route of synthesis of silicon nanoparticles, due to the inherent 
advantages of this approach. There is absence of solvent contamination in the prepared 
materials and there is uniformity of nanoparticle distribution in the physical route of 
synthesis when compared to the chemical approach (Korbekandi and Iravani 2012). Also, 
a chemical route of synthesis often involves the production of materials of less well-
defined composition and size (O'Farrell, Houlton et al. 2006). When nanoparticles are 
synthesized using the ball milling technique, there are no solvents involved in the process, 
minimizing contamination and characterization using SEM revealed good size 
distribution of the nanoparticles. We noticed that better size distribution was offered by 
planetary milling than ball milling. This is due to the extremely high centrifugal forces of 
the planetary mill resulting in very high pulverization energy and short grinding time. 
The difference in speed between the grinding jar and the balls produces an interaction 
between impact and frictional forces releasing high dynamic energy. This causes efficient 
size reduction. The forces influencing the materials under synthesis exceeds by ten-fold 
the forces imposed in conventional milling. The energy density of a planetary mill is 
about 1000 times that seen in vibratory mills, jet type mills, etc. making the planetary 
milling process faster and more efficient (Tsetsekou and Chernik 2005). Size distribution 
of the sample plays an important role in protein adsorption, and also their uptake in 
biological systems. Narrow size distribution is preferred over wide size distribution and 
this is offered by planetary ball milling. Peak broadening seen in the X-ray diffraction 
data from the particles synthesized in a planetary mill shows a reduction in the size of the 
particles (Fultz and Howe 2013). Smaller particles have a larger surface to volume ratio 
and thus, facilitate higher loading capacity for the therapeutic payload (De Jong and Borm 
2008). Planetary milling yielded nanoparticles less than 50 nm in size. This is 
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advantageous in our study for increasing the complex loading capacity of the 
nanoparticles, facilitating delivery of higher doses of the therapeutic agent. We also know 
that the increase in surface area prolongs circulation time and reduces detection by 
immune cells (Alexis, Pridgen et al. 2010).  
Silicon nanoparticles are known to be biocompatible and biodegradable (Anglin, Cheng 
et al. 2008). In order to determine the stability of these nanoparticles in a biological 
medium, we conducted a serum stability study using the dynamic light scattering (DLS) 
method (Lazzari, Moscatelli et al. 2012). There was no degradation seen in the medium 
with FBS since there was no size reduction, indicating their stable nature. However, there 
was an increase in the size of the particles. This may be attributed to two reasons- serum 
proteins tend to promote aggregation of the particles, and agglutination of the particles 
by macromolecular bridges between the nanoparticle surfaces (Mahmoudi, Lynch et al. 
2011). However, this does not alter with the loading capacity of the nanoparticles. 
Internalization of the nanoparticles into MCF-7 cells within 3 hours of incubation was a 
promising observation in our study. We know that due to the leaky vasculature seen in 
cancerous cells and their poor lymphatic drainage, they tend to imbibe and retain 
nanoparticles, whereas healthy cells do not (Maeda 2010). This technique of enhanced 
permeation and retention (EPR) by the tumor cells, also called passive targeting is 
envisioned to be used in this model of study. Tissue diffusion and extravascular leakage 
rely on the thermodynamic movement of nano-sized molecules, allowing smaller 
particles to perfuse deeper and more homogeneously into the tumor tissue (Prabhakar, 
Maeda et al. 2013, Kobayashi, Watanabe et al. 2014). Hence, smaller nano-sized agents 
between 10 and 200 nm are ideally suited for passive targeting (Allen and Cullis 2004). 
The nanoparticles synthesized in our study fall into this category and hence can be used 
for passive targeting of tumor tissue. However, less is known about the uptake of these 
nanoparticles into the cells. We have shown that the nanoparticles synthesized in our 
study are capable of getting internalized into cells, facilitating access of the therapeutic 
agent to the cell. This is significant as this study uses the novel therapeutic agent, 
BAMLET, that requires internalization for its activity (Hoque, Dave et al. 2013). This 
complex has a number of targets in a cancer cell, including the accumulation of the 
complex in the nuclei, where it impairs the function of nucleosomes (Gustafsson, 
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Hallgren et al. 2005). Thus, internalization of the nanoparticles into the cell would result 
in impaired transcription and irreversible apoptosis of the tumor cells. Future work will 
involve delivering the complex loaded nanoparticles to the tumor cells and normal cells 
and performing time course imaging to study their uptake in both the cell types.  
Earlier studies have shown that exposure to HAMLET induced apoptosis in tumor cells 
but not in healthy cells (Svanborg, Agerstam et al. 2003). Thus, there is dual targeting in 
the model in this study in the form of passive targeting due to enhanced permeation and 
retention (EPR) effect and the specificity of the LALBA-oleic acid complex to tumor 
cells, sparing the healthy cells. An earlier study showed that the apoptotic effect of the 
complex was ablated in the presence of BSA and FCS/FBS, rendering the molecule inert 
(Pettersson, Mossberg et al. 2006). When cells were treated with HAMLET in the absence 
of BSA or FCS, there was mitochondrial damage and cytochrome C release and a caspase 
response (Kohler, Gogvadze et al. 2001, Hallgren, Gustafsson et al. 2006). Since the 
LALBA-oleic acid complex was adsorbed on the surface of the nanoparticles in our study, 
a similar effect of FBS was hypothesized in the complex loaded nanoparticle treatments. 
Hence, all LALBA-oleic acid treatments and complex loaded nanoparticles treatments 
were carried out in the absence of FBS in the media. This is not an ideal scenario in vivo 
since the particles would circulate in serum and the payload in this study is only adsorbed 
onto the nanoparticle surface, thus exposing it to serum the moment it comes in contact 
with the biological system. Literature suggests that the proteins in the serum influence 
the corona of the nanoparticles and influence the therapeutic potential of the nanocarrier 
system (Monopoli, Walczyk et al. 2011). In addition, the payload was released into the 
serum within 30 minutes, whereas the nanoparticle took 3 hours to be internalized into 
the cell. It is therefore proposed that in order to overcome this shortcoming, the complex 
adsorbed nanoparticle could be encapsulated in a stealth, biocompatible molecule such as 
poly-ethylene glycol (PEG). This polymer is non-toxic, non-antigenic, non-
immunogenic, highly water soluble and FDA approved. Some of the advantages of 
PEGylation include decreased degradation by metabolic enzymes, prolonged residence 
in the body and reduction or elimination of protein immunogenicity (Veronese and Pasut 
2005). PEGylation plays an important role in drug delivery by enhancing the potential of 
peptides and proteins as therapeutic agents. This would allow the nanoparticle to be taken 
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up by the cell first and the payload released after uptake. Since the possible effects of 
nanoparticle uptake in normal cells is hard to study in an in vitro cell culture model system 
due to the absence of the lymphatic drainage system, future work will involve injecting 
PEGylated complex loaded nanoparticles into mice and tracking the localization of these 
particles. The photoluminescent nature of silicon nanoparticles (Carlisle, Germanenko et 
al. 2001, Liu, Sato et al. 2005) would be of use here in assisting in live cell imaging of 
these nanoparticles inside a biological system.  
A study undertaken last year revealed that bovine lactoferrin also binds to oleic acid and 
forms an anti-tumor complex similar to HAMLET (Fang, Zhang et al. 2014). Studies in 
our laboratory have also shown that LALBA may not be the only protein that undergoes 
a functional change when complexed with a fatty acid to form an apoptotic complex. 
Beta-lactoglobulin, when dimerized in the presence of oleic acid has been shown to gain 
apoptotic potential (Sharp et al., unpublished data). This suggests that the incorporation 
of fat by protein dimerization to produce an apoptotic complex may be a more general 
phenomenon that needs to be investigated in detail. It would be interesting to further 
investigate the whey proteins in milk that can form potential anti-tumor complexes with 
fatty acids as this would have possible implications on mammary gland involution, where 
there is accumulation of milk following weaning, thus forming a conducive environment 
for the formation of such complexes and in potential therapeutic benefits for cancer 
patients. Although HAMLET and BAMLET-like complexes have shown apoptotic 
activity, the possibility of oleic acid stripping from the complex and causing toxic effects 
as seen in our study raises risk factors in the use of these complexes in biological systems. 
In order to overcome these side-effects, native dimeric LALBA could be used as a 
potential therapeutic agent. 
28kD LALBA occurs naturally in milk in low concentrations during mid-lactation but 
accumulates as a result of milk stasis during weaning (Brennan , Sharp et al. 2008). This 
milk-borne 28kD LALBA has been proposed to be involved in the local control of 
mammary gland involution and apoptosis. This is supported by data from in vivo studies 
in Cape fur seals which do not produce LALBA and subsequently do not undergo 
mammary involution during milk stasis (Sharp, Lefevre et al. 2008). The activity of this 
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dimer has been shown to be dose dependent. The low concentration of 28kD LALBA 
during mid-lactation has been predicted to induce no cell death in the mammary gland, 
however during weaning, milk stasis leads to an increase in concentration of this protein 
that may be lethal to the cells (Brennan , Sharp et al. 2008). The LALBA gene is known 
to be expressed only by the mammary epithelial cells upon lactogenic hormone induction 
and is not expressed by any other cells in the body (Vilotte and Soulier 1992). The LALBA 
gene has also been reported to be expressed in more than 60% of breast cancer clinical 
cases that have been tested so far (Thean and Toh 1990, de Almeida and Pestana 1992, 
Anderson, Swaminathan et al. 1999). A hormone treatment to increase the levels of 
LALBA expression in breast tumors in order to initiate apoptosis appears to be a promising 
therapy for breast cancer patients. Since LALBA occurs naturally in the body, the 
induction of 28kD LALBA in tumor cells will only effect a local response similar to the 
one seen in mammary gland involution and not have adverse side effects for cancer 
patients.   
 
4.5 Conclusion 
We have successfully developed a silicon nanoparticle based system to load LALBA-
oleic acid complex that induces apoptosis in MCF-7 breast cancer cell line. The optimal 
concentration of the complex to induce cell death in the tumor cells was identified to be 
2 mg/mL and the complex loaded nanoparticle treatment showed sustained release of the 
payload enabling prolonged activity of the complex. To further extend this study, we 
propose to test the PEGylated complex loaded nanoparticle system on a panel of breast 
cancer cell lines and ultimately in a mouse model to better understand the uptake of these 
nanocarrier systems in normal and tumor cells. It is also proposed to use the native form 
of the dimeric protein LALBA (28kD milk-borne dimeric protein) which accumulates 
naturally in the mammary gland during weaning and is thought to be a trigger of 
mammary involution. The induction of the expression of this protein hormonally in the 
tumor cells is predicted to stimulate the tumors’ own death by initiating apoptosis, thereby 
activating the involution cascade within the tumor mass followed by tissue remodelling 
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in the absence of an immune response, thus negating the adverse side effects of 
conventional cancer therapies.   
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Chapter 5: General Discussion 
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This research has predominantly focused on exploring the mechanisms that regulate 
apoptosis and involution in the murine mammary gland. The majority of in vitro 
experiments used to study the regulation of genes and molecular pathways involved in 
apoptosis have been cell culture based models (Gordon, Binas et al. 2000, Campbell and 
Watson 2009, Jechlinger, Podsypanina et al. 2009). However, whole organ culture and 
mammary explants have also been used to investigate mammary involution (Atwood, 
Ikeda et al. 1995, Casey, Chen et al. 1996). The need for an in vitro model to study the 
extracellular matrix-cell interactions, effect of milk-borne factors and hormones that 
govern the organization of mammary epithelium during the two phases of murine 
mammary involution was addressed in this study with the use of the mammosphere 
model.  
5.1 ECM signals during involution 
Mammary epithelial cells in the mammary gland depend on interaction with substratum 
for cytological and functional differentiation even in the presence of lactogenic hormones 
(Hall 1987). A complex substrata with an interconnected meshwork of secreted proteins, 
like the extracellular matrix interacts with the cell to form a functional unit (Bissell and 
Barcellos-Hoff 1987). It confers the cellular functions like survival, apoptosis, polarity, 
cell adhesion, proliferation and differentiation through structural properties like physical 
support and boundary constraints, by providing mechanosensory cues and through the 
classical signal transduction pathways (Butcher, Allison et al. 2009). We know that cell-
matrix interaction in the mammary gland regulates cell polarity and milk protein gene 
expression with the induction of lactogenic hormones (Topper and Freeman 1980, 
Aggeler and Bissell 1987). The current study elucidated the effect of matrix isolated from 
the two phases of involution on the polarity and milk protein gene expression of 
mammary epithelial cells in culture. Matrix from early involution promoted the formation 
of polarized 3-dimensional acini structures similar to the alveolar structures seen during 
lactation in the mammary gland. During early involution, the ECM and its components 
therefore appears to remain intact and unaltered promoting epithelial cell survival, cell 
polarity and capability to express milk protein gene expression upon hormone induction. 
This confers the reversibility of the involution process during the early stages of 
involution. Several studies conducted earlier have shown minimal ECM remodeling 
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during lactation and early involution and dramatic increase of tissue remodeling occurring 
from day 4 involution (Talhouk, Bissell et al. 1992, Frisch and Francis 1994, Boudreau, 
Sympson et al. 1995, Lund, Romer et al. 1996, Pullan, Wilson et al. 1996).  
A small amount of apoptosis occurs during the start of the second phase of involution and 
by late involution, apoptosis is well underway within the gland accompanied by matrix 
remodeling (Green and Lund 2005). Matrix metalloproteinases play an important role in 
matrix remodeling by cleaving ECM substrates like collagen IV, laminins, chemokines 
and E-cadherins (Watson and Kreuzaler 2011). Most MMPs are synthesized as pre-
proenzymes and the removal of signal peptide during translation generates the proMMPs. 
The activation of the precursor zymogen regulates MMP activity (Nagase, Visse et al. 
2005). During early involution, the activity of these MMPs is suppressed by its 
endogenous inhibitors, tissue inhibitor of metalloproteases (Green and Lund 2005). This 
was seen in microarray analysis, where there was an up-regulation of TIMPs in early 
involution followed by its subsequent down-regulation during late involution. Changes 
in ECM receptor functions due to breakdown of ECM components by MMPS during late 
involution causes matrix detachment of epithelial cells leading to anoikis. Cells cultured 
on late involuting matrices lost their cell survival ability, cell polarity and milk protein 
gene expression due to changes in the ECM composition owing to the matrix remodeling 
events during this phase. Thus, the extracellular matrix, its components and signals 
contribute to the irreversibility of the second stage of the involution process and plays an 
important role in the transition from phase I to phase II involution. Extensive tissue 
remodeling occurring during the second stage of involution act as mediators of mammary 
gland PCD during involution (Walker, Bennett et al. 1989).     
The stunning capacity of the mammary gland to produce milk is matched by another 
spectacular event in which the milk producing cells are removed when they are no longer 
required. This stage in the mammary development cycle, involution, is associated with 
the mechanism of programmed cell death, apoptosis in the destruction of the secretory 
epithelium (Watson 2006). During the first phase of involution, lactation can be re-
established if pups are returned back to the mother within 48 hours enabling the mammary 
epithelial cells which have entered the initial non-committed apoptosis stage to return to 
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an active secretory state in response to milk removal (Jaggi, Marti et al. 1996, Li, Liu et 
al. 1997, McMahon, Farr et al. 2004). This phase is assumed to be initiated by local 
factors and intra-mammary death signals are known to dominate the protective effects of 
systemic survival during this phase (Quarrie, Addey et al. 1996, Li, Liu et al. 1997, Marti, 
Feng et al. 1997). It is clear from results in chapter 2 of our study that the initiation of 
apoptosis during involution is unlikely due to loss of matrix availability for cell 
attachment.  
5.2 Phase I involution trigger 
Chapter 3 aimed at elucidating a possible trigger for the onset of apoptosis during early 
involution (phase I involution). Among the different mechanisms involved in the initial 
trigger, one is related to the accumulation of inhibitory or pro-apoptotic factors in milk 
that are normally removed during nursing (Shamay, Shapiro et al. 2002). Our study 
showed a similar scenario when milk collected from various stages of involution (both 
phase I and phase II) was used to treat functionalized mammospheres formed on early 
involuting matrices. Milk samples collected from involuting mice caused morphological 
disruption of mammospheres and cell death. The mammary epithelial cells forming the 
mammospheres in this study were exposed to milk collected from involuting mice from 
their basolateral side, whereas in vivo they are exposed from the apical side. Thus, it 
would be interesting to study the response of a monolayer of epithelial cells to involuting 
milk. It was also interesting to note that the incubated milk i.e. day 15 lactating milk 
incubated for 4 days also had a similar effect on mammospheres. There is down-
regulation of milk protein genes and cessation of their production at the onset of 
involution. The accumulated proteins in milk are known to be broken down by the action 
of proteases (Politis 1996). Our study showed the breakdown of important milk proteins 
like caseins by the action of proteases accumulated in milk. One such serine protease, 
plasmin is a predominant protease in milk that produces peptides from β-casein, αS1 and 
αS2 caseins (Politis 1996). Studies involving the identification of secreted proteases that 
are upregulated during involution and potentially produce pro-apoptotic and bioactive 
peptides will help us understand the initial trigger for the onset of involution. Although 
our analysis of the microarray databases yielded a list of secreted proteins, most were 
involved in the immune cascade, wound healing process and structural components of the 
 189 
 
ECM. Previous research carried out to identify the role of oral cavity and gut in the 
proteolytic digestion of milk proteins aimed at elucidating the functions of milk peptides 
as antimicrobial (Liepke, Zucht et al. 2001, Gifford, Hunter et al. 2005, Dallas, Guerrero 
et al. 2013a), anti-thrombic (Fiat, Migliore-Samour et al. 1993, Chabancea, Jollesa et al. 
1995), immunomodulatory (Migliore-Samour, Floc'h et al. 1989, Qian, Xing et al. 2011, 
Adel-Patient, Nutten et al. 2012), ACE inhibitors (Wu, Pan et al. 2013) and opioid agents 
(Koch, Wiedemann et al. 1985, Teschemacher, Koch et al. 1997, Meisel and Fitzgerald 
2000). Other studies in our laboratory involving incubating human milk samples collected 
during peak lactation have shown the presence of bioactive peptides and the ability of 
milk to process itself to provide specific bioactivity including anti-bacterial and anti-
inflammatory activities (Watt, Sharp and Nicholas, unpublished data). Importantly, this 
work also demonstrated that incubated peak lactation milk did not induce cell death 
suggesting that local milk factors involved in involution must only be produced during 
the weaning phase. This was in contrast to what was observed in this study where 
incubated day 15 lactation mouse milk caused mammosphere disruption and induced 
mammary epithelial cell death. The absence of apoptotic activity in incubated human milk 
could be attributed to the gradual process of involution occurring in the humans (Radisky 
and Hartmann 2009) and suggests a contribution from the involuting breast to processing 
milk for a role in involution a necessary part of the process. The involution response 
cascade occurs more rapidly in the mouse when compared to the humans and hence it is 
speculated that human apoptotic peptides may not be observed even if the milk is 
incubated for longer than 7 days. Chapter 3 focused on demonstrating the capacity of 
mouse milk collected during day 0 involution (mice weaned at day 15 lactation) to process 
itself to provide potential apoptotic activity during murine mammary gland involution. 
When this milk was incubated for 4 days and run on the gel, it showed a similar profile 
with casein breakdown and difference in expression of proteins like alpha-lactalbumin, 
WAP, cystatin C, etc. When the incubated milk was examined for an effect on functional 
mammospheres, it induced epithelial cell death, again, emphasizing the similarity in 
function to the milk collected from involuting mice. Although proteins in the involuting 
milk could be different from those in the incubated milk due to the influence of stromal 
factors, the apoptotic potential of both milk samples were similar. Specific peptides that 
 190 
 
could potentially drive apoptosis were not identified in our study but, we showed that 
milk processes itself (when incubated in the absence of stromal factors and contact with 
the mammary gland) and this when treated on MECs in culture induced cell death. To 
extend this concept to further detail, specific peptide fractions could be isolated from 
involuting milk samples and incubated milk samples, identified using mass spectrometry 
analysis and tested on MECs in culture for specific apoptotic activity. Milk-borne factors 
like alpha-lactalbumin and feedback inhibitor of lactation have been suggested to 
stimulate apoptosis and act as triggers for involution (Wilde, Addey et al. 1995, Hendry, 
Simpson et al. 1998, Sharp, Lefevre et al. 2008). The absence of apoptosis and initiation 
of involution in the lactating fur seal during its long foraging trips to the sea has been 
attributed to the lack of alpha-lactalbumin in its milk and suggests its role in regulating 
mammary gland involution (Sharp, Lefevre et al. 2008).  The fur seal mammary gland 
enters phase I involution by down-regulation of milk protein genes and decreased milk 
production in the absence of sucking, but fails to continue the involution cascade (Sharp, 
Lefevre et al. 2007b). This makes the fur seal an interesting model to study the factors 
that trigger apoptosis during involution. In mice, at weaning, there is accumulation of 
milk in the gland increasing the concentration of milk proteins like LALBA. It is 
speculated that when it reaches a particular concentration and undergoes a conformational 
change, it gains apoptotic potential and exposure of mammary epithelial cells to LALBA 
triggers mammary gland involution (Sharp, Lefevre et al. 2008).  
5.3 Possible triggers for phase II involution 
The second phase of murine mammary gland involution is an irreversible phase and 
involves extensive apoptosis of the secretory epithelium and tissue remodeling (Strange, 
Li et al. 1992). Results from chapters 2 and 3 have given an insight into the initial trigger 
for the onset of involution being the milk-borne factors and the contribution of the 
extracellular matrix to the second irreversible stage of involution. The ECM remains 
intact during phase I involution and supports the reversibility of the first stage of the 
involution process, however, during the second phase of involution, the MMPs act to 
degrade the ECM and promote apoptosis and mammary gland remodeling. This was 
supported by results in chapter 3 where we analyzed the expression of these genes from 
publicly available databases. Earlier microarray analysis focused on identifying the 
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inflammatory mediators, immune mediators and members of the acute phase response 
(APR) complex involved in the 2 phases (Clarkson and Watson 2003, Clarkson, Wayland 
et al. 2004, Stein, Morris et al. 2004). We aimed to identify secreted proteins and milk-
borne factors that could potentially contribute to the onset of the irreversible phase of 
involution. Possible triggers included the secreted proteins that are involved in the 
regulation of cell growth such as the insulin like growth factor binding proteins. Our 
analysis of the microarray database confirmed the previously reported down-regulation 
of milk protein genes and up-regulation of metalloproteases for tissue remodeling. The 
list of differentially regulated genes coding for secreted proteins failed to yield an 
extensive list of proteases and milk factors triggering the irreversible phase.  
Although a number of studies have focused on the molecular mechanisms behind the two 
phases of involution (Green and Streuli 2004, Watson 2006), the exact trigger for the 
switch to the irreversible phase is yet to be identified. A cascade of events occurring over 
the period of involution leads to the transition from the reversible to the irreversible phase. 
Studies have shown that within 24 hours of litter removal, a 95% fall in the abundance of 
α-, β- and γ- casein mRNA was observed in the mice (Wilde, Knight et al. 1999). This 
decline in activity was also accompanied by loss of luminal epithelial cells. The apoptotic 
cell loss has been suggested to be a coordinated response which rapidly shuts down milk 
secretion and initiates the removal of the mammary epithelial cell population (Wilde, 
Knight et al. 1999). During early involution (up to 48 hours), if the pups are returned back 
to the mother, the involution cascade can be stopped and beyond this point, the gland is 
programmed to irreversibly lose its milk producing potential. We observed this in our 
study when mammary epithelial cells cultured on late involuting matrices were returned 
to matrices from early involution, they failed to form functional mammospheres ensuring 
the irreversibility of the second phase. This strategy prepares the mammary gland for the 
next cycle of pregnancy and lactation. The lactating fur seal, however, circumvents this 
stage during its long foraging trips to the sea. Although, there is no suckling during these 
trips and milk production is stopped, lactation resumes upon the mother’s return to the 
shore. This model paved the way to search for clues into factors that control and regulate 
involution and led to the identification of LALBA by Sharp, et. al. (2008) as a potential 
apoptotic trigger. It is believed that this strategy was an adaptation of lactation that 
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allowed the survival of the species and ways to modulate this effect can improve our 
ability to prevent premature cessation of milk production. It is interesting to note that a 
marsupial, the tammar wallaby (Macropus eugenii) secretes LALBA in the milk during 
the later stages of lactation when lactose is not present in the milk (Watson 2006, Khalil, 
Digby et al. 2011). This would be consistent with LALBA having a potential second role 
in the process of involution rather than the primary role of producing lactose that is 
observed during the earlier phases of lactation.  
5.4 Mammary epithelial cell regulation by adipocytes during involution 
Fibroblasts and adipocytes in the stromal environment have been shown to play an 
important role through cell-cell interaction in regulating milk protein gene synthesis and 
thus, in the regulation of mammary gland development (Levine and Stockdale 1984, 
Levine and Stockdale 1985, Polyak and Kalluri 2010). They have been shown to exert 
paracrine control by generating signals for the regulation of the secretory epithelium 
(Knight 1995). One such paracrine signalling molecule has been postulated to belong to 
the caveolin family of proteins and earlier studies in our laboratory has shown that the 
cell-cell interactions between the mammary epithelial cells, adipocytes and myoepithelial 
cells is mediated by a complex interplay of hormones (Kuruppath, Sharp et al. 2014). In 
the mouse mammary gland, the expression of caveolin 1 and 2 genes is elevated before 
and during early pregnancy, down-regulated during lactation and subsequently up-
regulated with the onset of involution (Park, Lee et al. 2001). Our analysis of the 
microarray database showed the up-regulation of caveolin 1 during involution. These 
caveolins were found localized in the myoepithelial cells and adipocytes and not in the 
secretory epithelial cells (Hue-Beauvais, Pechoux et al. 2007). The study undertaken in 
chapter 3 investigated the negative correlation between the expression of caveolin 1 and 
milk protein, β-casein as a potential trigger for the onset of involution. The expression of 
caveolin 1 by 3T3L1 adipocytes upon insulin induction during adipogenesis (Scherer, 
Lisanti et al. 1994) and their non-responsiveness to prolactin after achieving a fully 
differentiated state (McAveney, Gimble et al. 1996) made an excellent model to study the 
paracrine signalling between adipocytes and epithelial cells. The results obtained in 
chapter 3 showed that when caveolin 1 protein was used to treat milk protein gene 
expressing mammospheres, it caused a down-regulation of β-casein expression. An 
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antibody was used to block caveolin 1 in the control study negating the effect on beta-
casein levels. Although the antibody treatment showed positive results, it doesn’t 
completely confirm the blocking effect on caveolin 1. One major part of our future study 
will include confirming the secretion of caveolin 1 by assessing whether the gene codes 
for a signal peptide for caveolin 1. Future work will also involve identifying other 
secreted signalling factors that are thought to cause the down-regulation of milk protein 
genes, either by a direct action on the mammary epithelial cells or by processing milk to 
alter its bioactivity towards these cells. It will also be interesting to see the effect of this 
paracrine signalling on other milk proteins to ensure that the effect is consistent with the 
synthesis and secretion of milk. Investigation of whether suppression of Caveolin 1 
signalling could delay the onset of involution would be an interesting future initiative as 
this concept can be potentially extended to other species like bovine and human in order 
to prevent early onset of involution. Equally important would be the potential to impact 
on the milking period in dairy cattle to achieve improved outcomes in milk production.  
5.5 Significance of involution in breast disease studies 
There is a critical connection between breast pathologies and involution responses. When 
involution occurs unexpectedly, it has been linked to increased breast cancer risk and may 
facilitate aggressive and metastatic cancers (Clarkson, Wayland et al. 2004, Hayanama 
and Nagata 2005, Atabi, Sheppard et al. 2007). A chemical regulator accumulated in milk 
during involution that has been shown to stimulate apoptosis in culture is alpha-
lactalbumin (Hakansson, Zhivotovsky et al. 1995, Hakansson, Andreasson et al. 1999, 
Sharp, Lefevre et al. 2008). It is well established that chemically induced forms of 
LALBA can cause apoptosis of immature and transformed cells while sparing healthy 
cells (Hakansson, Zhivotovsky et al. 1995). Commercial preparations of native bovine 
LALBA has been demonstrated to have direct apoptotic effect on intestinal cell line (Xu, 
Sugiura et al. 2005) and primary seal mammary epithelial cells (Sharp, Lefevre et al. 
2008). Earlier studies in Nicholas laboratory have shown that a 28kD variant of alpha-
lactalbumin is capable of having potent apoptotic effects on a number of mammary cell 
types (Brennan , Sharp et al. 2008).  Chapter 4 highlights the use of LALBA-oleic acid 
complex in a nanocarrier delivery system for breast cancer treatment. We successfully 
developed a biocompatible, biodegradable silicon nanocarrier system for loading the 
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alpha-lactalbumin-oleic acid complex without chemically modifying the complex and 
retaining its activity to deliver to breast cancer cells. Previous studies have shown that 
not all forms of LALBA possess apoptotic potential (Hakansson, Zhivotovsky et al. 1995, 
Hakansson, Andreasson et al. 1999) and hence, using the complex without other 
modifications is a significant step in this study. The activity of the alpha-lactalbumin-
oleic acid complex loaded nanoparticle was tested on breast cancer cell line as previous 
studies have shown that this complex does not affect healthy cells (Svanborg, Agerstam 
et al. 2003). The specificity and uptake of the complex loaded nanoparticle system in a 
co-culture of normal and cancer cells will be an important future initiative. A significant 
challenge is to target nanoparticle delivery of ‘kill agents’ to cancer cells. The specificity 
can be delivered by using either a payload or nanoparticle, or both, that targets cancer 
cells. To extend this concept further, it will be interesting to see whether the enhanced 
permeation retention effect of the nanoparticles in cancer cells (Maeda 2010) and their 
more rapid elimination from normal cells before release of the payload is a viable strategy 
using live cell imaging in an animal model. It has been shown recently that bovine 
lactoferrin binds to oleic acid to form an anti-tumor complex similar to HAMLET (Fang, 
Zhang et al. 2014). Whether other whey proteins that accumulate in milk during 
involution form similar complexes with other fatty acids will need to be elucidated in the 
future as this will have possible implications in mammary involution and the potential 
therapeutic benefits for breast cancer patients.  
There have been studies indicating how pregnancy-dependent breast cancer protection 
arises and several schools of thought concerning the mechanisms of this protection (Britt, 
Ashworth et al. 2007). Parity specific changes in levels of hormones such as prolactin, 
growth hormone and estradiol has been associated with decreased breast cancer risk 
(Emerman, Leahy et al. 1985, Henderson and Feigelson 2000). It is also suggested that 
parity induces terminal differentiation of early progenitors and stem cells of the mammary 
gland making them resistant to transforming stimuli (Russo and Russo 1997). Hartmann, 
Milanese et al. (2007) observed that completing the process of involution appeared to be 
associated with further risk reduction. The reduction in apoptosis or lack of involution 
after a pregnancy leads to the lack of post-menopausal lobular involution in humans 
(Haricharan, Dong et al. 2013). This has been shown to be associated with higher risk of 
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breast cancer (Milanese, Hartmann et al. 2006, Howell, Anderson et al. 2014). It is also 
possible that involution associated apoptosis leads to a decrease in mammary stem cell 
numbers and hence a decrease in the pool of potentially transformation susceptible 
epithelial precursors (Britt, Ashworth et al. 2007). Tthe increase in concentration of 
LALBA during cessation of suckling could potentially contribute to reduced breast cancer 
risk by eliminating the transformation susceptible epithelial precursors. It is interesting 
to note that normal mammary cells are not primed to produce milk proteins upon 
induction by lactogenic hormones in the absence of a pregnancy (Hartmann, Milanese et 
al. 2007). However, LALBA has been reported to be expressed in >60 % of breast cancers 
and the hormonal perturbation in breast carcinomas makes the gene transcriptionally 
active (Thean and Toh 1990, de Almeida and Pestana 1992, Anderson, Swaminathan et 
al. 1999). Although, this production of milk proteins in breast cancer is similar to that 
seen during lactation, the apoptotic potential of LALBA is not observed in the tumors. 
This is attributed to the low levels of LALBA found in the tumor microenvironment. 
When induced to significant levels by hormone treatment, it is possible that initiation of 
apoptosis may lead to tumorigenic suicide. Since LALBA is not expressed by any other 
cell type in the body, this makes it an exceptional anti-cancer agent eliminating potential 
side effects.  
5.6 Significance of mammary involution 
The studies in this thesis have successfully developed an in vitro model to explore the 
concept of concurrent mechanisms regulating murine mammary gland involution and the 
potential signaling factors involved in this process. This study has provided a better 
understanding of the relationship between ECM, milk-borne factors, other cell types and 
hormones in regulating mammary gland development and function. These outcomes 
provide a better understanding of regulating the mammary gland during the lactation 
cycle and provide new opportunities for future studies to harness potential therapeutic 
applications in breast disease and cancer study. Understanding the molecular mechanisms 
underlying the onset of involution would also be of economic significance to the dairy 
industry. The decline in milk yield after peak lactation in dairy animals leads to 
considerable financial loss and this decline is primarily caused by an increased rate of cell 
death of the secretory epithelium due to early onset of involution (Capuco, Ellis et al. 
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2003). Identifying factors in chapter 2 and 3 that are involved in triggers for phase 1 
involution and the switch to an irreversible phase of involution has the potential to 
significantly improve milk yield and lactation persistency either by exploring strategies 
for direct manipulation of udder function or looking for association with DNA markers 
for proteins such as caveolin and LALBA.  
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Appendix 1 
R script for bioinformatics analysis 
library (affy)  
library (limma)  
targets <- readTargets("rudolph_stein_watson.txt")  
library (affy); data <- ReadAffy(filenames=targets$FileName)  
eset <- rma(data)  
pData(eset)  
write.exprs(eset, file="affy_all.txt")  
design <- model.matrix(~ - 
1+factor(c(1,1,2,2,2,2,2,3,3,3,3,3,3,3,3,3,4,4,4,5,5,5,5,5,6,6,6,6,6,7,7,8,8,8,8,8,8,8,9,9,1
0,10,10,10,11,11,11,12,12,13,13,13,14,14,14,14,15,15,15,15,15,15,15,16,16,17,17,17,1
7,17,17,17,18,18,18,18,18,19,19,19,19,19,19,19,20,20,20,20,21,21,21,22,22,22,22,22,2
2,22,23,23,24,24,24,24,25,25,25,26,26,26,26,26,26,26,26,26,26,26)) 
colnames(design) <- 
c("group1","group2","group3","group4","group5","group6","group7","group8","group9
","group10","group11","group12","group13","group14","group15","group16","group17
","group18","group19","group20","group21","group22","group23","group24","group25
","group26")  
fit <- lmFit(eset, design)  
contrast.matrix <- makeContrasts(group4-group1, levels=design)  
fit2 <- contrasts.fit(fit, contrast.matrix)  
fit2 <- eBayes(fit2)  
topTable(fit2, coef=1, adjust="fdr", sort.by="B", number=10)  
 257 
 
write.table(topTable(fit2, coef=1, adjust="fdr", sort.by="B", number=50000), 
file="limma_complete.xls", row.names=T, sep="\t")  
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Appendix 2 
Proteins identified by mass spectrometry 
Day Band Protein Nominal mass 
(Da) 
D0 involution 1 WAP(precursor) 15267 
D1 involution 1 WAP(precursor) 15267 
Glutaredoxin 12148 
D2 involution 1 WAP(precursor) 15267 
D3 involution 1 WAP(precursor) 15267 
Glutaredoxin 12148 
D0 milk incubated for 1 day 1 WAP(precursor) 15267 
D0 milk incubated for 2 days 1 WAP(precursor) 15267 
D0 milk incubated for 3 days 1 WAP(precursor) 15267 
D0 milk incubated for 4 days 1 WAP(precursor) 15267 
 
Day Band Protein Nominal mass 
(Da) 
D0 involution 2 WAP(precursor) 15267 
Transthyretin 15880 
Cystatin C 15749 
Profilin 15119 
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Fatty acid binding 
protein 3 
14810 
Alpha Lactalbumin 16762 
Hemoglobin subunit 
beta-1 
15944 
Hemoglobin subunit 
beta-1 
15982 
Hemoglobin subunit 
alpha 
15133 
D1 involution 2 WAP(precursor) 15267 
Alpha Lactalbumin 16762 
Transthyretin 15880 
Cystatin C 15749 
Profilin 15119 
Fatty acid binding 
protein 3 
14810 
Prolactin induced 
protein isoform CRA 
17098 
D2 involution 2 WAP(precursor) 15267 
Hemoglobin subunit 
beta-1 
15944 
Hemoglobin subunit 
beta-1 
15982 
Alpha Lactalbumin 16762 
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Fatty acid binding 
protein 3 
14810 
Cystatin C 15749 
Profilin 15119 
Prolactin induced 
protein isoform 
CRA_c 
17098 
D3 involution 2 WAP(precursor) 15267 
WAP 15268 
Hemoglobin subunit 
beta-1 
15944 
Hemoglobin subunit 
beta-1 
15982 
Prolactin induced 
protein isoform 
CRA_c 
17098 
Alpha Lactalbumin 16762 
Cystatin C 15749 
Fabp4 protein 14755 
D0 milk incubated for 1 day 2 WAP(precursor) 15267 
Prolactin induced 
protein isoform 
CRA_a 
17098 
Cystatin C 15749 
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Fatty acid binding 
protein 3, muscle and 
heart 
14810 
Hemoglobin subunit 
beta-2 
15982 
Alpha Lactalbumin 16762 
Profilin 15119 
D0 milk incubated for 2 days 2 WAP(precursor) 15267 
Prolactin induced 
protein isoform 
CRA_a 
17098 
Fatty acid binding 
protein 3, muscle and 
heart 
14810 
Transthyretin 15880 
Hemoglobin subunit 
beta-2 
15982 
Hemoglobin subunit 
beta-1 
15944 
Cystatin C 15749 
Alpha Lactalbumin 16762 
Profilin 15119 
D0 milk incubated for 3 days 2 WAP(precursor) 15267 
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Prolactin induced 
protein isoform 
CRA_c 
17098 
Cystatin C 15749 
Alpha Lactalbumin 16762 
Transthyretin 15880 
D0 milk incubated for 4 days 2 WAP(precursor) 15267 
Prolactin induced 
protein isoform 
CRA_c 
17098 
Cystatin C 15749 
Hemoglobin subunit 
beta-2 
15982 
Fatty acid binding 
protein 3, muscle and 
heart 
14810 
Hemoglobin subunit 
beta-1 
15944 
Alpha Lactalbumin 16762 
Profilin 15119 
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Day Band Protein Nominal mass 
(Da) 
D0 involution 3 Alpha S2 casein like B 16957 
Peptidyl-prolyl cis-
trans isomerase 
18131 
Cofilin-1 18776 
ADP-ribosylation 
factor 3 
20645 
D1 involution 3 Alpha S2 casein like B 16957 
Casein alpha S2 like A 21258 
Peptidyl-prolyl cis-
trans isomerase 
18131 
D2 involution 3 Alpha S2 casein like B 16957 
Casein alpha S2 like A 21258 
Major urinary protein 
8 
20953 
Peptidyl-prolyl cis-
trans isomerase 
18131 
ADP-ribosylation 
factor 3 
20645 
ADP-ribosylation 
factor 2 
20790 
Peptidyl-prolyl cis-
trans isomerase 
FKBP11 
22294 
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D3 involution 3 Alpha S2 casein like B 16957 
Casein alpha S2 like A 21258 
Peptidyl-prolyl cis-
trans isomerase 
18131 
ADP-ribosylation 
factor 3 
20645 
D0 milk incubated for 1 day 3 Casein alpha S2 like A 21258 
ADP-ribosylation 
factor 3 
20645 
ADP-ribosylation 
factor 4 
20555 
ADP-ribosylation 
factor 2 
20790 
Peptidyl-prolyl cis-
trans isomerase 
18131 
D0 milk incubated for 2 days 3 ADP-ribosylation 
factor 3 
20645 
Peptidyl-prolyl cis-
trans isomerase 
18131 
Alpha S2 casein like B 16957 
D0 milk incubated for 3 days 3 ADP-ribosylation 
factor 3 
20645 
D0 milk incubated for 4 days 3 ADP-ribosylation 
factor 3 
20645 
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Peptidyl-prolyl cis-
trans isomerase 
18131 
 
Day Band Protein Nominal mass 
(Da) 
D0 involution 4 Csnk protein 20074 
Major urinary protein 
8 
20953 
Casein alpha S2 like A 21258 
Peptidyl-prolyl cis-
trans isomerase 
23669 
Beta casein 25435 
Glutathione 
peroxidase 3 
25580 
D1 involution 4 Casein alpha S2 like A 21258 
Neutrophil gelatinase 
associated lipocalin 
23032 
Beta casein 25435 
D2 involution 4 Casein alpha S2 like A 21258 
Neutrophil gelatinase 
associated lipocalin 
23032 
Beta casein 25435 
Clusterin (Fragment) 26366 
Protein Trf (Fragment) 26457 
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D3 involution 4 Ras related protein 1b 21040 
Casein alpha S2 like A 21258 
Ras related protein 
Rap-1A 
21316 
Peroxiredoxin-2 21936 
Neutrophil gelatinase 
associated lipocalin 
23032 
RAB18, member RAS 
oncogene family, 
isoform CRA_a 
23306 
Beta casein 25435 
D0 milk incubated for 1 day 4 Beta casein 25435 
D0 milk incubated for 2 days 4 Glutathione 
peroxidase 3 
25580 
D0 milk incubated for 3 days 4 Casein alpha S2 like A 21258 
Glutathione 
peroxidase 3 
25580 
D0 milk incubated for 4 days 4 Casein alpha S2 like A 21258 
Glutathione 
peroxidase 3 
25580 
Beta casein 25435 
Major urinary protein 
8 
20953 
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Major urinary protein 
2 
20935 
 
Day Band Protein Nominal mass 
(Da) 
D0 involution 5 Neutrophil gelatinase 
associated lipocalin 
23032 
Beta casein 25435 
Apolipoprotein E 
(Fragment) 
26496 
Tyrosine 3-
monooxygenase/trypto
phan 5-
monooxygenase 
activation protein, beta 
28183 
D1 involution 5 Neutrophil gelatinase 
associated lipocalin 
23032 
Beta casein 25435 
Tyrosine 3-
monooxygenase/trypto
phan 5-
monooxygenase 
activation protein, beta 
28183 
Truncated 
apolipoprotein A-I 
30597 
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D2 involution 5 Neutrophil gelatinase 
associated lipocalin 
23032 
Beta casein 25435 
ATP synthase subunit 
O, mitochondrial 
23406 
Cytochrome b-c1 
complex subunit 
Rieske,mitochondrial 
29634 
Truncated 
apolipoprotein A-I 
30597 
D3 involution 5 Neutrophil gelatinase 
associated lipocalin 
23032 
Beta casein 25435 
60S ribosomal protein 
L10 
25044 
Truncated 
apolipoprotein A-I 
30597 
D0 milk incubated for 1 day 5 Beta casein 25435 
D0 milk incubated for 2 days 5 Rab 18, member RAS 
oncogene family, 
isoform CRA_a 
23306 
Glutathione 
peroxidase 3 
25580 
D0 milk incubated for 3 days 5 Beta casein 25435 
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D0 milk incubated for 4 days 5 Neutrophil gelatinase 
associated lipocalin 
23032 
Beta casein 25435 
Clusterin (fragment) 26366 
Rab 18, member RAS 
oncogene family, 
isoform CRA_a 
23306 
 
Day Band Protein Nominal mass 
(Da) 
D0 involution 6 Beta casein 25435 
Tyrosine 3-
monooxygenase/trypto
phan 5-
monooxygenase 
activation protein, beta 
28183 
Truncated 
apolipoprotein A 
30597 
D1 involution 6 Beta casein 25435 
14-3-3 protein 
zeta/delta 
27925 
Tyrosine 3-
monooxygenase/trypto
phan 5-
monooxygenase 
29326 
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activation protein, 
epsilon polypeptide 
Oleoyl-ACP hydrolase 30573 
Truncated 
apolipoprotein A-I 
30597 
Triosephosphate 
isomerase 
32684 
D2 involution 6 Beta casein 25435 
Clusterin (Fragment) 26366 
14-3-3 protein 
zeta/delta 
27925 
D3 involution 6 Beta casein 25435 
APCS amyloid P-
component serum 
protein 
26401 
Protein Trf (fragment) 26457 
14-3-3 protein 
zeta/delta 
27925 
Carbonic anhydrase 3 29633 
Peroxiredoxin-4 31261 
Triosephosphate 
isomerase 
32684 
D0 milk incubated for 1 day 6 Beta casein 25435 
MCG140784 26888 
 271 
 
Uncharacterized 
protein (Fragment) 
31986 
D0 milk incubated for 2 days 6 Beta casein 25435 
MCG140784 26888 
D0 milk incubated for 3 days 6 Uncharacterized 
protein (Fragment) 
31986 
Truncated 
apolipoprotein A-1 
30597 
D0 milk incubated for 4 days 6 Truncated 
apolipoprotein A-1 
30597 
 
 
Day Band Protein Nominal mass 
(Da) 
D0 involution 7 Beta casein 25435 
Clusterin (fragment) 26366 
APCS amyloid P-
component serum 
protein 
26401 
Apolipoprotein A-I 30569 
Oleoyl-ACP hydrolase 30573 
D1 involution 7 Beta casein 25435 
D2 involution 7 Beta casein 25435 
D3 involution 7 Beta casein 25435 
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Protein Trf (fragment) 26457 
Ribosomal protein S3 26828 
D0 milk incubated for 1 day 7 Beta casein 25435 
Truncated 
apolipoprotein A-1 
30597 
Peroxiredoxin 4 31261 
D0 milk incubated for 2 days 7 Beta casein 25435 
Oleoyl ACP hydrolase 30573 
Peroxiredoxin 4 31261 
D0 milk incubated for 3 days 7 Beta casein 25435 
APCS amyloid P-
component serum 
protein 
26401 
D0 milk incubated for 4 days 7 Beta casein 25435 
Truncated 
apolipoprotein A-1 
30597 
Peroxiredoxin 4 31261 
 
Day Band Protein Nominal mass 
(Da) 
D0 involution 8 Alpha S1 casein 34889 
Glyceraldehyde 3 
phosphate 
dehydrogenase 
36072 
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Malate dehydrogenase, 
cytoplasmic 
36659 
L-Lactate 
dehydrogenase 
40075 
D1 involution 8 Alpha S1 casein 34889 
Glycerol 3 phosphate 
dehydrogenase 
(NAD(+)), 
cytoplasmic 
35835 
Glyceraldehyde 3 
phosphate 
dehydrogenase 
36072 
Malate dehydrogenase, 
cytoplasmic 
36659 
Cathepsin L 38093 
Cathepsin B 38168 
D2 involution 8 Alpha S1 casein 34889 
Cathepsin B 38168 
Fructose bisphosphate 
aldolase 
39769 
H2 class I 
histocompatibility 
antigen, Q10 alpha 
chain 
40421 
D3 involution 8 Alpha S1 casein 34889 
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Glyceraldehyde 3 
phosphate 
dehydrogenase 
36072 
Malate dehydrogenase, 
cytoplasmic 
36659 
Cathepsin B 38168 
L-Lactate 
dehydrogenase 
40075 
D0 milk incubated for 1 day 8 Alpha S1 casein 34889 
Malate dehydrogenase, 
cytoplasmic 
36659 
L-Lactate 
dehydrogenase 
40075 
D0 milk incubated for 2 days 8 Alpha S1 casein 34889 
Glycerol 3 phosphate 
dehydrogenase(NAD 
+), cytoplasmic 
38176 
L-Lactate 
dehydrogenase 
40075 
D0 milk incubated for 3 days 8 Alpha S1 casein 34889 
D0 milk incubated for 4 days 8 Alpha S1 casein 34889 
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Day Band Protein Nominal mass 
(Da) 
D0 involution 9 Alpha S1 casein 34889 
Hyaluronan and 
proteoglycan link 
protein 1 
41079 
D1 involution 9 Alpha S1 casein 34889 
Transaldolase 37534 
Cathepsin B 38168 
Fructose bisphosphate 
aldolase 
39769 
H 2 class I 
histocompatibility 
antigen, Q10 alpha 
chain 
40421 
D2 involution 9 Alpha S1 casein 34889 
D3 involution 9 Alpha S1 casein 34889 
Cathepsin B 38168 
Fructose bisphosphate 
aldolase 
39769 
D0 milk incubated for 1 day 9 Alpha S1 casein 34889 
Cathepsin B 38168 
D0 milk incubated for 2 days 9 Alpha S1 casein 34889 
Cathepsin B 38168 
 276 
 
Fructose bisphosphate 
aldolase 
39769 
D0 milk incubated for 3 days 9 Alpha S1 casein 34889 
Fructose bisphosphate 
aldolase 
39769 
D0 milk incubated for 4 days 9 Alpha S1 casein 34889 
Cathepsin B 38168 
Fructose bisphosphate 
aldolase 
39769 
 
 
Day Band Protein Nominal mass 
(Da) 
D0 involution 10 Actin,beta 42052 
Actin alpha cardiac 42334 
Apolipoprotein A-IV 45001 
Phosphatidylinositol 
3,4,5-trisphosphate 3-
phosphatase and dual-
specificity protein 
phosphatase PTEN 
47692 
Transcobalamin 2 48012 
D1 involution 10 Actin,beta 42052 
Beta actin like protein 
2 
42319 
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Actin alpha cardiac 42334 
UDP-Gal: beta 
GlcNAc beta 1,4 
galactosyltransferase, 
polypeptide 1 
44782 
Apolipoprotein A-IV 45001 
Phosphatidylinositol 
3,4,5-trisphosphate 3-
phosphatase and dual-
specificity protein 
phosphatase PTEN 
47692 
Transcobalamin 2 48012 
Isoform 2 of 
Lactadherin 
48279 
D2 involution 10 Monocyte 
differentiation  antigen 
CD14 
39636 
Cathepsin D,isoform 
CRA_a 
45381 
Lysosomal acid 
lipase/cholesteryl ester 
hydrolase 
45581 
Alpha 1 antitrypsin 1-3 45966 
Alpha 1 antitrypsin 1-2 46117 
Enolase 3, beta muscle 47337 
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Enolase 1, alpha non 
neuron 
47453 
Phosphatidylinositol 
3,4,5-trisphosphate 3-
phosphatase and dual-
specificity protein 
phosphatase PTEN 
47692 
Isoform 2 of 
Lactadherin 
48279 
Protein disulfide 
isomerase A6 
48469 
D3 involution 10 Monocyte 
differentiation  antigen 
CD14 
39636 
Actin,beta 42052 
Actin alpha cardiac 42334 
Apolipoprotein A-IV 45001 
Cathepsin D,isoform 
CRA_a 
45381 
Isoform 2 of Rab GDP 
dissociation inhibitor 
beta 
47084 
Enolase 1, alpha non 
neuron 
47453 
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Enolase 2,gamma 
neuronal, isoform 
CRA_a 
47609 
Phosphatidylinositol 
3,4,5-trisphosphate 3-
phosphatase and dual-
specificity protein 
phosphatase PTEN 
47692 
Transcobalamin 2 48012 
Isoform 2 of 
Lactadherin 
48279 
D0 milk incubated for 1 day 10 Actin, cytoplasmic 2, 
N terminally processed 
43784 
Apolipoprotein A-IV 45001 
Transcobalamin 2 48012 
D0 milk incubated for 2 days 10 Actin, beta 42052 
Apolipoprotein A-IV 45001 
Transcobalamin 2 48012 
D0 milk incubated for 3 days 10 Apolipoprotein A-IV 45001 
Transcobalamin 2 48012 
D0 milk incubated for 4 days 10 Apolipoprotein A-IV 45001 
Transcobalamin 2 48012 
Isoform 2 of 
Lactadherin 
48279 
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Day Band Protein Nominal mass 
(Da) 
D0 involution 11 Apolipoprotein A-IV 45001 
Cathepsin D,isoform 
CRA_a 
45381 
Alpha 1 antitrypsin 1-3 45966 
Alpha 1 antitrypsin 1-5 46091 
Alpha 1 antitrypsin 1-2 46117 
Alpha 1 antitrypsin 1-4 46140 
Enolase 3, beta muscle 47337 
Enolase 1, alpha non 
neuron 
47453 
Phosphatidylinositol 
3,4,5-trisphosphate 3-
phosphatase and dual-
specificity protein 
phosphatase PTEN 
47692 
Isoform 2 of 
Lactadherin 
48279 
D1 involution 11 Alpha 1 antitrypsin 1-3 45966 
Alpha 1 antitrypsin 1-5 46091 
Alpha 1 antitrypsin 1-2 46117 
Alpha 1 antitrypsin 1-4 46140 
Alpha 1 antitrypsin 1-1 46145 
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Serine protease 
inhibitor A3K 
47021 
Enolase 1, alpha non-
neuron 
47453 
Isoform 2 of 
Lactadherin 
48279 
D2 involution 11 Alpha 1 antitrypsin 1-3 45966 
Alpha 1 antitrypsin 1-5 46091 
Alpha 1 antitrypsin 1-2 46117 
Alpha 1 antitrypsin 1-4 46140 
Serine protease 
inhibitor A3K 
47021 
Enolase 1, alpha non-
neuron 
47453 
D3 involution 11 Alpha 1 antitrypsin 1-3 45966 
Alpha 1 antitrypsin 1-5 46091 
Alpha 1 antitrypsin 1-2 46117 
Alpha 1 antitrypsin 1-4 46140 
Alpha 1 antitrypsin 1-1 46145 
Serine protease 
inhibitor A3K 
47021 
Enolase 1, alpha non-
neuron 
47453 
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D0 milk incubated for 1 day 11 Enolase 1, alpha, non 
neuron 
47453 
Isoform 2 of 
Lactadherin 
48279 
D0 milk incubated for 2 days 11 Alpha 1 antitrypsin 1-3 45966 
Alpha 1 antitrypsin 1-5 46091 
Alpha 1 antitrypsin 1-2 46117 
Alpha 1 antitrypsin 1-4 46140 
Serine protease 
inhibitor A3K 
47021 
D0 milk incubated for 3 days 11 Alpha 1 antitrypsin 1-3 45966 
Enolase 1, alpha, non 
neuron 
47453 
Isoform 2 of 
Lactadherin 
48279 
D0 milk incubated for 4 days 11 Enolase 1, alpha, non 
neuron 
47453 
Isoform 2 of 
Lactadherin 
48279 
 
Day Band Protein Nominal mass 
(Da) 
D0 involution 12 Alpha 1 antitrypsin 1-3 45966 
Alpha 1 antitrypsin 1-5 46091 
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Alpha 1 antitrypsin 1-2 46117 
Alpha 1 antitrypsin 1-4 46140 
Alpha 1 antitrypsin 1-1 46145 
Serine protease 
inhibitor A3N 
46859 
Serine protease 
inhibitor A3K 
47021 
Putative 
uncharacterized 
protein 
50044 
Lactadherin 52348 
Vitamin D binding 
protein 
55162 
Fibrinogen ,B beta 
polypeptide,isoform 
CRA_a 
55402 
D1 involution 12 Alpha 1 antitrypsin 1-3 45966 
Alpha 1 antitrypsin 1-5 46091 
Alpha 1 antitrypsin 1-2 46117 
Alpha 1 antitrypsin 1-4 46140 
Serine protease 
inhibitor A3N 
46859 
Serine protease 
inhibitor A3K 
47021 
 284 
 
Serine protease 
inhibitor A3M 
47205 
Lactadherin 52348 
Antithrombin 52484 
Kininogen-1 light 
chain 
54254 
Fibrinogen, B beta 
polypeptide, isoform 
CRA_a 
55402 
Protein disulfide-
isomerase 
57422 
L-amino acid oxidase 
1 
58471 
D2 involution 12 Alpha 1 antitrypsin 1-3 45966 
Alpha 1 antitrypsin 1-2 46117 
Alpha 1 antitrypsin 1-4 46140 
Serine protease 
inhibitor A3N 
46859 
Serine protease 
inhibitor A3K 
47021 
Serine protease 
inhibitor A3M 
47205 
Lactadherin 52348 
Antithrombin 52484 
 285 
 
Fibrinogen, B beta 
polypeptide, isoform 
CRA_a 
55402 
Protein disulfide 
isomerase A3 
57099 
Protein disulfide-
isomerase 
57422 
L-amino acid oxidase 
1 
58471 
D3 involution 12 Corticosteroid binding 
globulin 
 
Serine protease 
inhibitor A3N 
46859 
Serine protease 
inhibitor A3C 
46908 
Serine protease 
inhibitor A3K 
47021 
Serine protease 
inhibitor A3M 
47205 
Lactadherin 52348 
Antithrombin 52484 
Kininogen-1 light 
chain 
54524 
Protein disulfide-
isomerase 
57422 
 286 
 
L-amino acid oxidase 
1 
58471 
D0 milk incubated for 1 day 12 Alpha 1 antitrypsin 1-3 45966 
Alpha 1 antitrypsin 1-5 46091 
Alpha 1 antitrypsin 1-2 46117 
Alpha 1 antitrypsin 1-4 46140 
Alpha 1 antitrypsin 1-1 46145 
Putative 
uncharacterized 
protein 
50044 
Lactadherin 52348 
Vitamin D binding 
protein 
55162 
Fibrinogen, B beta 
polypeptide, isoform 
CRA_a 
55402 
L-amino acid oxidase 
1 
58471 
D0 milk incubated for 2 days 12 Alpha 1 antitrypsin 1-3 45966 
Alpha 1 antitrypsin 1-2 46117 
Alpha 1 antitrypsin 1-4 46140 
Alpha 1 antitrypsin 1-1 46145 
Lactadherin 52348 
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L-amino acid oxidase 
1 
58471 
D0 milk incubated for 3 days 12 L-amino acid oxidase 
1 
58471 
D0 milk incubated for 4 days 12 Alpha 1 antitrypsin 1-3 45966 
Alpha 1 antitrypsin 1-5 46091 
Alpha 1 antitrypsin 1-2 46117 
Alpha 1 antitrypsin 1-4 46140 
Alpha 1 antitrypsin 1-1 46145 
Lactadherin 52348 
Vitamin D binding 
protein 
55162 
Fibrinogen, B beta 
polypeptide, isoform 
CRA_a 
55402 
L-amino acid oxidase 
1 
58471 
 
Day Band Protein Nominal mass 
(Da) 
D0 involution 13 Hemopexin 52026 
L-amino acid oxidase 
1 
58471 
Isoform 3 of sulfhydryl 
oxidase 1 
64038 
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D1 involution 13 Tubulin, alpha 1C 50562 
Pyruvate kinase 
isozyme M1/M2 
58378 
D2 involution 13 Lactadherin 52348 
Antithrombin 52484 
Isoform 2 of 
serine/threonine 
protein kinase SIK3 
55254 
Isoform 2 of APC 
membrane recruitment 
protein 2 
57946 
D3 involution 13 Hemopexin 52026 
Lactadherin 52348 
L-amino acid oxidase 
1 
58471 
Isoform 3 of sulfhydryl 
oxidase 1 
64038 
D0 milk incubated for 1 day 13 Hemopexin 52026 
Antithrombin 52484 
L-amino acid oxidase 
1 
58471 
Protein Lao1 58572 
Isoform 3 of sulfhydryl 
oxidase 1 
64038 
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D0 milk incubated for 2 days 13 Lactadherin 52348 
Vitamin D binding 
protein 
55162 
L-amino acid oxidase 
1 
58471 
D0 milk incubated for 3 days 13 L-amino acid oxidase 
1 
58471 
Isoform 3 of sulfhydryl 
oxidase 1 
64038 
D0 milk incubated for 4 days 13 Antithrombin 52484 
L-amino acid oxidase 
1 
58471 
Isoform 3 of sulfhydryl 
oxidase 1 
64038 
 
Day Band Protein Nominal mass 
(Da) 
D0 involution 14 Carboxylesterase 1C 61302 
Protein Ces1b 62500 
Carboxyl ester lipase 66170 
Heat shock cognate 71 
kDa protein 
71055 
Isoform 2 of sulfhydryl 
oxidase 1 
73992 
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Insulin like growth 
factor binding protein 
complex acid labile 
subunit 
77234 
Serotransferrin 78841 
Lactotransferrin 79670 
D1 involution 14 Carboxylesterase 1C 61302 
Protein Ces1b 62500 
Isoform 3 of sulfhydryl 
oxidase 1 
64038 
Carboxyl ester lipase 66170 
Heat shock cognate 
71kDa protein 
71055 
Isoform 2 of sulfhydryl 
oxidase 1 
73992 
Heat shock 70kD 
protein 5(glucose 
regulated protein) 
72492 
Inhibitor of carbonic 
anhydrase 
78711 
Serotransferrin 78841 
Lactotransferrin 79670 
D2 involution 14 Carboxylesterase 1C 61302 
Protein Ces1b 62500 
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Carboxyl ester lipase 66170 
Heat shock cognate 
71kDa protein 
71055 
Heat shock protein 1-
like 
70992 
Heat shock 70kD 
protein 5(glucose 
regulated protein) 
72492 
Isoform 2 of sulfhydryl 
oxidase 1 
73992 
Lactotransferrin 79760 
D3 involution 14 Carboxylesterase 1C 61302 
Protein Ces1b 62500 
Carboxyl ester lipase 66170 
Heat shock cognate 
71kDa protein 
71055 
Heat shock 70kD 
protein 5(glucose 
regulated protein) 
72492 
Isoform 2 of sulfhydryl 
oxidase 1 
73992 
Serotransferrin 78841 
Lactotransferrin 79670 
D0 milk incubated for 1 day 14 Carboxylesterase 1C 61302 
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Carboxyl ester lipase 66170 
Isoform 2 of sulhydryl 
oxidase 1 
73992 
Lactotransferrin 79670 
D0 milk incubated for 2 days 14 Carboxylesterase 1C 61302 
Carboxyl ester lipase 66170 
Lactotransferrin 79670 
D0 milk incubated for 3 days 14 Carboxylesterase 1C 61302 
Protein Ces1b 62500 
Carboxyl ester lipase 66170 
Lactotransferrin 79670 
D0 milk incubated for 4 days 14 Carboxylesterase 1C 61302 
Protein Ces1b 62500 
Carboxyl ester lipase 66170 
Lactotransferrin 79670 
 
 
Day Band Protein Nominal mass 
(Da) 
D0 involution 15 Isoform 2 of sulfhydryl 
oxidase 1 
73992 
Serotransferrin 78841 
Lactotransferrin 79670 
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Heat shock protein 84b 83571 
Heat shock protein 90, 
alpha (cystosolic), 
class A member 1 
85134 
Polymeric 
immunoglobulin 
receptor 
86257 
Gelsolin 86287 
D1 involution 15 Isoform 2 of sulfhydryl 
oxidase 1 
73992 
Afamin 74251 
Serotransferrin 78841 
Lactotransferrin 79670 
Polymeric 
immunoglobulin 
receptor 
86257 
Gelsolin 86287 
D2 involution 15 Isoform 2 of sulfhydryl 
oxidase 1 
73992 
Serotransferrin 78841 
Lactotransferrin 79670 
Heat shock protein 84b 83571 
Polymeric 
immunoglobulin 
receptor 
86257 
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Gelsolin 86287 
Heat shock protein 
90kDa beta (Grp94), 
member 1 
92703 
D3 involution 15 Isoform 2 of sulfhydryl 
oxidase 1 
73992 
Serotransferrin 78841 
Lactotransferrin 79670 
Heat shock protein 84b 83571 
Heat shock protein 90, 
alpha (cystosolic), 
class A member 1 
85134 
Polymeric 
immunoglobulin 
receptor 
86257 
Gelsolin 86287 
Transitional 
endoplasmic reticulum 
ATPase 
89950 
Heat shock protein 
90kDa beta (Grp94), 
member 1 
92703 
Plasminogen 93486 
Elongation factor 2 96222 
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D0 milk incubated for 1 day 15 Isoform 2 of sulfhydryl 
oxidase 1 
73992 
Lactotransferrin 79670 
Polymeric 
immunoglobulin 
receptor 
86257 
Gelsolin 86287 
Plasminogen 93486 
D0 milk incubated for 2 days 15 Lactotransferrin 79670 
Heat shock protein 84b 83571 
Polymeric 
immunoglobulin 
receptor 
86257 
Gelsolin 86287 
Plasminogen 93486 
Elongation factor 2 96222 
D0 milk incubated for 3 days 15 Polymeric 
immunoglobulin 
receptor 
86257 
Gelsolin 86287 
Plasminogen 93486 
D0 milk incubated for 4 days 15 Lactotransferrin 79670 
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Polymeric 
immunoglobulin 
receptor 
86257 
Gelsolin 86287 
Plasminogen 93486 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
